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ABSTRACT 
Cytokines and steroidal hormones modulate HLA-DR expression on breast cancer 
cell lines (BCCL ). This study compared the individual and combined quantitative effects 
of IFN-y, IL-4, TGF-J31, and 17J3-estradiol on HLA-DR expression on 8 human breast 
carcinoma cell lines (MCF-7, T47D, BT-474, BT-20, MDA MB 157, MDA MB 231, 
MDA MB 468, SKBR3) through the use of monoclonal antibodies and flow cytometry 
and CELISA. 
Due to problems with the reconstitution solvents, we were unable to determine the 
effects of estradiol treatment on HLA-DR expression. However, comparison of 
constitutive and IFN-y-induced HLA-DR expression in medium containing or depleted of 
estrogen illustrated that media components, particularly estrogen, significantly modulated 
HLA-DR expression on BCCL. 
We report distinct patterns in cytokine modulation of HLA-DR expression when 
co-cultured in estrogen-depleted media. Although IFN-y increased HLA-DR expression 
on all cell lines, addition of IL-4 selectively increased HLA-DR expression on MCF-7 
and SKBR3, and addition of TGF-J31 selectively increased expression on BT-20 and 
SKBR3. Furthermore, analysis of TGF-J31 sensitivity through detection of 
phosphorylated Smad2 and Smad3 proteins (P-Smad2, P-Smad3) by Western blotting 
showed differential expression of P-Smad proteins in BCCL, as both BT -20 and SKBR3 
expressed P-Smad3 but not P-Smad2. Since P-Smad3 is thought to inhibit CIITA in most 
cell types, we suggest that TGF-J31 mediated up-regulation of HLA-DR on breast cancer 
cell lines may be mediated through a Smad-independent pathway. 
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Chapter 1: Introduction 
1.1. Major Histocompatibility Complex (MHC) 
The major histocompatibility complex (MHC), also referred to as human 
leukocyte antigen (HLA) complex, is a collection of highly polymorphic genes that 
encode cell surface glycoproteins essential in the induction and regulation of adaptive 
immune responses. HLA proteins are divided into three groups: HLA class I, class II, and 
class III. HLA class I (HLA-A, -B, -C) and class II (HLA-DR, -DP, -DQ) molecules are 
vital in adaptive immune responses by virtue of their ability to bind and present antigenic 
peptides to CD8+ and CD4+ T cells respectively. HLA molecules on thymic epithelial 
cells (TEC) are also crucial for positive selection, negative selection, and maturation ofT 
cells in the thymus. This ensures survival ofT cells that carry T cell receptors (TCR) 
capable of recognizing self-MHC molecules, while eliminating autoreactive T cells (for 
review see [1]). 
While MHC class I molecules are present on most nucleated cells, constitutive 
expression of MHC class II molecules is largely restricted to antigen presenting cells 
(APCs), namely dendritic cells (DC), B cells, and macrophages. MHC Class II expression 
is regulated on these cells in a maturation-dependent manner, such that MHC expression 
on DC increases with maturation, whereas B cells lose MHC expression when they 
mature to plasma cells [2-4]. In addition, TEC and activated T cells also express HLA 
class II, and expression may be induced on most other MHC negative cell types by 
various stimuli, such as interferon gamma (IFN-y). 
1 
1.1.1. Nomenclature ofHLA Class II Molecules 
Nomenclature of HLA class II molecules consists of three letters: the first (D) 
indicates the class, the second (M, 0, P, Q, orR) the family, and the third (a or P) the 
chain. Individual genes are numbered, and the numerous allelic variants of these genes 
are noted by a number preceded by an asterisk. For example, HLA-DRBI *0401 stands 
for allelic variant 0401 of gene 1, which encodes the P chain of a class II molecule 
belonging to the R family [5]. 
1.1. 2. Structure of HLA Class II Molecules 
HLA class II genes are located within approximately 4 Mb of DNA on the distal 
part of chromosome 6p21.3 and encode the polymorphic HLA-DR, HLA-DP, and HLA-
DQ proteins. Each HLA class II molecule is a heterodimer, composed of two 
transmembrane glycoproteins, a (34 kDa) and p (29 kDa), which associate through non-
covalent interactions (Figure 1.1 ). 
Each chain has four domains: the peptide-binding domain (a1 or PI), the 
immunoglobulin-like domain ( a2 or P2), the transmembrane region, and the cytoplasmic 
tail. The peptide binding groove of HLA class II molecules consists of two parts. The 
floor consists of a rather flat antiparallel p-pleated sheet composed by both a and p 
chains, while both walls are coiled into a-helix formations. The peptide-binding groove 
is formed between the al and PI domains [5] and remains open-ended to accommodate 
longer peptides [6]. Peptides bind in an extended conformation and are held by a series of 
hydrogen bonds between the peptide backbone and conserved amino acid side chains 
2 
Plasma 
membrane 
Peptide-binding I 
groove -+ 
a1 
d2 
v 
Cytoplasmic 
tail 
Figure 1.1. Structure of HLA class II molecules. Each of the Class II a and p chains has 
four domains: the peptide-binding domain (formed by al and pl), the immunoglobulin-
like domain ( a2 or P2), the transmembrane region (TM), and the cytoplasmic tail. 
Adapted from [5]. 
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lining the groove. There is an extreme degree of variation concentrated on amino acid 
residues shaping the peptide-binding site, leading to a high degree of peptide-binding 
specificity. 
1.1.3. HLA-DR Polymorphism 
Both a and p chains may contribute to HLA-DR polymorphism. Currently, the 
HLA-DR a-chain has only three DRA alleles (DRA*0101, DRA*Ol0201, and 
DRA *010202) [7] offering limited polymorphism, while there are 394 HLA-DRB1 
alleles, 41 HLA-DRB3 alleles, 13 HLA-DRB4 alleles, and 18 HLA-DRB5 alleles [7]. 
Thus, most HLA-DR polymorphism is derived from DRB genes. 
The complete set of HLA alleles present on each chromosome is referred to as the 
HLA haplotype, and the number ofHLA-DRB genes expressed by an individual depends 
on the haplotype inherited. These haplotypes include DRB1 *15 and 16 expressed in 
association with DRB5; DRB1 *03, 11, 12, 13, and 14 with DRB3; DRB1 *04, 07, and 09 
with DRB4; and DRBl *01, 10 and 08, which are not in association with any other DRB-
expressed genes [8]. Thus, assuming heterozygosity, an individual can express as many 
as 4 HLA-DR allotypes. 
1.2. MHC Class II Antigen Presentation Pathway 
Alpha and P chains of MHC class II molecules are rapidly synthesized within the 
endoplasmic reticulum. There they associate with the invariant chain (Ii), which acts as a 
chaperone to ensure efficient folding of newly synthesized a and p subunits. The Ii forms 
4 
trimers, with each subunit non-covalently binding to an a:f3 class II heterodimer, forming 
a large nonameric structure. The Ii binds to HLA class II molecules such that part of the 
polypeptide chain, the class II-associated invariant chain peptide (CLIP), occupies the 
peptide-binding groove [9] preventing loading of endogenous peptides within the 
endoplasmic reticulum [ 1 0]. 
Ii also directs assembled heterodimers out of the endoplasmic reticulum, through 
the Golgi apparatus, and into primary lysosomes which fuse with early endosomes to 
form the MHC class II compartment (MIIC) [11]. The cytoplasmic tail of Ii contains a 
dileucine motif that directs class II I Ii chain complexes to localize within the endocytic 
pathway [12]. It is within the MIIC that the majority of peptide loading will occur [13] as 
class II molecules encounter antigenic peptides generated by proteolytic degradation of 
endocytosed exogenous proteins [ 14]. 
Ii is degraded within the MIIC by lysosomal proteases, such as cathepsin LandS 
[15-17]. However the CLIP fragment is protected from degradation by being deeply 
embedded in the class II structure, and therefore continues to occupy the peptide -
binding groove. The exchange of CLIP for antigenic peptides is facilitated by the low pH 
of lysosomal MIICs [18]. Additional support is supplied by HLA-DM, a specialized 
lysosomal chaperone encoded by HLA-DMA and HLA-DMB genes in the HLA locus 
[19]. HLA-DM functions as a "peptide editor," releasing CLIP and unstable, low-affinity 
binding peptides from the peptide-binding groove, while retaining stable, high-affinity 
bound peptides [20-24]. HLA-DM also stabilizes empty class II molecules that would 
5 
otherwise aggregate into nonfunctional complexes [21, 25]. Most HLA-DM heterodimers 
reside in the MIICs with very low amounts detected on the cell surface [26, 27]. 
HLA-DO, a heterodimer composed of gene products of HLA-DNa and HLA-
DOP [28, 29], is a negative regulator ofHLA-DM. HLA-DO is predominantly expressed 
in B cells, and regulates HLA-DM mediated CLIP release and formation of class II-
peptide antigenic complexes [30]. 
1.3. Regulation of HLA Class II Gene Expression 
Expression of HLA class II and related genes is regulated mainly at the level of 
transcription and is characterized by the presence of a conserved sequence of cis-acting 
elements within the promoter region. These elements include the W (or S), X, X2 and Y 
boxes, and are collectively known as the S-X-Y module [31, 32]. 
Transcription of HLA class II genes requires the assembly of a highly stable 
macromolecular nucleoprotein complex that binds on the S-X-Y module. This complex, 
referred to as the enhanceosome, consists of regulatory factor X (RFX), X2-binding 
protein (X2BP) I cyclic adenosine monophosphate (cAMP) response element binding 
protein, and nuclear factorY (NF-Y) multimeric factors [33] (Figure 1.2). 
The transcription factors that compose the enhanceosome are well characterized. 
The X box is bound by RFX, a trimeric complex composed ofRFX5, RFXANK (RFX-B) 
and RFXAP [34-37]. The downstream X2 box is recognized by X2BP, a complex that 
includes cAMP response element binding protein (CREB) [38]. The trimeric NF-Y 
complex, composed ofNF-Y A, NF-YB, and NF-YC, binds to the Y box [39]. The in vivo 
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Figure 1.2. CIITA interaction with MHC enhanceosome on the HLA-DRa promoter. 
MHC Class II promoters share a common set of cis-acting elements, the W /S, XI, X2, 
and Y boxes (S-X-Y module) which are bound by constitutive and ubiquitous 
transcription factors forming the multiprotein MHC Class II enhanceosome complex. The 
enhanceosome provides an appropriate interaction surface for recruitment of CIIT A. 
CIITA associates with an array of TAFs and elongation factors which lead to initiation of 
mRNA synthesis. Upstream of the proximal promoter is a recently discovered inverted S-
X-Y module, known as the locus control region, which also associates with CIIT A and 
RFX. Adapted from [33]. 
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W-box-binding protein remains unclear, although a number of proteins including RFX 
have been shown to bind the W box in vitro [ 40]. 
The DRa promoter also includes an ATGCAAAT octamer-binding site (OBS). In 
B cells this site is bound by transcription factors Oct-1 and Oct-2 [41]. Octamer binding 
factor 1 (OBF-1) binds to Oct-1 and Oct-2, increasing their ability to activate 
transcription [42, 43]. 
The transcription factors described above are ubiquitously and constitutively 
expressed, but fail to induce MHC class II expression on their own. Instead they form the 
enhanceosome complex which provides an appropriate interaction surface for recruitment 
ofthe class II transactivator (CIITA) [31, 44, 45]. 
CIIT A is believed to activate transcription by recruiting various components of 
the basal transcription machinery via its amino-terminal activation domains. CIITA can 
interact with general transcription factors TFIIB (TATA binding protein-associated 
transcription factor liB), TAFn32, and TAFn70, which promote transcription initiation 
[46, 47]; TIIH and p-TEFb (positive elongation factor b) which enhance promoter 
clearance and transcription elongation [47, 48]; and CREB-binding protein (CBP) 
involved in chromatin remodeling [49, 50]. These transcription factors are not mutually 
exclusive, thus several factors may activate transcription simultaneously. Recent studies 
also show that CIITA interacts with the cyclin-dependent kinases 7 (CDK7) and CDK9 
and enhances their ability to phosphorylate the carboxy-terminal domain of RNA 
polymerase II (Pol II), thereby initiating promoter clearance and mRNA synthesis [51]. 
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I. 3.1. Class II Trans activator 
CIITA functions as a non-DNA binding coactivator that exerts its activity through 
multiple protein-protein interactions with the enhanceosome complex [45, 52, 53]. 
Binding of CIIT A to the enhanceosome requires stereospecific alignment and stringent 
spacing, such that a 1-2 bp change in the S-X distance is detrimental for CIITA 
recruitment and function [54, 55]. Although multiple interactions between CIITA and the 
proximal S-X-Y module are essential for MHC Class II expression, basal and induced 
class II gene expression is also regulated by a putative Locus Control Region (LCR) that 
lies approximately 2.3 kb upstream of the HLA-DRa gene in humans [56]. 
In contrast to the relative constitutive expression of DNA-binding factors 
composing the HLA enhanceosome complex, expression of the MHC2TA gene encoding 
CIITA is tightly regulated. In most situations, the expression pattern of MHC2TA largely 
parallels MHC class II expression with CIITA dictating the extent to which MHC class II 
genes are expressed (for review see [57]). CIITA is thus referred to as the "master 
regulator" of MHC class II genes. 
In addition, CIIT A is important in the regulation of several other genes containing 
S-X-Y boxes within their promoters. These include genes encoding accessory proteins 
required for MHC class II restricted antigen presentation [58], such as Ii [59], HLA-DM 
[60, 61], and HLA-DO [15, 60, 62-64]. Expression ofthese proteins is essential for MHC 
class II complex assembly and translocation to the cell surface [23, 65, 66]. Reports also 
indicate that CIITA contributes, albeit to a lesser extent, to expression of classical MHC 
class I and P2 microglobulin CP2M) genes via interaction with a region showing homology 
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to the S-X-Y module within the MHC class I promoter and [32M promoter [67-69]. Thus, 
CUT A either partly or completely controls multiple genes involved in antigen 
presentation. 
1.3.1.1. Structure ofCIITA 
CIITA protein contains four domains (Figure 1.3). The amino-terminal contains a 
region rich in acidic amino acids (residues 1-125) which has transactivation properties, 
possibly achieved by providing surfaces for interaction with the histone acetylase CBP 
and RFXANK [44, 49, 50]. Downstream of this acidic region is a domain rich in proline, 
serine, and threonine (residues 126-336), containing multiple phosphorylation sites. The 
midsection of the protein contains a GTP-binding domain (residues 337-702), involved in 
protein self-association and is important in nuclear import [70-72]. Finally, the carboxy-
terminus contains a leucine-rich (LRR) domain (residues 930-1130) that affects nuclear 
translocation and self-association [73, 7 4]. In total, three regions of CIIT A are implicated 
in nuclear localization: the carboxy-terminus [75], the GTP-binding motif [76], and the 
LLR [73]. 
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Figure 1.3. Structure and functional regions of CIIT A protein. CIIT A contains an acidic 
domain (red), a P/S/T domain (blue), three nuclear localization domains (NLS), and a 
LRR (pink). The Gl, G3, and G4 domains (gray boxes) define a GTP-binding domain. 
The four LXXL sites (green boxes) are thought to be involved in protein-protein 
interactions. Bars underneath schematic indicate regions of CIIT A found to interact with 
transcription factors and coactivators. Adapted from [31] and [77]. 
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1.3.1.2. Modulation ofCIITA Expression 
Since enhanceosome components are ubiquitously expressed, differences in MHC 
class II expression between cell lines, during differentiation, and induced by cytokines is 
due to differences in CIIT A expression. CIIT A transcription may be up-regulated by 
IFN-y [59, 78, 79], lipopolysaccharide [80], and interleukin-4 (IL-4) [80]. However, both 
constitutive and IFN-y-induced CIITA expressions are frequently silenced in tumor cells 
of various origins. 
CIIT A is also negatively regulated by several factors, such as interleukin-1-beta 
(IL-1P) [81], IFN-P [82], tumor necrosis factor-alpha (TNFa) [83], IL-10 [84], nitric 
oxide [85], transforming growth factor-beta (TGF-P) [86-88], prostaglandins [89], and 
statins [90, 91]. In addition, many human pathogens down-regulate MHC class II 
expression and evade the immune system by inhibiting CIITA expression [92-94]. 
1.3.2. MHC2TA Promoters 
Transcriptional activation of the MHC2TA gene encoding CIITA is controlled by 
four independent promoters (I-IV). These promoters are distributed over approximately 
12 kb, but do not share any sequence homology and are not co-regulated. Immediately 
downstream of each promoter exists a unique exon 1 that is spliced with the remaining 
shared exons to form three different types of CIIT A (I, III, and IV) (Figure 1.4 ). 
Translation of CIITA mRNA may begin in exon 2; however, types I and III CIIT A 
mRNA contain translational start sites in exon 1 that give rise to distinct mRNA 
transcripts encoding CIIT A molecules with different amino-terminal protein sequences 
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Figure 1.4. Expression of the MHC2TA gene. Four promoters (pi, pii, pill, piV) have 
been identified in humans. Usage of these promoters leads to the splicing (dashed lines) 
of alternative first exons (shaded boxes) to a shared second exon, forming three types of 
CIITA mRNA that encode three different protein isoforms (black bars). These proteins 
differ only at their amino-terminal ends. The boundary between the alternative first exons 
and the shared second exon is indicated by a vertical line. pii displays very low 
transcriptional activity and its significance is unknown. Adapted from [95]. 
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[96]. These three isoforms of CIITA (121, 124, and 132 kDa) are all known to exist in 
vivo [97]. 
Promoters I, III, and IV are highly conserved between the human and mouse 
genome, while promoter II has only been found in the human genome and its function 
remains unknown. Promoter I is active in myeloid cells (conventional DC and IFN-y 
activated macrophages); promoter III is active in lymphoid cells (B-1 and B-2 cells, 
activated T cells, and plasmacytoid DC) [96]; and promoter IV is mainly responsible for 
induction by IFN-y in non-bone marrow-derived cells (endothelial, epithelial, fibroblasts, 
and astrocytes) [98], but is constitutively expressed in TEC [99]. 
1.4. Cytokine Modulation of HLA-Class II Expression 
1.4.1. Interferon-gamma (IFN-rJ 
Induction of MHC class II molecules by IFN-y is CIITA-dependent [59, 78, 79]. 
IFN-y binds to the IFN-y-receptor and induces synthesis of CIITA through promoter IV 
in most cell types [81, 96, 98-100]. IFN-y may also contribute to CIITA induction via 
promoter III in human fibroblasts and B cells [100-102]. 
IFN-y induction via piV is dependent on three cis-acting sequences, a gamma 
activating sequence (GAS) element, an interferon regulatory factor (IRF) binding site, 
and an E box, which all function in synergy (Figure 1.5). Interaction of IFN-y with its 
receptor activates Janus activating kinases (JAK) 1 and JAK2, which leads to 
phosphorylation, dimerization, and nuclear import of signal transducer and activator of 
transcription 1 (STAT-1). STAT-1 binds cooperatively to the GAS sequences only in the 
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Figure 1.5. Signal transduction cascade mediating IFN-y induction of HLA class II. 
JAKl and JAK2 kinases become activated following interaction of IFN-y with its 
receptor. This leads to phosphorylation, dimerization, and nuclear import of STAT-I. 
STAT -1 binds cooperatively with USF -1 to the GAS/E box motif present in piV of the 
MHC2TA gene. STAT-I also activates IRF-1, which collectively with STAT-I and USF-
lleads to expression ofCIITA and induction ofMHC class II. Adapted from [57]. 
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presence of a ubiquitously expressed transcription factor, upstream stimulatory factor 1 
(USF-1), which binds to the adjacent E box motif present in piV of the MHCT2A gene 
[99]. STAT-I also activates expression ofiRF-1, which binds to the IRF sequence [100]. 
Activation of piV by STAT-1, USF-1, and IRF-1 leads to expression of CIITA and 
subsequent induction ofMHC class II expression. 
In contrast to-the IFN-y response activated through piV, pili is activated directly 
by IFN-y-induced phosphorylation of STAT-1 [100, 101]. Thus, cooperation between 
STAT -1 and IRF -1 is not necessary for induction of CIIT A through pili, but may explain 
the enhanced response of piV to IFN-y. Activation of STAT-1 is an immediate response 
and does not require protein synthesis, while activation of IRF -1 is a secondary response 
that requires protein synthesis and prior activaction of other molecules, including STAT-
I [ 1 00]. Therefore, STAT -1 mediates a faster IFN -y response via pi II, while IRF -1 
mediates a slower response via piV [100]. 
IFN-y-induced gene activation is generally a transient event. Suppressor of 
cytokine signaling -1 (SOCS-1) is induced by IFN-y and this protein negatively regulates 
the IFN-y signal transduction pathway by binding to JAK2 and inhibiting its kinase 
activity [103, 104]. SOCS-1 can also suppress IFN-y-activated expression ofpiV of the 
MHC2TA gene [84]. Hypermethylation and silencing of specific SOCS genes has been 
reported in breast and ovarian cancers, and may augment cytokine responses in these 
tissues [1 05]. 
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1.4.2. Interleukin-4 (JL-4) 
IL-4 is a pleiotrophic cytokine typically produced by mast cells, basophils, and 
TH2 lymphocytes [106, 107], but also produced by tumor infiltrating lymphocytes in 
breast cancer [ 108, 1 09]. IL-4 regulates differentiation of na'ive T lymphocytes, promotes 
proliferation and immunoglobulin class-switching in B cells, and controls growth and 
differentiation of other hematopoietic cells (for review see [110] and [111]). These 
actions are mediated via a multiunit transmembrane receptor, the IL-4 receptor (IL-4R) 
[112, 113]. 
The IL-4R is composed of two subunits, the first being the ligand-binding chain, 
IL-4Ra. The second subunit, in hematopoietic cells, is typically they-common chain (yc), 
first identified as a component of the IL-2R [114, 115], and forms type I IL-4Rs. 
However, recent studies indicate that in nonhematopoietic cells the IL-13Ra' chain is the 
predominant accessory chain of the IL-4R complex [116, 117], forming type II IL-4Rs. 
This agrees with other reports that the a chain is necessary for IL-4 activity but IL-4R 
may also act independently of yc chain [118, 119]. Breast tumor cells are reported to 
express type II IL-4Rs [120, 121]. 
The IL-4R lacks intrinsic kinase activity; therefore it requires receptor-associated 
kinases for the initiation of signal transduction. Binding of IL-4 to the IL-4R activates 
JAKI and JAK3 [122], which phosphorylate the cytoplasmic domain of the receptor as 
well as downstream signaling molecules. Two main pathways are activated in this 
manner, the insulin-receptor substrate-! (IRS-I) I IRS-2 pathway and the STAT-6 
pathway [123, 124]. Both of these pathways are thought to communicate with several 
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signaling pathways, including the phosphoinositol-3-kinase (PI3K), Ras/mitogen 
activated protein kinase (MAPK), and AKT pathways (for review see [111, 125]). 
Studies indicate that IL-4-mediated signaling by STAT -6 (Figure 1.6) plays a role 
in the transcription activation of MHC class II. IL-4 has been shown to increase MHC 
class II antigen expression on B cells [126-128], human endometrial adenocarcinoma cell 
lines [129], and to selectively increase HLA-DR and HLA-DP antigens on human 
monocytes [130]. However, IL-4-induced cell surface expression of both MHC class II 
antigens and IL-4 receptor are completely abrogated in lymphocytes from STAT -6-
knockout mice [131, 132], suggesting that such effects are STAT-6-dependent. 
Furthermore, transfection of STAT -6c, a dominant negative form of STAT -6 lacking the 
functionally critical SH2 domain residues, prevents cells from expressing MHC class II 
by inhibiting endogenous STAT-6 dimer formation [133]. 
IL-4 may also up-regulate MHC class I, class II, lhM, and tumor associated 
antigens on human melanoma cells and human renal cell carcinomas, and these effects 
are enhanced by combination with IFN-y [134, 135]. A similar additive effect ofiL-4 and 
IFN-y on HLA-DR expression in melanoma and breast carcinoma cells was reported by 
Obiri et al. [136], while contrasting reports indicate IL-4 suppresses IFN-y-induction of 
CIITA and MHC class II expression in microglial cells, astrocytes, and monocytes [84, 
130, 137-139]. It is currently unknown if IL-4-mediated induction of MHC on cancer 
cells is also STAT-6-dependent. Nevertheless, the combined augmentation ofMHC class 
II by IFN-y and IL-4 is of particular interest as these cytokines are generally known to 
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IL-4 
Figure 1.6. IL-4 receptor signaling through the STAT-6 pathway. IL-4 engagement of 
the IL-4R results in the activation of JAK1 and JAK3 and phosphorylation of specific 
tyrosine residues in the receptor cytoplasmic region. STAT-6 binds to the phosphorylated 
receptor by a highly conserved SH2 domain and becomes phosphorylated. 
Phosphorylated STAT-6 disengages from the IL-4Ra cytoplasmic tail, forms 
homodimers with a second P-STAT-6, and translocates to the nucleus where it activates 
transcription of responsive genes in cooperation with other transcription factors. 
Alternatively spliced forms ofSTAT-6 have deletion in the amino-terminal (STAT-6b) or 
SH2 regions (STAT-6c) and regulate STAT-6 signaling. The exact mechanism by which 
STAT-6 activates transcription is still being determined. Adapted from [111]. 
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have antagonist effects, such as during the differentiation of naive CD4+ T cells into TH1 
and T H2 subsets. 
1.4.3. Transforming Growth Factor-Beta (TGF-fJ) 
TGF -~ was first identified and named for its ability to stimulate the proliferation 
and transformation of mesenchymal cells [140]. It is now known as a ubiquitous and 
essential regulator of cellular and physiological processes including proliferation, 
differentiation, migration, cell survival, angiogenesis, and immunosurveillance (for 
review see [141]). 
Three TGF-~ isoforms are expressed in mammals (TGF-~1,-~2, -~3) and each is 
encoded by a unique gene and expressed in a tissue-specific and developmentally 
regulated fashion. Of these, TGF-~1 is the most abundant and universally expressed 
isoform [141]. 
TGF -~ is secreted into the extracellular matrix as a latent protein complex bound 
to a latency-associated-protein and one of four isoforms of the TGF-~ binding protein. 
Activation of TGF-~ is required for biological activity, which occurs through poorly 
understood mechanisms, likely involving proteolytic processing of associated proteins 
and release of the TGF-~ ligand. Once activated, TGF-~ regulates cellular processes by 
binding to three high-affinity surface receptors: T~RI, T~RII, and T~RIII [142]. Where 
expressed, T~RIII is the most abundant TGF-~ receptor and classically functions by 
binding TGF-~ ligand and transferring it to signaling receptors, T~RI and T~RII [143]. In 
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this manner, recent reports suggest that TPRIII plays an important role in regulating 
TGF-P signaling [144]. 
TPRI and TPRII contain serine I threonine protein kinases in their intracellular 
domains, and TPRI initiates intracellular signaling by phosphorylating the Smad family 
of proteins (depicted in Figure 1.7). The importance of this pathway in cancer 
development is underscored by the observation that Smad2 and Smad4 are deleted or 
mutated in some cancer cell lines and tumors [145-147]. Aside from the Smad-dependent 
signaling pathway, Smad-independent signaling may also occur through MAPK signaling 
pathways [148, 149], Rho guanosine triphophatases [150], PI3K I AKT [151], and protein 
phosphate 2A [152]. The precise molecular mechanism by which TGF-P signals through 
these alternative pathways has not been established. 
Reports indicate that TGF-P markedly attenuates IFN-y-induced CIITA 
expression by inhibition of MHC2TA transcription in various cell types, including 
astroglioma, fibrosarcoma, epithelial, monocyte, synovial, microglial, and B cells [84, 87, 
88, 101, 153]. This inhibition occurs through suppression of both CIITA pili and piV 
[101, 153]. Surprisingly however, TGF-P does not affect IFN-y-induced phosphorylation 
of JAK1, JAK2 or STAT-1, nor does it interfere with binding of STAT-1, USF-1 or IRF-
1 to piV of the MHC2TA gene [86, 154]. Thus, TGFP inhibits IFN-y-induced Class II 
expression without affecting the individual components of the IFN-y signaling pathway. 
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Figure 1.7. Transforming growth factor-P signaling through the SMAD pathway. TGF-P 
binds TPRII directly or through TPRIII, inducing association of TPRII with TpRI. The 
TPRII kinase is constitutively active and activates TPRI by phosphorylation of serine and 
threonine residues [155], which propagates the signal by phosphorylation of Smad2 or 
Smad3. Phosphorylated Smad2 or Smad3 associate with Smad4, a common partner for all 
receptor activated Smads, forming a heteromeric complex that translocates to the nucleus 
and regulates gene transcription in a cell-specific manner [156, 157]. Smad6 and Smad7 
are inhibitory Smads that block TGF-P signaling by preventing the activation of Smad2 
or Smad3 by TPRI [158]. Adapted from [141] and [159]. 
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1.5. Estrogen and Estrogen Receptors 
Approximately 60% of breast cancer patients have hormone-dependent breast 
cancer, which expresses estrogen receptors and requires estrogen for growth [ 160]. 
However, the proportion of patients with hormone-sensitive tumors is higher among 
postmenopausal women [160]. Studies illustrate that breast cancer development and 
progression are directly influenced by steroid hormones, particularly estrogen, via its 
interaction with specific target cell promoters (reviewed by [161]). Studies also indicate 
that prolonged stimulation of breast ductal epithelium by estrogen contributes to an 
increase in cell proliferation and an increase in cell survival (reviewed by [162]). 
Furthermore, the risk of developing breast cancer is enhanced in individuals experiencing 
early menarche or late menopause as these increase the exposure time to endogenous 
ovarian hormones [163]. 
Estradiol, the most biologically active estrogen, is synthesized primarily from 
androgens by the enzyme aromatase in the ovaries of premenopausal woman [ 164, 165]. 
This enzyme is also present in various tissues, including adipose tissue, skin, brain, bone, 
and placenta. It has been demonstrated that despite low serum levels, certain breast 
carcinomas display high concentrations of estrogen [166, 167] due to local synthesis and 
increased expression of intratumoral aromatase [168, 169]. This suggests that the 
estrogen responsible for breast cancer development may not be circulating estrogen, but 
rather that produced locally. 
Estrogen typically exerts its effects through the estrogen receptor (ER) [170]. Free 
estrogens passively diffuse across the cell membrane and are preferentially retained in 
23 
target cells through formation of a high affinity complex with nuclear ERs. ER variant 
proteins lacking the nuclear localization signals are also known to occur, causing them to 
remain in the cytoplasm or cell membrane [ 1 71-1 73]. 
Two forms of the human ER gene exist, the first identified was ERa [174], and 
the second was ERI3 [175]. ERI3 was originally cloned from the rat prostate [176], but has 
since been identified in mice [ 1 77], and in the human thymus, spleen, ovaries, and testis 
[175]. Low levels are also detected in normal and carcinoma human breast tissue [178, 
179]. However, the function and potential role of ERI3 in cancer progression is presently 
unclear. 
In the absence of ligand, ER exists as a monomer bound by heat shock proteins 
(HSPs) [180, 181]. Ligand binding activates the receptor, dissociating the HSPs, causing 
a conformational change in the receptor, phosphorylation of distinct serine I threonine 
residues [182], and nuclear translocation. Activated receptors dimerize, interact with a 
variety of coregulatory molecules forming a receptor complex that acts as a transcription 
factor by binding to estrogen-responsive elements (ERE) located in the promoter region 
of target genes. The classical ERE is a palindromic sequence composed of two inverted 
hexanucleotide repeats [180]. Ligand-bound ERa and/or ERI3 may bind to EREs as 
homo- or heterodimers to alter gene transcription [180, 181] (Figure 1.8A). Coactivators 
and corepressors may modulate this classical pathway of ER transcriptional activation by 
interacting with basal transcription machinery to either help unwind or repress the 
chromatin structure [183-189]. 
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In contrast to ERI3, ERa has been extensively studied. Protein levels of ERa and 
the ER-regulated progesterone receptor are elevated in premalignant and malignant breast 
lesions as opposed to normal tissue, and both receptors currently serve as predictive and 
prognostic factors in the clinical management of breast cancer [190]. Consequently, 
inhibition of ERa has become one of the major strategies for the prevention and 
treatment of breast cancer [191, 192]. ERa expression in breast tumor is considered a 
good prognostic indicator, identifying patients with a lower risk of relapse, better overall 
survival [193], and more likely to respond to antiestrogen therapy. 
The ERa protein is highly homologous between species, and several important 
domains (A-F) have been identified [194] (Figure 1.8B). The ligand-binding domain 
resides in the carboxy-terminal (region E) and contains an estrogen-inducible 
transcription-activating function, known as AF-2 [195, 196]. A second transcription-
activating function (AF-1) is localized in the amino-terminal (AlB region) and is believed 
to be constitutively active in a cell- and promoter-specific manner [197]. Between AF-
1and AF-2 is the centrally located DNA-binding domain (DBD) (region C) and hinge 
region (region D). The DBD interacts with EREs [170, 192]. The flexible hinge region 
allows rotation of the DBD to accommodate bindings to DNA response elements and 
interaction with HSPs. The D region also contains a putative nuclear localization 
sequence [198]. 
25 
A) 
B) 
1 
Estradiol 
• • 
• 
• 
AF1 
DBD 
Cytoplasm 
Nucleus 
ER-regulated gene 
~mRNA 
LBO 
AF2a AF2 595 
Figure 1.8. Estrogen receptor structure and signaling pathway. A) Estrogen signaling 
through the estrogen receptor. B) Functional domains of ERa. AFl, AF2, and AF2a 
function in transcriptional activation, DBD functions in DNA-binding, and LBD 
functions in ligand-binding. Adapted from [162]. 
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1. 5.1. Estrogen and MHC Class II Expression 
17P-estradiol has been shown to have immunomodulatory effects on MHC class 
II expression. In the early 1990s, investigators showed estrogen-mediated down-
regulation of MHC class II expression on breast carcinoma epithelial cells and leukocytes 
[199, 200]. Furthermore, using different animal models it has repeatedly been shown that 
estrogen treatment of rodents receiving tissue transplants leads to better graft survival, 
accompanied by a significant reduction or complete abolishment of MHC class II on the 
allograft vasculature [201-203]. 
More recently, ovariectomy has been shown to up-regulate IFN-y-induced CIITA 
expression on macrophages [204]. ER-deficient mice also demonstrate increased 
stimulation of CD4+ T cells by splenic macrophages [205], suggesting that estrogen 
suppresses MHC class II expression. In addition, 17p-estradiol has been shown to down-
regulate constitutive and IFN-y-induced class II expression on astrocytes, fibrosarcoma 
cells, macrophages, and brain endothelial cells [206]. 1 7P-estradiol stimulation also 
results in ERa association with the MHC class II promoter [207]. These inhibitory effects 
are not mediated by changes in IFN-y signaling components, or CIITA mRNA, or CIITA 
protein levels, but by inhibition of chromatin remodeling and recruitment of transcription 
factors to the class II promoter [206]. 
Reports indicate that association of CIITA with the class II MHC promoter 
correlates with H3 and H4 histone acetylation, and that histone acetylation is necessary 
for MHA class II transcription [56, 208]. 17P-estradiol attenuates H3 and H4 histone 
acetylation, as well as CBP recruitment to the class II promoter, thereby inhibiting 
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histone acetylation and ultimately inhibiting the chromatin conformation involved in 
MHC gene transcription [206]. 
Through the use of multiple pharmacological inhibitors and blocking of the 
classical estrogen-signaling pathway, Adamski and Beneveniste [207] demonstrated that 
estradiol-mediated inhibition ofMHC class II occurs through activation of a nonclassical 
signaling pathway, the c-Jun N-terminal kinase (JNK) pathway. Of further interest is the 
fact that the JNK signaling pathway is primarily activated by cytokines and cellular stress 
[209]. Moreover, increasing evidence suggests that other pathways, aside form the JNK 
pathway, can also phosphorylate and/or activate the ER. These pathways include PI3K I 
AKT, ERKl/2 (extracellular-signal-regulated kinase) MAPK, p38 MAPK, and SMAD 
signaling pathways, which may also become activated by cytokines. 
1. 6. Hypothesis 
Previous studies in our laboratory and by others showed that HLA class II 
expression on synovial fibroblasts and carcinoma cell lines is modulated by treatment 
with IFN-y [210-213]. Furthermore, generic HLA class II expression induced by IFN-y is 
further up-regulated by cytokines such as IL-4 on human melanomas, renal cell 
carcinomas, and breast carcinomas [134-136], or down-regulated by cytokines such as 
TGF-~ on astrocytes, monocytes, microglial cells, fibrosarcoma cells, epithelial cells, 
melanoma cells, and synovial cells [84, 87, 88]. More recently, Sharon A. Oldford in our 
laboratory showed that HLA-DR allotypic expression on breast carcinoma in situ is 
significantly associated with reduced ERa, reduced PgR, and reduced diagnosis age, 
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suggesting estrogen may be implicated (S.O., unpublished data). Her study also suggests 
that allotypic expression is influenced by the in situ cytokine milieu, particularly IFN-y, 
IL-4 and TGF-p. Based on these studies, we hypothesized that ERa, 17P-estradiol, and 
cytokines IFN-y, IL-4 and TGF-P 1 differentially modulate allotypic HLA-DR expression 
on breast carcinoma cell lines. 
1. 7. Objectives 
1) To examine the effects of 17p-estradiol on constitutive and IFN-y-induced HLA-
DR expression on ER+ and ER- breast cancer cell lines. 
2) To investigate the individual and combined effects of IFN-y, IL-4, and TGF-P1 
treatments on HLA-DR allelic expression on breast cancer cell lines and correlate 
these results with ERa classification. 
As this study evolved, we found that TGF -P 1 treatment mediated differential 
effects on HLA-DR expression on breast cancer cell lines. Therefore, we extended the 
study to include a third objective: 
3) To examine breast cancer cell lines for differences in TGF-P1 sensitivity and 
particular components of the Smad signaling pathway to explain cell line specific effects 
ofTGF-Pl on HLA-DR expression. 
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Chapter 2: Materials and Methods 
2.1. Cell cultures 
Breast carcinoma cell lines BT-20, BT-474, MCF-7, MDA MB 157, MDA MB-
231, MDA MB 468, SKBR3, and T47D (Table 2.1) were generous gifts from Dr. Shou-
Ching Tang and Dr. Alan Pater (Memorial University ofNewfoundland, St. John's, NL). 
These cell lines were maintained as adherent cultures in Iscove's Modified Dulbecco's 
Medium (IMDM) (Invitrogen, Burlington, ON) supplemented with 10% heat-inactivated 
FCS (fetal calf serum) (Invitrogen), 2 mM L-glutamine (Invitrogen), 100 units/ml 
penicillin G sodium (Invitrogen), 100 J.lg/ml streptomycin sulfate (Invitrogen), and 0.25 
)lg/ml amphotericin B as Fungizone® in 0.85% saline (Invitrogen). Cultures were 
incubated at 37°C in a 7% C02 atmosphere in 25 cm2 cell culture flasks (Coming 
Incorporated, Coming NY). The medium was refreshed every 3 days. 
Non-adherent B cell lines COX, VAVY, SAVC, MT14B, CB6B, SLE-005, 
MGAR, and PLH (Table 2.2) were used as positive controls throughout this study. B 
cells were grown as suspension cultures in 25 cm2 cell culture flasks and maintained at 
3.0 x105 cells/ml in IMDM under similar culture conditions as above. 
2. 2. Estrogen-Depleted Medium 
Standard medium components often contain steroidal estrogens within FCS and 
non-steroidal estrogen-like isomers in the form of the standard pH indicator phenol red 
[214, 215]. Phenol red has been shown to simulate estrogenic activity through 
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Table 2.1. Description of human breast carcinoma cell lines used in this study 
Breast Cancer Cell Line ATCCa Type of Cancer a HLA-DR type b Identification 
BT-20 HTB-19 Adenocarcinoma DRf31 *0404, DRf34, 
DRf31 *1301, DRf33*01 
BT-474 HTB-20 Invasive Ductal DRf31 *0401, DRf34, Carcinoma DRf31 *15, DRf35 
MCF-7 HTB-22 Adenocarcinoma DRf31 *03, DRf33*0202, 
DRf31 * 15, DRf35 
MDAMB 157 HTB-24 Medullary Carcinoma DRf31 *0401, DRf34, 
DRf31 *15, DRf35 
MDAMB 231 HTB-26 Adenocarcinoma DRf31 *07, DRf34, 
DRf31 *13, DRf33*0202 
MDAMB468 HTB-132 Adenocarcinoma DRf31 *0102, 
DRf31 *07, DRf34 
SKBR3 HTB-30 Adenocarcinoma DRf31 *07, DRf34, 
DRf31 *1302, DRf33*0302 
T47D HTB-133 Ductal Carcinoma DRf31 *0102 
a American Type Culture Collection (Manassas, VA) 
bPreviously determined by A.D. Edgecombe 2002 [210] by DNA typing using commercially available kits. 
c Lacroix and Leclercq 2004 [216]. 
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ERa. PgR 
status c status c 
- -
+ + 
+ + 
-
-
- -
- -
- -
+ + 
Table 2.2. B cell controls used in this study 
B Cell Line IHW a Identification HLA-DR Type 
cox IHW9022 DRP1 *0301, DRP3*0101 
VAVY IHW 9023 DRP1 *0301, DRP3*0101 
SAVC IHW9034 DRP1 *0401, DRP4*0101 
MT14B IHW 9098 DRP1 *0404, DRP4*0101 
CB6B IHW9060 DRP1 *1301, DRP3*0202 
SLE-005 IHW9059 DRP1 *13, DRP3*0301 
MGAR IHW 9014 DRP1 *1501, DRP5*0101 
PLH IHW9047 DRP1 *0701, DRP4*0101 
a , th ... 11 InternatiOnal Histocompatibility Workshop 
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competitive binding to the estrogen receptor, stimulation of the growth rate of human 
breast cancer (MCF -7) cells, and elevation of progesterone receptor levels in these cells 
(217]. For some experiments where it was necessary to exclude exogenous steroids, 
adherent breast cancer cell lines were cultured in Phenol Red-free IMDM medium 
supplemented with 10% inactivated charcoal-dextran treated FCS (HyClone, Logan, UT), 
for a maximum of 5 days before assays. Estrogen-depleted (E2-depleted) medium was 
further supplemented with L-glutamine, penicillin G sodium, streptomycin sulfate, and 
amphotericin B as before. Cell lines could not be maintained in such medium as studies 
indicate that ER+ breast cancer cells lose hormone responsiveness if maintained for 
prolonged periods in an estrogen-free environment [218]. 
2. 3. Harvesting of Breast Cancer Cell Lines 
Cultures were harvested once 80-1 00% confluent, as determined by phase 
contrast microscopy. Harvesting was accomplished by aspiration of medium from culture 
flasks and incubation with 0.25% trypsin (Invitrogen) diluted in phosphate buffered 
saline (PBS) for a maximum of 5 minutes at 3 7°C or until cells were no longer adherent. 
An equivalent volume of medium was added to quench trypsin activity before cell 
suspensions were transferred to 15 ml centrifuge tubes. Cells were centrifuged at 290 x g 
for 7 minutes at 7°C, after which supernatant was decanted, and pellet re-suspended in 5 
mls media. Cells were then washed as before, re-suspended in 5 ml medium, and counted 
using a hemocytometer and phase contrast microscopy. A volume containing 3.0 x 105 
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cells was re-plated into 25 cm2 cell culture flasks in a final volume of 7 ml medium to 
maintain cultures. Medium was refreshed every 3 days. 
B cells were maintained in standard medium at 3.0 x 105 cells/mi. Cells were 
removed and replaced with fresh medium every 3 days. 
2. 4. Cytokine and Hormone Treatment of Breast Cancer Cell Lines 
To determine the effects of cytokine and hormone treatments on HLA-DR 
expression, BCCL were treated with either 100 units/ml of human recombinant IFN-y 
(BD Pharmingen), or 500 units/ml of human recombinant IL-4 (BD Pharmingen), or 10 
ng/ml of human ;ecombinant TGF -P 1 (Chemicon International), or 10-9M 17p-estradiol 
(E-2257, Sigma), or combinations of the above treatments. Twenty-four hours prior to 
cytokine treatment, cell lines were subcultured as described above in 25 cm2 tissue 
culture flasks at 4.0 x 105 in 7 ml of medium or in 6 well plates at 1.5 x 105 in 2 ml of 
medium. 
At the time of treatment, standard medium was aspirated from cells and replaced 
with either standard medium or E2-depleted medium containing the respective cytokine(s) 
and/or hormone of interest. To identify constitutive gene expression, one flask/well 
received medium without addition of cytokine or hormone. Cell cultures were incubated 
for 96 hours (previously determined to be the optimal incubation period by A. 
Edgecombe [210]), after which HLA-DR expression was assessed by either flow 
cytometry or CELISA. 
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2. 5. Flow Cytometry 
2.5.1. Cell Surface Protein Expression 
Flow cytometry was used to detect cell surface expression of HLA-DR antigens. 
Adherent cell cultures were harvested using 0.25% trypsin as previously described and 
aliquots of non-adherent B cell lines were used as positive controls (Table 2.4). Cells 
were washed in medium, re-suspended in an appropriate volume ofF ACS buffer to give 
3.0 x 106 cells/ml, and 50 J.ll of cell suspension was added to each 5 ml polystyrene 
round-bottom tube (Falcon, Becton Dickson Bioscience). F ACS buffer contained 0.2% 
fetal bovine serum (Invitrogen) and 0.02% sodium azide (BDH Chemicals, Poole, 
England) in PBS. Twenty-five microlitres of primary mAb (monoclonal antibody), 
diluted to a predetermined concentration (Table 2.3) in F ACS buffer, was also added to 
each tube and mixture was incubated in the dark for 30 minutes at 4°C. 
Following this incubation, cells were washed twice with 2 ml F ACS buffer and 
centrifuged at 453 x g for 5 minutes. After the second wash, supernatants were decanted 
and tubes were blotted on gauze before 25 J.ll of secondary antibody, goat anti-mouse 
immunoglobulin-G labeled with phycoerythrin flurochrome (Jackson ImmunoResearch) 
diluted 1140 in F ACS buffer, was added to each tube. Following another 30 minute 
incubation in the dark at 4°C, cells were washed twice in F ACS buffer as before, and 
finally, 150 J.!ll% paraformaldehyde in PBS was added to each tube. Cells were stored in 
the dark at 4°C until analysis was done using a FACSCalibur flow cytometer (Becton-
Dickinson, Franklin Lakes, NJ) and CellquestPro Software (Becton-Dickinson). 
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Table 2.3. Primary antibodies used to detect expression ofHLA-DR allelic products by flow cytometry and CELISA. 
Antibody Isotype Specificity Concentration Reference/Source 
Flow CELIS A 
L243 Mouse panHLA-DR 2.4 f.!g/ml 2.4 f.!g/ml Lampson and Levy 1980 [219] 
(Supernatant) IgG2a 
NFLD.D1 Mouse panDR4 39 f.!g/ml 50 f..lg/ml Drover et al. 1994 [220] 
(Purified) IgG1 
NFLD.D7 Mouse DR4, DR15, DR16, DR~3 Undiluted Undiluted Drover et al. 1994 [220] 
(Supernatant) IgG1 
NFLD.DIO Mouse DR1, DR4 except ~1 *0402, DR9, 2.5 f.!g/ml 1.0 f..lg/ml Drover et al. 1994 [220] 
(Purified) IgG1 DR10, DR14, DR15, DR~5*0201 
NFLD.M1 Mouse DR4, DRS, DR52 Undiluted Undiluted Drover et al. 1985 [221], 
(Supernatant) IgG1 Fu et al. 1995 [222] 
UK8.1 Mouse DR3, DR11, DR13, DR14 except 1/200 NT Bodmer et al. 1985 [223], 
(Supernatant) IgG2b ~1*1404 11th International Histocompatibility 
Workshop 
TAL8.1 Mouse DR3, DR6, DR11, DR13 50 f.!g/ml 50 f..lg/ml Research Diagnostics Inc. (Flanders, 
IgG2b NJ) 
7.3.19.1 Mouse DR3,DR~3 1/100 1/25000 Koning et al. 1984 [224], 
(Supernatant) IgG2b 11th International Histocompatibility 
Workshop 
SFR16.DR7G Rat panDR7 1125 1/20 Radka et al. 1984 [225], 
(Supernatant) IgG2b 11th International Histocompatibility 
Workshop 
359-13F10 Mouse panDR4 Undiluted 1/2 Radka et al. 1984 [225] 
(Supernatant) IgG1 
NT: Not Tested. 
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Table 2.4. Binding a ofHLA-DR specific monoclonal antibodies to cell surface HLA-DR on B cell lines. 
B Cell Line 
Antibody cox VAVY SAVC MT14B CB6B SLE-005 MGAR PLH 
P1*0301 P1*0301 P1*0401 P1*0404 P1*1301 p1 *13 P1*1501 P1*0701 
P3*0101 P3*0101 P4*0101 P4*0101 p3*0202 P5*0101 P4*0101 
L243 c 5633.1 1090.0 6824.5 3387.2 1480.9 3254.8 3722.1 2245.7 
bAll DR 
NFLD.D1 - - 3026.6 1380.1 - - - -
DR4 
NFLD.D7 a+ - 6293.1 - d+ - 2791.0 -
DR4, DR15, DRP3 
NFLD.D10 - - 6242.5 4489.3 - - 2661.5 -
DR1, DR4, R15 
NFLD.M1 d+ - 1407.5 a+ 1588.1 - 187.4 -
DR4,DRP3 
UK8.1 1570.5 - - - - - - -
DR3,DR13 
TAL8.1 - 30.4 - - - 27.8 - -
DR3,DR13 
7.3.19.1 8527.4 752.2 - - 1745.5 - - -
DR3,DRP3 
SFR16.DR7G - - - - - - 1370.7 
DR7 
359-13F10 - - 3262.6 2876.6 - - -
DR4 
a Antibody bmdmg was determined by flow cytometry. Data are the average of at least two separate experiments. 
b HLA-DR type recognized by the antibody. Antibodies may recognize more HLA-DR types than listed (see Table 2.3). 
c Mean fluorescence intensity with the background subtracted. 
dBindings previously reported by A. E. Edgecombe [210] through flow cytometry analysis. 
37 
2. 5. 2. Interpretation of Flow Cytometry Results 
HLA-DR expression was determined as: 
Mean Fluorescence Intensity (MFI) Test - MFI Negative control 
or as the degree ofHLA-DR expression determined as: 
MFI Test 
MFI Negative Control 
Values twice the backgrounds were considered positive. When two or more experiments 
were conducted, data were averaged and standard deviations were calculated. 
2. 6. Cell Enzyme Linked Immunosorbant Assay (CELISA) 
2.6.1. Cell Surface Protein Expression 
In addition to flow cytometry, CELISA was preformed to determine cell surface 
HLA-DR antigen expression. Adherent cell cultures were harvested using 0.25% trypsin 
as previously described and non-adherent B cell lines were used as positive controls. 
Appropriate volumes of cells were removed and centrifuged at 290 x g for 7 minutes at 
7°C, after which cells were re-suspended in 2 ml 0.5% bovine serum albumin (BSA) 
(Sigma Aldrich) in PBS, and centrifuged at 453 x g for 6 minutes at 7°C. Supernatants 
were decanted, and cells re-suspended in appropriate volume of 0.5% BSA to give 2.5 x 
106 cells/mi. Ten microliters of cell suspension and 10 ~-tl primary mAb, diluted to a 
predetermined concentration using 0.5% BSA (Table 2.3), was then added to each well of 
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polyvinyl chloride treated 96-well U-bottom flexible plates (Becton Dickinson, Franklin 
Lakes, NJ) before 1 hour incubation at room temperature. 
Cells were then washed three times with 100 ).d of 0.5% BSA and centrifuged at 
387 x g for 6 minutes at 7°C. Following each wash, supernatants were decanted and 
plates blotted on paper towel. After the third wash, 50 )..1.1 of secondary antibody, goat 
anti-mouse immunoglobulin-G specific for Fey chains and labeled with horseradish 
peroxidase (HRP) (Jackson ImmunoResearch), diluted 1/5000 in 2% BSA, was added to 
each well and incubated for I hour at room temperature. At this time, 75 )ll of IX poly-L-
lysine (PLL) (Sigma) in PBS was added to each well of the reading plates, PRO-BIND 
polystyrene flat bottom plates (Becton Dickinson). 
Following this incubation, cells were washed three times with 0.5% BSA as 
before, and PLL was removed from the reading plates. One hundred microliters of IX 
PBS was then added to each well of the flex plates, and cells were transferred from a flex 
plate to a reading plate. Once transferred, cells were centrifuged at 248 x g for 6 min at 
7°C, supernatants decanted, and cells incubated in the dark for 30 minutes at room 
temperature with 50 )..1.1 of substrate. The substrate was prepared using 4.9 ml O.lM Citric 
Acid, 5.I ml 0.2M Phosphate, 10 ml dH20, 8 mg orthrophenylenediamine (Sigma), and 8 
)ll 30% hydrogen peroxide (BDH). The reaction was stopped by adding 50 )..1.1 of 2.5 N 
hydrogen sulphate in dH20 per well and the plates were read at 490 nm using a 3550 
BioRad Microplate Reader (Bio-Rad, Richmond, CA) and Microman software (BioRad). 
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2. 6. 2. Interpretation of CELISA results 
HLA-DR expression was determined as: 
Optical Density (OD) Test- OD Background 
or as a ratio of: 
ODTest 
0 D background 
Values less than 2 were considered negative. CELISA assays were performed in triplicate 
wells, allowing averages and standard deviations to be determined within each assay. 
When experiments were preformed more than once, data were averaged and standard 
deviations were determined between experiments. Student two-tailed t-tests were used to 
determine differences in HLA-DR expression. Differences were considered significant if 
p < 0.05. 
2. 7. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
2. 7.1. RNA extraction 
Culture supernatant was aspirated from adherent breast cancer cell lines which 
had been cultured for 96 hours in 25 cm2 tissue culture flasks containing either untreated 
standard media or untreated estrogen-depleted medium, and cells were washed once with 
5 ml PBS. PBS was then aspirated and cells detached from culture flasks by addition of 1 
ml TRIZOL reagent (Invitrogen). Once detached, cells were transferred to a 1.5 ml 
Eppendorf tube and incubated for 4 minutes at room temperature to allow cell lysis. Cells 
40 
were then centrifuged at 16,000 x g for 10 min at room temperature. Following 
centrifugation, supernatant was transferred to a fresh 1.5 ml Eppendorf tube, and 0.2 ml 
chloroform (Sigma) added and shaken vigorously for 30 seconds. Mixtures were then 
centrifuged at 16,000 x g for 15 minutes at 4°C. After this incubation, the clear aqueous 
phase containing the RNA was removed and an equivalent volume of isopropanol 
(Sigma) was added. RNA was precipitated overnight at -20 °C. 
RNA was centrifuged at 16,000 x g for 15 minutes at 4°C, after which the 
supernatant was decanted and the pellet washed with 1 ml 75% ethanol dissolved in 
DEPC (diethyl procarbonate) water. Following centrifugation at 13,714 x g for 5 minutes 
at room temperature, the supernatant was removed, the pellet was allowed to air dry for 5 
minutes, and RNA was re-suspended in 20-50 !-!1 DEPC water depending on pellet size. 
RNA was quantified using UV spectrophotometry. A A26o/A2soratio of approximately 1.8 
was used to estimate RNA purity. The following calculation was used to measure RNA 
concentration: 
(A26o- A32o) x ( 40 ~-Lg/ml) x (reciprocal of dilution) = concentration RNA (1-!g/ml) 
2. 7.2. DNase Treatment of RNA 
All RNA extracts were subjected to DNase treatment (Ambion, Austin, TX) to 
remove any DNA contamination. 0.1% volume of DNA-free 1 OX DNase Buffer and 1 !-!1 
of DNA-free DNase was added to RNA samples, mixed gently, and incubated in a 37°C 
water bath for 30 minutes. After incubation, 0.1% total volume of DNase Inactivation 
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Reagent was added to the RNA preparation and incubated for 2 minutes at room 
temperature. Samples were then centrifuged at 13,714 x g for 1 min at room temperature 
to pellet the DNase Inactivation Reagent. Following centrifugation, supernatants were 
removed and RNA was transferred to a 1.5 ml Eppendorf tube. To prevent ribonuclease 
activity, 0.5 j..tl ofRNasine inhibitor (Promega, Madison, WI) was added to RNA samples 
before storage at -70°C. 
2. 7. 3. eDNA synthesis 
eDNA was synthesized from DNase treated RNA samples using a First Strand 
eDNA Synthesis Kit (Arnersham Pharmacia Biotech UK limited, Little Chaifont 
Buckinghamshire, England). 1 j.lg of RNA was diluted in a total volume of 8 j..tl DEPC 
water in 0.2 ml thin walled micro tubes (Gordon Technologies Inc., Mississauga, ON) 
and incubated at 65°C for 10 minutes to denature the RNA. Following this incubation, 
samples were quickly placed on ice. PCR reaction mixture consisting of 5 j..tl Bulk First-
Strand Reaction Mix, 1 j..tl Not I-d (T)1 8 primer diluted 1125 in DEPC water, and 1 j..tl of 
DTT ( dithiothreitol) solution were added to each tube of denatured RNA. Samples were 
then incubated at 37°C for 1 hour, and 70°C for 10 minute in a Biometra T-Gradient 
(Montreal Biotech Inc., Kirkland, PQ). eDNA was stored at -70°C until needed. 
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2. 7.4. RT-PCR primers 
Primers used to analyze mRNA transcription of IFN-y, IL-4, and TGF-P were 
currently available in the laboratory, and had been previously synthesized by Invitrogen 
from sequences acquired from published references (Table 2.5). P-actin primers were 
kind gifts from Dr. Laura Gillespie and Dr. Gary Paterno (Memorial University of 
Newfoundland, St. John's, NL). ERa and GAPDH (glyceraldehyde phosphate 
dehydrogenase) primer sequences were acquired from published references and entered 
into the AmplifY program (Engels, 1993) to assess primer affinity to the gene of interest, 
as well as product size and possible primer dimer formations. ERa and GAPDH primer 
sequences were also analyzed using OligoTech Analysis software (Wilsonville, OR) to 
determine G+C content and melting temperature. Selection of ERa and GAPDH primers 
were based on the above analysis and were synthesized by Invitrogen. 
2. 7. 5. PCR Amplification 
For each reaction, 1 J.tl of eDNA or RNA was added to one well of a 96 well 0.2 
ml thin walled polypropylene PCR microplate (BioCan Scientific Inc., Gordon 
Technologies) in combination with a PCR reaction mix consisting of PCR buffer 
(Invitrogen) containing 200 mM Tris-HCl buffer (pH 8.4), 500 mM KCl, 10 mM dNTP 
(deoxyribonucleotide triphosphates) (Invitrogen), 50 mM MgClz (Invitrogen), Taq DNA 
polymerase (Invitrogen), 1 J.tl of both forward and reverse primers, and DNA-free RNA-
free water in a final volume of 50 J.tl. Concentration of primers, and quantity ofMgClz, 
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Table 2.5. Primers used in this study to detect cytokine and ERa transcription by RT-PCR. 
Primer Sequence (5'-3') Size Reference/Source 
ERa sense GCTGCAAGGCCTTCTTCAA 550 Jazaeri et al. 1999 [226] 
ERa antisense TCATCAGGATCTCTAGCCAG 
IFN-y sense AGTTATATCTTGGCTTTTCA 356 Kotake et al. 1996 [227] 
IFN-y antisense ACCGAATAATTAGTCAGCTT 
IL-4 sense CCTCTGTTCTTCCTGCTAGCATGTGCC 373 Kotake et al. 1996 [227] 
IL-4 antisense CCAACGTACTCTGGTTGGCTTCCTTCA 
TGF -P 1 sense GCCCTGGACACCAACTATTGC 161 Marrogi et al. 1997 [228] 
TGF -P 1 antisense AGGCTCCAAATGTAGGGGCAGG 
pactin sense ATCTGGCACCACACCTTCTACAATGAGCTGCG 837 Paterno et al. 1998 [229] 
pactin antisense CGTCATACTCCTGCTTGCTGATCCACATCTGC 
GAPDH sense TGACCTTGCCCACAGCCTTG 443 Gottwald et al. 2001 [230] 
GAPDH antisense CATCACCATCTTCCAGGAGCG 
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Taq polymerase, and DNA-free RNA-free water varied depending of the gene of interest 
(Table 2.6). RNA samples were run simultaneously to ensure that RNA used in eDNA 
synthesis did not contain DNA contamination. PCR microplates were covered with 
domed caps, placed in a Biomed T -Gradient, and eDNA amplified using the respective 
35-cycle PCR protocol (Table 2.7). 
2. 7. 6. Electrophoresis of PCR Products 
Five microliters of each PCR reaction was mixed with 1 Ill of loading buffer and 
loaded onto a 1.5% agarose gel. Gels were composed of 0.6 g agarose (Invitrogen) 
dissolved in 40 ml 0.5X TBE buffer containing 0.5 llg/ml ethidium bromide. To access 
product size, gels were also loaded with 3 Ill of 100 bp DNA ladder (Invitrogen) mixed 
with loading buffer. PCR products were electrophoresed at 120V for 20-30 minutes in a 
Mini Sub DNA Cell electrophoresis chamber (Bio-Rad) containing 0.5X TBE buffer. 
Once separated, PCR products were visualized and photographed under UV light using 
Eagle Eye II Still Video system (Stratagene, La Jolla, CA), or ChemiGenius bio-imaging 
system (SYNGENE, Frederick, MD). 
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Table 2.6. PCR reaction mixtures used in eDNA amplification. 
PCRmix P-actin GAPDH IL-2 IL-4 TGFp IFN-y ERa 
(20 pM) (20 pM) (10 pM) (10 pM) (10 pM) (10 pM) (20 pM) 
(f.ll) (f.ll) (f.ll) (f.ll) (I-ll) (f.ll) (f.ll) 
lOX Buffer 5 5 5 5 5 5 5 
DNTP 1 1 1 1 1 1 1 
MgCh 1.5 2 2 1.5 2 2 2 
Primer+ 1 1 1 1 1 1 1 
Primer- 1 1 1 1 1 1 1 
TaqDNA 0.2 0.2 0.25 0.25 0.25 0.25 0.25 
polymerase 
H20 39.3 38.8 39 39.3 39 39 38.75 
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Table 2.7. PCR cycling conditions used to amplify gene transcription 
Primer PCR conditions 
IFN-y 94°C for 1 min, 55°C for 1 min, 72°C for 1 min for 35 cycles. 
IL-4 94°C for 1 min, 65°C for 1 min, 72°C for 1 min for 35 cycles. Final 
extension at 72°C for 5 min. 
TGF-f31 94°C for 1 min, 65°C for 1 min, 72°C for 1 min for 35 cycles. Final 
extension at 72°C for 5 min 
ERa 95°C for 2 min, 95°C for 2 min, 51 °C for 45 sec, 72°C for 45 sec for 35 
cycles. Final extension at 72°C for 10 min 
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2. 7. 7. Interpretation of RT-PCR Results 
The density of gene transcription was normalized to GAPDH according to the 
following calculation: 
Test ( cytokine or ERa) - water ( cytokine or ERa) 
Value X 100% 
Test (GAPDH) -Water (GAPDH) 
2. 8. Western Blots 
2.8.1. Preparation ofCell Lysates 
Western blots were used to assess breast cancer cell lines responsive to TGF -P 1 
stimulation. Adherent breast cancer cell lines were harvested using trypsin, plated in E2-
depleted medium at a density of 1.5 x 105 cells/well in 6 well plates and placed at 37°C in 
a 7% C02 incubator overnight. Medium was then replaced with fresh E2-depleted 
medium and cells were incubated for 96 hours. Following this incubation, ligand 
stimulations were performed by addition of 5 ng/ml TGF-P 1 (Chemicon) for 1 hour. 
Control wells were left untreated. Cells were placed on ice and washed twice with 2 ml 
cold PBS. After complete removal of PBS, cells were incubated on ice for 2 minutes with 
75 J.!l cold Ripa lysis buffer (0.5 ml lOX PBS, 0.5 ml Triton X 100, 0.5 ml lOX Roche 
complete EDTA-free (ethylenediaminetetraacetic acid) protease inhibitor cocktail 
(Roche, Mississauga, ON), 250 J.!l 1M p-glycerolphosphate, 250 J.!l 1M Tris pH 7.4, 250 
J.!l 10% deoxycholate, 50 J.!l 0.5M EDTA pH 7.5, 25 J.!l 20% SDS (sodium dodecyl 
sulfate), 50 J.!l sodium-ortha-vanadate, 7.5 J.!l PMSF (phenylmethylsulfanylfluoride), and 
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distilled water to a total volume of 5 ml). Cell lysates were scraped from wells using a 
micropoliceman and Ripa/lysis suspension was transferred to a 1.5 ml Eppendorf tube. 
Cell debris was removed by centrifugation at 21,890 x g for 10 minutes at 4°C. 
Supernatants containing isolated protein were transferred to 1.5 ml Eppendorf tubes. 
2.8.2. Quantification of Protein in Cell Lysates 
Protein within cell lysates was quantified by comparison with BSA standards. 
Five microliters of each sample and known amounts ofBSA: 0 Jlg, 2.5 jlg, 5.0 Jlg, 10 jlg, 
and 20 Jlg, were loaded in duplicate into a flat bottom 96-well plate. 5 Jll of lysis buffer 
was added to each well containing BSA. After addition of 300 Jlllwell BCA protein assay 
reagent (50:1, reagent A: reagent B) (Pierce, Rockford, IL), plates were incubated for 30 
minutes at 37°C. Absorbance at 562 nm was measured using a Polorstar Optima Plate 
reader (BMG, Durham, NC) and protein concentration was assessed using FLUOstar 
OPTIMA version 1.30 software (BMG). 
2. 8. 3. Electrophoresis of Cell Lysates 
Cell lysates were separated by SDS-P AGE (sodium dodecyl sulphate -
polyacrylamide gel electrophoresis). An appropriate volume of lysate to give 30 jlg of 
protein was removed from each sample and denatured in 1 00°C dry heat for 3 minutes. 
Following centrifugation at 16,060 x g for 1 minute to further remove cellular debris, 
samples were mixed with 10 Jllloading buffer and loaded onto 8.5 % SDS-PAGE gels. 
The loading buffer consisted of 5X sample buffer, 5% SDS, 10% glycerol, 0.5X stacking 
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gel buffer, J3-mercapoethanol, and bromophenyl blue to color. To access protein product 
size, gels were simultaneously loaded with 10 ~-tl BenchMark™ Pre-Stained Protein 
Ladder (Invitrogen). 
The SDS acrylamide gel was divided into two components: stacking gel and 8.5% 
running gel. The stacking gel consisted of 1.5 ml acrylamide, 1.15 ml stacking buffer 
(Tris HCl buffer) pH 6.8, 0.05 ml 20% SDS, 7 ml H20, 5 ~-tl TEMED, and 0.3 ml 2.8% 
APS (ammonium persulfate). Running gel consisted of 5.66 ml acrylamide, 5 ml running 
buffer (1.5M Tris HCL buffer) pH 8.9, 0.1 ml 20% SDS, 8.6 ml H20 20 ~-tl TEMED, and 
0.66 ml 2.8% APS. Cell lysates were electrophoresed in Mini-PROTEIN® Cell 
electrophoresis chambers (Bio-Rad) containing running buffer (1.5 M Tris HCl buffer) 
pH 8.9 at 15 rnA constant current until sample separations were below 5.5 em from gel 
bottom, then current was increased to 1 7 rnA until separation was completed. 
2. 8. 4. Transferring Protein Products 
Nitrocellulose membranes were activated by soaking in 1 00% methanol for 10 
seconds, in distilled water for 10 minutes, and in transfer buffer until use. Gels were 
removed from electrophoresis apparatus and placed in transfer buffer (20% methanol) for 
10 minutes. The transfer cassette was assembled as follows: plastic base, brillo pad (pre-
soaked in transfer buffer), two 3M filter papers (pre-soaked in transfer buffer), 
nitrocellulose membrane, gel(s), two 3M filter paper (pre-soaked in transfer buffer), brillo 
pad (pre-soaked in transfer buffer), and plastic top. The transfer cassette was placed in a 
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Bio-Rad Trans-blot cell (Bio-Rad), which itself was immersed in a circulating 6°C water 
bath. Transfer was performed at 100 V for 60 minutes. 
2. 8. 5. Immunodetection of Proteins 
Following transfer, sticky surfaces of membranes were blocked by 45 minute 
incubation in Blotto Solution (20 mll.OM Tris HCl buffer pH 7.6, 56ml 5M NaCl, 20 ml 
10% Tween 20, 5% non-fat dry evaporated milk). Membranes were then incubated 
overnight at 4 °C while rocking with a predetermined concentration of primary Ab (Table 
2.8) diluted in Blotto solution containing 1 !J.l per ml 20% sodium azide solution. To 
remove unbound primary antibodies, membranes were washed 5 times in a TBST bath 
for 5 minutes while rocking. TBST solution was the same as Blotto solution with the 
exemption of dry milk. Next, membranes were incubated with an appropriate secondary 
Ab labeled with HRP (Table 2.9) diluted to a predetermined concentration in Blotto 
Solution without sodium azide. Membranes were then washed with TBST, once for 5 
minutes, then 4 times for 10 minutes. Finally, the location of bound Ab was revealed by 
incubating membranes in SuperSignal® West Pi co Chemiluminescent Substrate (Pierce) 
(1: 1 Peroxide solution: Enhancer solution) for 5 minutes while rocking. 
2. 8. 6. Interpretation of Western Blot Results 
Proteins immobilized onto membranes were detected using a traditional ECL 
Western blotting system where a HRP-conjugated secondary Ab in conjunction with a 
chemiluminescent substrate, luminal, generates a signal that can be captured on film. 
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Table 2.8. Primary antibodies used in the detection of proteins by Western blotting. 
Antibody Isotype Cone. Reference/Source 
anti-P-Smad3 Rabbit 1/2000 Murphy et al. 2004 [231] 
(anti-serum) IgG 
anti-Smad3 Rabbit 1 ~-tg/ml Zymed Laboratories Inc. 
(purified) IgG (Cat# 51-500) 
anti-P-Smad2 (Ser 465/467) Rabbit 1/1000 Cell Signaling Technology 
IgG (Cat# 3101) 
anti-Smad2 Mouse 1/500 Transduction Laboratories 
IgG1 (Cat# 610842) 
anti-aTublin (Clone DMIA) Mouse 1/5000 Sigma-Aldrich 
(ascites fluid) IgG1 (T-9026) 
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Table 2.9. Secondary antibodies used in the detection of proteins by Western blotting. 
Antibody Concentration Reference/Source 
Goat anti-Rabbit HRP-Linked 1/15,000 Cell Signaling Technology 
(H&L) (Cat# 7074) 
Goat anti-Mouse IgG-HRP 1110,000 Santa Cruz Biotechnology 
' (sc-2055) 
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After quick exposure of membranes to AGAF X-ray film in a dark room, X-rays 
were developed using a Konica SRX-101A developer. Protein expression was determined 
on the basis of presence or absence of appropriate band size. 
2. 8. 7. Repro bing Membranes 
Membranes to be reprobed were stripped of antibody by immersion in a stripping 
solution bath for 30 minutes at 55°C while rocking. Stripping solution contained 42.5 ml 
distilled water, 5 ml 20% SDS, 2.1 ml 1.5M Tris stripping buffer pH 6.8, and 405 J.ll P-
mercaptoethanol. Once stripped, membranes were washed twice for 5 minutes in a TBST 
bath while rocking, and sticky surfaces were blocked by 1 hour incubation in Blotto 
Solution. Membranes were then incubated overnight with primary Ab (Table 2.8) at 4 °C 
as before (Section 2.8.5). 
54 
Chapter 3: Results 
3.1. Prdiminary Experiments to Assess the Effects of Different Cytokines on HLA-DR 
Expression. 
The purpose of this set of experiments was to evaluate whether IL-4 and/or TGF-
p1 individually or in combination with IFN-y modulated HLA-DRP allelic expression on 
an ER+ (MCF-7) and an ER- (BT-20) breast cancer cell line (BCCL). Cells were cultured 
and treated with cytokine combinations in standard E2-containing media. Resulting HLA-
DR expression was measured using antibodies L243 (pan HLA-DR), NFLD.DlO 
(DRP1 *15), UK8.1 (DRP1 *03, DRP1 *13), 7.3.19.1 (DRP3), NFLD.D1 (pan DRP1 *04), 
359-13F10 (pan DRP1 *04) and flow cytometry following 96 hour incubation with 
cytokines. 
The results, depicted in Figures 3.1, revealed no constitutive HLA-DR (L243) or 
allelic expression (NFLD.D10, UK8.1, 7.3.19.1) on MCF-7. Expression was not 
modulated by treatment with IL-4 or TGF-p1, but IFN-y strongly up-regulated HLA-DR, 
DRP1 *15, and DRp3. DRP1 *03 was not up-regulated by IFN-y alone, as indicated by 
poor UK8.1 binding (2.4% positive cells) (Figure 3.1A) and fluorescence intensity 
(Figure 3.1B). IL-4 augmented IFN-y-induced overall and allelic HLA-DR expression, 
while TGF-P1 had no modulatory effect. IFN-y + IL-4 and IFN-y + TGF-P1 did slightly 
increase the percentage of cells bound by UK8.1, however the fluorescent intensity of 
these cells was negligible. The combination of all three cytokines induced similar generic 
and allelic expression as IFNy + IL-4. 
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Figure 3.1. Preliminary data determining the effects of cytokine treatment on HLA-DR expression on MCF-7. Cells were 
cultured in standard E2-containing media and HLA-DR expression was assessed using the antibodies: L243 (pan HLA-DR); 
NFLD.D10 (DRP1 *15); UK8.1 (DRP1 *03); 7.3.19.1 (DRP3) and flow cytometry. Data are reported as: (A) histogram 
overlays where filled histograms = IgG isotype control; open histogram = test mAb; percentages indicate the percent of 
positive cells, or (B) MFI Test- MFI Background· 
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Overall, the results for MCF-7 suggested that modulation of allelic HLA-DR 
expression in response to individual and combined cytokine treatments displayed similar 
trends to that of generic HLA-DR. However, failure to up-regulate DRP 1 *03 suggested 
this allele was poorly expressed, or alternatively, that allotypic expression on MCF-7 was 
selectively-up-regulated in response to cytokine treatments. 
The results for BT-20 differed from MCF-7 as it displayed low constitutive HLA-
DR (L243) and DRP1 *04 (359-13F10) expression. There was a notable difference in the 
amount of DRP1 *04 detected by NFLD.D1 and 359-13F10 despite equivalent 
recognition of DRP 1 *04 on B cell line control SA VC (Table 2.4). As these antibodies 
bind to different domains of HLA-DRP 1 *04 (Sheila Drover, personal communication), 
this suggested that the 359-13F10 epitope was more accessible than the NFLD.Dl 
epitope on BT-20 and was thus more representative ofDRPI *04 expression on BT-20. 
Constitutive HLA-DR and DRP 1 *04 expression was rather unaffected by IL-4, 
despite the slight increase in percentage of positive cells (Figure 3.2A). On the other 
hand, TGF -P suppressed this constitutive expression, as indicated by a small decrease in 
the percentage of positive cells (Figure 3.2A) and fluorescence intensity (Figure 3.2B). 
IFN-y strongly up-regulated HLA-DR and DRP 1 *04, but only moderately up-regulated 
DRPI *13 (UK8.1). Addition ofiL-4 or TGF-Pl decreased IFN-y induced pan- and allelic 
HLA-DR expression. However, treatment with IFN-y + IL-4 + TGF-Pl had no 
modulatory effect on generic HLA-DR and DRP 1 *04 expression compared to 
observations with IFN-y-treatment alone, but all three cytokines together slightly 
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Figure 3.2. Preliminary data illustrating effects of cytokine combinations on HLA-DR allelic expression of BT -20. HLA-DR 
expression was assessed using the antibodies: L243 (panHLA-DR); NFLD.Dl (pan DR~l *04); 359-13F10 (pan DR~l *04); 
UK8.1 (DR~ 1 * 13) and flow cytometry. Data are reported as: (A) histogram overlays where filled histograms = lgG isotype 
control; open histogram= test mAb; percentages indicate the percent of positive cells, or (B) MFI Test- MFI Background· 
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suppressed DRI31 * 13 expression. 
Taken together with the results for MCF-7, moderate up-regulation of DRI31 *13 
on BT-20 in response to IFN-y and selective suppressive of this allele by IFN-y + IL-4 + 
TGF -131 suggested that BCCL selectively modulated allelic expression in response to 
cytokine treatments. The results also suggested that ER+ and ER-BCCL may respond 
differently to individual and combined cytokine treatments, particularly as IFN-y + TGF-
13 did not modulate HLA-DR expression on MCF-7 but suppressed expression on BT-20. 
Alternatively, the results may simply reflect differential responses to the various cytokine 
treatments by different HLA-DR alleles, which were not common to either cell line. 
Furthermore, other factors such as estrogen or estrogen-like components in medium and 
production of endogenous cytokines by BCCL may also influence HLA-DR expression. 
Therefore, we decided to compare both constitutive and IFN-y induced HLA-DR 
expression on a panel of ER+ and ER- BCCL cultured in E2-containing and E2-depleted 
medium to determine the effects of exogenous estrogen and estrogen-like components on 
HLA-DR expression. 
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3.2. Establishing Optimal Culture Conditions to Investigate ERa and HLA-DR 
Expression on Breast Cancer Cell Lines 
Media components may contain steroidal estrogens within FCS and non-steroidal 
estrogens which have hormonal activity. The popular pH indicator phenol red, present in 
a variety of culture medium, displays structural resemblance to some non-steroidal 
estrogens, allowing binding to ERa and stimulation of estrogenic activity, as indicated by 
induced proliferation and progesterone receptor expression [217, 232]. To determine 
whether such endogenous estrogens affect constitutive and IFN-y-induced HLA-DR 
expression on BCCL, a panel of ER + and ER- cells were cultured for 96 hours in both 
standard (E2-containing) medium and E2-depleted medium. HLA-DR expression was 
compared using L243 and CELISA. 
As shown in Figure 3.3 (all panels), no BCCL cultured in standard medium 
displayed constitutive HLA-DR, but all except BT-474 up-regulated HLA-DR in 
response to IFN-y. Following culture in E2-depleted medium, only MDA MB 231 
constitutively expressed HLA-DR (Figure 3.3A), while IFN-y induced HLA-DR on all 
BCCL except BT-474. The reason why BT-474 does not up-regulate HLA-DR is 
presently unclear, but confirms previous findings in our laboratory [210]. BT-474 was 
shown to contain DRA and DRB mRNA following IFNy treatment [210], therefore this 
problem does not appear to be at the transcriptional level and likely involves post-
transcriptional modification. 
Additionally, student two-tailed T -tests were used to analyze differences m 
constitutive and IFN-y-induced HLA-DR expression between culture conditions. 
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Figure 3.3. Effects of medium components on HLA-DR expression on breast cancer cell 
lines. Non-induced and IFN-y-induced HLA-DR expression was assessed using the 
antibody L243 by CELISA after 96 hour culture in standard medium (light gray bars) or 
E2-depleted medium (dark gray bars). Results are reported as the average and standard 
deviations of 2-3 experiments. Values greater than 2 are considered positive. *p < 0.05, 
** p < 0.01. 
64 
Constitutive HLA-DR expression on MDA MB 231 was higher in E2-depleted medium 
than standard medium (p = 0.017) (Figure 3.3A). Differences in IFN-y-induced 
expression were also found for SKBR3, MDA MB 157 and T47D. IFN-y-induced HLA-
DR expression was higher in standard medium on SKBR3 (p < 0.01) (Figures 3.3B) and 
T47D (p < 0.01) (Figure 3.3F), but higher in E2-depleted media for MDA MB 157 (p < 
0.01) (Figure 3.3C). No significant differences were observed for MDA MB 468, BT-20, 
MCF-7, or BT-474 (Figures 3.3D, 3.3E, 3.3G, and 3.3H, respectively). 
Taken together, these results showed that medium components can affect 
constitutive and inducible generic HLA-DR expression on some BCCL. We have 
highlighted differences in terms of estrogen content as this suggested that exogenous 
estradiol treatment may affect HLA-DR expression in a cell line specific manner. That 
being said, we realize other factors such as insulin, progesterone, and testosterone may 
too differ between the two media types and also affect HLA-DR expression. 
As the primary objective of this project was to assess the combined effects of 
17P-estradiol and cytokines on allelic HLA-DR expression, we decided to perform all 
future experiments in E2-depleted medium. By using E2-depleted medium, we minimize 
the variables of phenol red and high endogenous estradiol, thus allowing better 
assessment of the effects exogenous estradiol treatment may have on HLA-DR 
expression. 
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3.3. Estrogen Receptor-alpha Status ofBCCL 
The effects of estradiol are primarily mediated through ERa and ERP [233]. ERa 
status of each BCCL has been documented by the American Type Culture Collection 
(ATCC) and reported in various studies [216, 234, 235]. However, as cell lines may 
differ between laboratories and long term culture may change expression of various genes 
in cell lines, we decided to confirm the ERa status of each BCCL. Since expression of 
ERa also varies with amounts of estradiol components in medium [236, 237], we also 
compared the ERa status of cells cultured in standard medium to that in E2-depleted 
medium. To do this, we analyzed mRNA transcripts using an ERa exon 2 sequence 
specific primer and RT-PCR as described in Section 2.7. 
As shown in Figure 3.4, ERa mRNA was constitutively transcribed in BT-474, 
T47D, MCF-7, BT-20 (weak), and MDA MB 157 (weak). No detectable ERa mRNA 
was present in MDA MB 231, MDA MB 468, or SKBR3. However, differences in ERa 
transcription were observed for cells grown in the different media. ERa transcripts in 
T47D and MCF-7 were more prominent in cells cultured in standard medium than E2-
depleted medium (Figure 3.4A). We also found weak amplification of ERa in MDA MB 
157 cultured in both media (Figure 3.4B), which is in contrast to ATCC reports. As 
shown in Table 3.1 where results are also presented as a percentage of GAPDH 
expression, apart from MDA MB 157 our results agree with those published by the 
ATCC. 
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Figure 3.4. Representative gels depicting constitutive ERa expression in breast cancer 
cell lines cultured in standard medium (+) and estrogen-depleted medium (-). A) ERa 
transcription was analyzed by RT-PCR ,using sequence-specific primers. GAPDH was 
amplified as a control. RNA was subjected to PCR to ensure no DNA contamination. B) 
representative gel illustrating size of ERa transcripts in SKBR3, MDA MB 157 and BT-
474 alongside a 100 bp ladder with an arrow indicating 600 bp. 
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Table 3.1. Estrogen receptor-alpha transcription in breast cancer cell lines cultured in 
standard (E2-containing) medium or E2-depleted medium assessed using sequence 
specific primers and R T-PCR. 
Breast Cancer ERa. Constitutive mRNA 
Cell Lines Status 
(ATCC) Standard Medium E2-depleted Medium 
BT-474 + + (65.1 %) + (63.1 %) 
T47D + + (48.0 %) + (4.7 %) 
MCF-7 + + (14.2 %) + (4.1 %) 
BT-20 mRNA + (5.2 %) + (9.6 %) 
MDAMB 157 - + (7.3 %) + (8.0 %) 
MDAMB231 - - (0.0 %) - (0.0 %) 
MDAMB468 - - (1.6 %) - (1.7 %) 
SKBR3 - - (5.9 %) - (5.1 %) 
()Values in brackets indicate expression normalized in relation to GAPDH as described 
in section 2.8.7; +indicates visible band,- indicates no visible band. 
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3.4. Determining the Optimal Concentration of 17fJ-estradiolfor Modulating HLA-DR 
Expression 
To determine the optimal concentration of 17(3-estradiol, MCF-7 (ER+) and MDA 
MB 231 (ER-) were treated with 10-6 - 10-11 M estradiol in the presence I absence of 100 
units/ml IFN-y. Effects on HLA-DR expression were measured using the antibody L243 
and CELISA. Since our estradiol was reconstituted in absolute ethanol and diluted 1/50 in 
PRF-IMDM medium, appropriate dilutions of reconstitution solvent were also assessed 
as controls for each estradiol concentration. 
As shown in Figure 3.5, estradiol treatment did not induce HLA-DR expression 
on MCF-7 at any concentration tested. When co-cultured with IFN-y (Figure 3.6), the 
effects of estradiol on HLA-DR expression displayed discordant results, particularly at 
1o-6 M, 1o-7 M, 1o-8 M, and 1 o-11 M. At such concentrations, effects due to estradiol could 
not be distinguished from effects due to ethanol. In fact, estradiol-mediated effects could 
only be consistently distinguished from the vehicle control at 10-9 M. At this molarity, 
estradiol did not modulate IFN-y induction of HLA-DR while the vehicle control 
suppressed IFN-y induction. 
Analysis of estradiol treatment on MDA MB 231 also proved difficult. Again, the 
effects of estradiol could not be deciphered from the effects of ethanol on either 
constitutive (Figure 3.7) or IFN-y-induced HLA-DR expression (Figure 3.8). Therefore, 
we tried other reconstitution solvents for estradiol in hope of finding one that had 
minimal effects on HLA-DR expression. 
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Figure 3.5. Effects of estradiol treatment on HLA-DR expression on MCF-7. HLA-DR 
expression was assessed using the antibody L243 and CELISA after 96 hour culture in 
E2-depleted media in the presence of estradiol or vehicle control. Results are shown as 
OD Test- OD Background· Standard deviations were calculated from triplicates. 
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Figure 3.6. Effects of estradiol on IFN-y-induced HLA-DR expression on MCF-7. HLA 
DR expression was assessed using the antibody L243 and CELISA after 96 hour culture 
in Ez-depleted media in the presence of 100 units/ml IFN-y with estradiol or vehicle 
control. Results are shown as OD Test- OD Background· Standard deviations were calculated 
from triplicates. A) and B) depict replicate experiments. 
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Figure 3.7. Effects of estradiol treatment on HLA-DR expression on MDA MB 231. 
HLA-DR expression was assessed using the antibody L243 by CELISA after 96 hour 
culture in E2-depleted media in the presence I absence of estradiol or vehicle control. 
Results are shown as OD Test- OD Background· Standard deviations were calculated from 
triplicates. A) and B) depict replicate experiments. 
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Figure 3.8. Effects of estradiol on IFN-y-induced HLA-DR expression on MDA MB 231. 
HLA-DR expression was assessed using the antibody L243 by CELISA after 96 hour 
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Results are shown as OD Test- OD Background· Standard deviations were calculated from 
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3.5. Determining Optimal Reconstitution Solvent for Estradiol 
As ethanol affected HLA-DR expression on both MCF-7 (ER+) and MDA MB 
231 (ER-), an attempt was made to find another reconstitution solvent. According to the 
Merck Index [238], 1713-estradiol is insoluble in water, but soluble in alcohol, acetone, 
dioxane, and other organic solvents containing fixed alkali hydroxides. The manufacturer 
(Sigma) recommended we try dimethylsulfoxide (DMSO) in place of ethanol. 
To test this, MCF-7 and MDA MB 231 were exposed to various dilutions of 
DMSO and ethanol, equivalent to that found in E2 concentrations of 10-6 - 10-11 M, and 
effects on constitutive and IFN-y-induced HLA-DR expression were compared using 
L243 and CELISA. 
The results, depicted in Figures 3.09 and 3.10, revealed that both DMSO and 
ethanol did not induce HLA-DR expression on MCF-7 (Figure 3.9A), and had minimal 
effects on constitutive HLA-DR expression on MDA MB 231 (Figure 3.9B) at all 
molarities tested. When combined with IFN-y treatment (Figure 3.10), DMSO and 
ethanol had minimal effects on IFN-y-induced HLA-DR on MCF-7 (Figure 3.10A). 
However, DMSO suppressed IFN-y induction of HLA-DR on MDA MB 231 more than 
ethanol at all molarities except 2.7 x 10-6 M, equivalent to DMSO present in 10-8 M 
estradiol (Figure 3.1 OB). 
With DMSO now shown to suppress IFN-y-induction of HLA-DR on MDA MB 
231, other possible reconstitution solvents were tried, including 1-butanol, methanol, and 
acetone (results not shown). These solvents were also found to modulate both constitutive 
and IFN-y-induced HLA-DR expression. 
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Figure 3.9. Effects of ethanol and DMSO on HLA-DR expression on MCF-7 (A) and 
MDA MB 231 (B). HLA-DR expression was measured using the antibody L243 and 
CELISA after 96 hour incubation in the presence I absence ethanol or DMSO. Results are 
presented as OD Test- OD Background· Standard deviations are from triplicates. 
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ethanol or DMSO. Results are presented as OD Test- OD Background· Standard deviations 
are calculated from triplicates. 
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Since we were unsuccessful in finding an appropriate reconstitution solvent, we 
continued with objective #2 of our project: investigating the effects of individual and 
combined cytokine treatments on HLA-DR expression on BCCL. 
3. 6. Constitutive Transcription of Cytokine Genes 
Since a major objective of this study was to analyze the effects of exogenously 
added IFN-y, IL-4, and TGF-Pl either individually or in combination on HLA-DR 
expression of BCCL, we questioned if the cells were making any of these cytokines 
endogenously. To address this, we analyzed for constitutive cytokine mRNA expression 
using sequence specific primers (Table 2.5) and RT-PCR. As before, mRNA analysis was 
performed on cells cultured in both standard and E2-depleted media following 96 hour 
incubation. 
Analysis of IFN-y and IL-4 transcription, depicted in Figures 3.11 and 3.12, 
illustrated that no BCCL constitutively transcribed IFN-y or IL-4 following culture in 
either media. Conversely, TGF-Pl transcripts were observed in all BCCL cultured in 
standard media, and all BCCL cultured in E2-depleted media except SKBR3 (Figure 
3.13). A weak band is visible in the gel photograph ofSKBR3 cultured in standard media 
which may not be apparent in Figure 3.13. 
Results of cytokine mRNA analysis, summarized in Table 3.2, show that 
differences in TGF-P1 amplification depended on media conditions. Normalizing TGF-
Pl amplification to GAPDH indicated that transcripts were more intense in BT-474 and 
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Figure 3.11. Representative gels depicting constitutive IFN-y transcription in breast 
cancer cell lines cultured in standard medium(+) and estrogen-depleted medium(-). IFN-
y transcription was analyzed by RT-PCR using sequence-specific primers. ClO/MJ eDNA 
was used as positive control for IFN-y. GAPDH was amplified as a control. 
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Figure 3.12. Representative gels depicting constitutive IL-4 transcription in breast cancer 
cell lines cultured in standard medium (+) and estrogen-depleted medium (-). IL-4 
transcription was analyzed by RT-PCR using sequence-specific primers. Jurkat eDNA 
was used as positive control for IL-4. GAPDH was amplified as a control. 
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Figure 3.13. Representative gels depicting constitutive TGF-P transcription in breast 
cancer cell lines cultured in standard medium (+) and estrogen-depleted medium (-). 
TGFP transcription was analyzed by RT-PCR using sequence-specific primers. Jurkat 
eDNA was used as positive control for TGFp. GAPDH was amplified as a control. 
80 
Table 3.2. Cytokine transcription in breast cancer cell lines cultured in E2-containing and 
E2-depleted media as assessed using sequence specific primers and RT-PCR. 
Breast Cancer Media Constitutive mRNA 
Cell Lines Type IFN-y IL-4 TGF-JH 
BT-474 E2+ - (0.8%) - (0.0%) + (25.1%) 
E2- - (3.3%) - (0.0%) + (4.4%) 
T47D E2+ - (0.0%) - (0.0%) + (48.9%) 
E2- - (0.0%) - (1.8%) + (30.5%) 
MCF-7 E2+ - (3.4%) - (0.5%) + (53.4%) 
E2- - (2.4%) - (1.2%) + (63.6%) 
BT-20 E2+ - (2.7%) - (0.2%) + (62.9%) 
E2- - (6.5%) - (1.3%) + (74.5%) 
MDAMB 157 E2+ - (1.1%) - (0.4%) + (43.1 %) 
E2- - (1.2%) - (0.4%) + (49.5%) 
MDAMB231 E2+ - (0.8%) - (0.8%) + (24.1 %) 
E2- - (3.1%) - (0.5%) + (50.4%) 
MDAMB468 E2+ - (2.1%) - (0.7%) + (12.0%) 
E2- - (4.2%) - (0.5%) + (40.7%) 
SKBR3 E2+ - (1.1%) - (0.2%) + (2.4%) 
E2- - (2.2%) - (0.6%) - (0.8%) 
()Values m brackets mdicate expression normalized to GAPDH as described in 
section 2.8.7; +indicates visible band,- indicates no visible band. 
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T47D cultured in E2-containing medium, while they were more intense in MDA MB 231, 
MDA MB 468, MCF-7 and BT-20 cells cultured in E2-depleted medium. No difference 
in TGF-Pl amplification was found for MDA MB 157. As the above differences in 
intensity of TGF-P1 transcripts did not indicate trends in either ER+ or ER- BCCL, we 
report no correlation between differences in TGF -P 1 amplification and ERa status. 
3. 7. Determining the Optimal Concentrations of Cytokines for Stimulating HLA-DR 
expression 
Before performing preliminary experiments (Section 3.1), IFN-y, IL-4, and TGF-
p 1 were titered on MDA MB 231 cultured in standard medium. MDA MB 231 was 
chosen as this cell line constitutively expresses HLA-DR, and IFN-y strongly up-
regulates HLA-DR expression [210]. Furthermore, reports indicate that MDA MB 231 
contains high affinity IL-4 receptors [120], and is sensitive to TGF-P1 through retention 
of TPRII expression [239, 240]. Upon selection of optimal concentrations of these 
cytokines for stimulation of HLA-DR expression in standard medium, the same 
concentrations were used on breast cancer cell lines cultured in E2-depleted medium. 
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3. 7.1. IFN-y 
It is well documented that IFN-y induces HLA-DR expression on most cell types 
including breast carcinoma [84, 130, 211-213, 241, 242]. Previous research in our 
laboratory determined that 500 units/ml IFN-y was optimal for HLA Class II induction in 
synovial cells [211]. However, our laboratory also reported no difference in the up-
regulation of cell surface HLA-DR on T47D upon treatment with 100 units/ml or 500 
units/ml IFN-y [210]. 
Therefore, to assess whether 100 units/ml IFN-y was appropriate for induction of 
HLA-DR expression on other BCCL, MDA MB 231 and MCF-7 were exposed to 50-
500 units/ml IFN-y and resulting HLA-DR expression was measured using L243 and 
CELISA. Cells were treated for 96 hours as previous studies in our laboratory found this 
incubation period optimal for IFN-y induction ofHLA-DR on BCCL [210, 243]. 
As shown in Figure 3.14, HLA-DR induction on MCF-7 was virtually the same 
following 50 - 500 units/ml IFN-y, while expression on MDA MB 231 appeared to occur 
in a dose dependent manner. Based on these results, 100 units/ml IFN-y was selected to 
stimulate all BCCL as it provided appropriate up-regulation of HLA-DR on MCF-7 and 
MDAMB231. 
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Figure 3.14. Effects of various concentrations ofiFN-y on HLA-DR expression on MDA 
MB 231 and MCF-7. HLA-DR expression was assessed using the antibody L243 and 
CELISA following 96 hour culture in standard medium. Results are shown as OD Test -
OD Background· Standard deviations were calculated from triplicates. 
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3. 7.2. IL-4 
To determine the concentration ofiL-4 for induction ofHLA-DR in BCCL, MDA 
MB 231 was exposed to 50 - 500 units/ml IL-4 for 96 hours in the presence I absence of 
100 units/ml IFN-y. Resulting HLA-DR expression was measured using L243 and 
CELIS A. 
The results, depicted in Figure 3.15, showed that the greatest up-regulation of 
HLA-DR was found co-culturing 500 units/ml IL-4 with 100 units/ml IFN-y. Therefore, 
the concentration of 500 units/ml was chosen for all IL-4 stimulation assays. 
3. 7. 3. TGF-[31 
To determine the optimal concentration of TGF-f31 for experimentation, MDA 
MB 231 was exposed to 1- 10 ng/ml TGF-f31 for 96 hours in the presence or absence of 
100 units/ml IFN-y. Resulting HLA-DR expression was measured using L243 and 
CELIS A. 
As shown in Figure 3.16, TGF-f31 did not modulate constitutive HLA-DR 
expression at any concentration tested. Furthermore, when co-cultured with IFN-y, no 
TGF-f31 concentration suppressed IFN-y-induction of HLA-DR. Therefore, 10 ng/ml, 
which is commonly used in published studies [84, 86-88, 101], was considered a super-
saturating dose ofTGF-f31 and selected for subsequent experiments. 
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Figure 3.15. Effects of various concentrations of IL-4 on IFN-y induction of cell surface 
HLA-DR on MDA MB 231. Cells were cultured in the presence or absence of IL-4 
and/or 100 units/ml IFN-y for 96 hours and assayed for HLA-DR expression using the 
antibody L243 and CELISA. Expression is shown as the ratio of OD Test I OD Background· 
Standard deviations were calculated from triplicates. 
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Figure 3.16. Effects of various concentrations of TGF-~1 on IFN-y induction of HLA-
DR on MDA MB 231. Cells were cultured in the presence or absence of TGF-~ 1 and/or 
IFN-y for 96 hours and assayed for HLA-DR expression using the antibody L243 and 
CELISA. Expression is shown as the ratio of OD rest I OD Background· Standard deviations 
were calculated from triplicates. 
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3.8. Investigating Effects ofCytokine Combinations on HLA-DR Expression 
Preliminary data (Section 3.1) conducted in standard media illustrated the effects 
of combined cytokine treatment on HLA-DR expression on MCF-7 (ER+) and BT-20 
(ER-) BCCL. We decided to extend this study by examining BCCL cultured in E2-
depleted medium. We questioned if cells cultured in the absence of estrogen would also 
display cytokine-induced differences in HLA-DR expression in ER+ and ER- BCCL. 
To test this, ER+ (MCF-7 and T47D) and ER- (BT-20, MDA MB 157, MDA MB 
231, and SKBR3) BCCL were treated with IFN-y and/or IL-4 and/or TGF-Pl. Resulting 
effects on HLA-DR allelic expression were assessed using specific mAbs (Table 2.3) and 
both flow cytometry and CELISA. All assays were conducted following 96 hour culture 
in E2-depleted media. 
3.8.1. Estrogen Receptor-alpha Negative Breast Cancer Cell Lines 
3.8.1.1 MDA MB 157 
To evaluate the effects of cytokine co-culture on MDA MB 157, HLA-DR allelic 
expression was detected using the antibodies L243, pan HLA-DR; NFLD.D1, pan 
DRP1 *04; NFLD.D10, DRP1 *04 and DRP1 *15. CELISA analysis also incorporated 
NFLD.D7 for detection of DRP1 * 15. Expression of DRP4 and DRP5 proteins could not 
be determined due to lack of specific mAbs. 
The results of flow cytometry, depicted in Figures 3.17 A and 3.17B, showed that 
MDA MB 157 did not constitutively express generic HLA-DR (L243), and expression 
was unmodulated following treatment with IL-4, TGF -P 1, or IL-4 + TGF -P 1. Similar 
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results were also observed with NFLD.Dl (DRf31 *04) and NFLD.DIO (DRf31 *04, 
DRf31 *15). In contrast, IFN-y strongly up-regulated generic HLA-DR (L243) and a -DR 
epitope recognized by NFLD .D 10, as indicated by increased percentage of positive cells 
(Figure 3.17A) and fluorescence intensity (Figure 3.17B). However, NFLD.D1 binding 
was less than twice the background, suggesting that DRf31 *04 was not up-regulated on 
MDA MB 157. This is consistent with a previous study which showed poor DRf31 *04 
expression on MDA MB 157 [210]. Thus, we assume that NFLD.DlO staining indicated 
DRf31 * 15 expression. 
Addition of IL-4 to IFN-y had no effect on the percentage of positive cells or the 
expression of generic HLA-DR and DRf31 *15. In contrast, addition of TGF-f3 inhibited 
IFN-y induction of generic HLA-DR and DRf31 *15, as indicated by marked reductions in 
the percentage of positive cells and fluorescence intensity. Moreover, treatment of MDA 
MB 157 with the combination of IFN-y + IL-4 + TGF-f31 also resulted in severe 
suppression of generic HLA-DR and DRf31 *15. 
CELISA analysis (Figure 3.17C) confirmed flow cytometry results. Detection of 
DRf31 *04 was less than twice the background following IFN-y treatment, confirming that 
DRf31 *04 was poorly expressed on MDA MB 157. Therefore, NFLD.D7 staining 
indicated DRf31 *15 expression. Again, generic HLA-DR and DRf31 *15 expression 
induced by IFN -y or by IFN -y + IL-4 were inhibited by addition of TGF -f31, as indicated 
by sizeable reductions in optical density. Thus, CELISA and flow cytometry data suggest 
that TGF-f31 inhibits IFN-y-induced expression ofHLA-DR on MDA MB 157. This 
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Figure 3.17. Effects of cytokines on HLA-DR allelic expression on MDA MB 157. HLA-DR expression was measured using 
the antibodies L243 (pan HLA-DR); NFLD.D1 (pan HLA-DRp1 *04); NFLD.D7 (pan DRP1 *04, DRP1 *15); NFLD.D10 (pan 
DRP 1 *04, DRP 1 * 15). Results are reported as: (A) histogram overlays where filled histograms = IgG isotype control, open 
histogram = Test mAb and percents indicate the percentage of positive cells; (B) MFhest - MFisackgorund as measured by flow 
cytometry; and (C) ODrest- ODsackground as measured by CELISA. *p < 0.05. **p < 0.01. 
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finding also correlates with previous studies involving astrocytes, monocytes, microglial 
cells, fibrosarcoma cells, and synovial cells [84, 87, 88]. Aside from lack of DRP1 *04 
expression, allelic expression displayed similar trends as generic HLA-DR in terms of 
cytokine-mediated modulation. 
3.8.1.2. MDA MB 231 
The effects of cytokine combinations on allelic expression of MBA MB 231 were 
detected using the antibodies L243, pan HLA-DR; SFR16, HLA-DRP1 *07; and 7.3.19.1, 
HLA-DRp3. HLA-DRP4 expression could not be determined as no specific mAbs were 
available. 
Flow cytometry analysis, Figures 3 .18A and 3 .18B, showed strong constitutive 
expression of generic HLA-DR (L243) and DRP3 (7.3.19.1) on MDA MB 231, while 
DRP1 *07 (SFR16) expression was negligible. Expression of generic HLA-DR, 
DRP1 *07, and DRP3 was not altered by IL-4, but was inhibited by TGF-P1 and the 
combination of IL-4 and TGF -P 1, as indicated by the percentage of positive cells (Figure 
3.18A), and fluorescence intensity ofL243 and 7.3.19.1 (Figure 3.18B). In contrast, IFN-
y strongly up-regulated the percentage of positive cells and expression of generic HLA-
DR and DRp3, while the percentage ofDRP1 *07 positive cells was strongly up-regulated 
and DRP 1 *07 expression was poorly up-regulated. 
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Figure 3.18. Effects of cytokines on HLA-DR allelic expression on MDA MB 231. Cells were cultured in Ez-depleted media 
and HLA-DR expression was measured using the antibodies L243 (panHLA-DR); SFR16 (DR~1 *07); 7.3.19.1 (DR~3). 
Results are reported as: (A) histogram overlays where filled histograms= IgG isotype control, open histogram= Test mAb and 
percents indicate the percentage of positive cells; (B) MFhest - MFIBackgorund as measured by flow cytometry; and (C) ODTest-
ODBackground as measured by CELISA. *p < 0.05. 
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Addition of IL-4 to IFN -y had no effect on the percentage of cells stained with 
L243, SFR16, and 7.3.19.1, but reduced fluorescence intensity of generic HLA-DR, 
DRP1 *07, and DRp3. IFN-y + TGF-P1 and IFN-y + IL-4 + TGF-P1 specifically reduced 
the percentage of cells stained with SFR16, but both treatments caused considerable 
reduction in expression of generic HLA-DR, DRP1 *07, and DRp3. 
CELISA analysis (Figure 3.18C) confirmed flow cytometry findings, except, IL-4 
did not suppress IFN-y induction of generic HLA-DR, DRP 1 *07, or DRp3. As previously 
indicated, TGF-P1 did remarkably inhibit IFN-y-induced generic HLA-DR, DRP1 *07 
and DRp3. Furthermore, IFN-y + IL-4 + TGF-P1 inhibited, while IFNy + IL-4 did not 
modulate, IFNy-induced DRP1 *07 and DRp3. 
All together, the results for MDA MB 231 suggest that BCCL can display 
differential expression and induction of HLA-DR alleles, as DRP1 *07 was not 
constitutively expressed and was poorly up-regulated by cytokine treatments. In addition, 
the results for MDA MB 231 are similar to those ofMDA MB 157 and suggest that TGF-
P1 inhibits IFN-y induced HLA-DR expression on ER- breast cancer cell lines. 
3.8.1.3. SKBR3 
SKBR3 has a similar HLA-DR phenotype (DRP1 *07, DRP1 *13, DRp3, DRP4) 
to MDA MB 231, and both are ER-. Given this, we wondered if SKBR3 would display 
similar DR expression as MDA MB 231 following cytokine treatments. To answer this, 
we used the same antibodies: L243, pan HLA-DR; SFR16, HLA-DR1 *07; and 7.3.19.1, 
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HLA-DR~3. As previously stated, HLA-DR~4 expression could not be examined as no 
specific mAb was available. 
The results of flow cytometry analysis, Figures 3.19A and 3.19B, revealed that 
SKBR3 did not constitutively express generic HLA-DR (L243), DR~1 *07 (SFR16) or 
DRf33 (7.3.19.1), and expression was unmodulated by treatment with IL-4, TGF-~1, or 
IL-4 + TGF-~1. However, IFN-y strongly up-regulated generic HLA-DR, DR~1 *07, and 
DR~3, as indicated by increased percentage of positive cells (Figure 3.19A) and 
fluorescence intensity (Figure 3 .19B). 
Addition of IL-4 augmented IFN-y induction of generic HLA-DR, DR~ 1 *07 and 
DR~3, as indicated by increased percentage of positive cells, and more specifically, by 
increased fluorescence intensity. Similarly, addition of TGF-f31 to IFN-y increased the 
percentage of cells labeled with L243, SFR16, and 7.3.19.1, and increased fluorescence 
intensity. This suggested that either IL-4 or TGF-~1 could act synergistically with IFN-y 
to induce HLA-DR expression on SKBR3. However, IFN-y + IL-4 + TGF-~1 resulted in 
the highest percentage of generic HLA-DR and DR~3 positive cells and increased the 
expression of generic HLA-DR and DR~3, but did not modulate the percentage or 
expression ofDR~1 *07, indicating selective up-regulation ofHLA-DR alleles. 
CELIS A analysis, depicted in Figure 3 .19C, verified most flow cytometry 
findings. However, DR~1 *07 was poorly up-regulated, indicating a discrepancy with 
flow cytometry data that will be addressed in Chapter 4. Addition of IL-4 slightly 
increased IFN-y induction of generic HLA-DR, but did not affect DRf31 *07 or DR~3. 
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Figure 3.19. Effects of cytokines on HLA-DR allelic expression on SKBR3. HLA-DR expression was measured using the 
antibodies L243 (pan HLA-DR); SFR16 (DRIH *07); 7.3.19.1 (DR~3). Results are reported as: (A) histogram overlays where 
filled histograms = IgG isotype control, open histogram = Test mAb and percents indicate the percentage of positive cells; (B) 
* MFhest- MFIBackgorund as measured by flow cytometry; and (C) ODrest- ODBackground as measured by CELISA. p < 0.05. 
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IFNy + TGF-P1 up-regulated generic HLA-DR, while expression ofDRP1 *07 and DRP3 
was relatively unmodulated, suggesting that DRP 1 * 13 or DRP4 was up-regulated. 
Moreover, the highest expression of generic HLA-DR was found following IFN-y + IL-4 
+ TGF-p1, suggesting that TGF-P was not inhibitory to SKBR3. 
Taken together, the results of SKBR3 are in contrast to the results of MDA MB 
157 and MDA MB 231 as we showed that TGF-P does not inhibit IFN-y induction of 
generic or allelic HLA-DR on SKBR3. Moreover, as the BCCL examined thus far have 
all been ER-, these current results suggest that TGF-P is not inhibitory to all BCCL. 
Furthermore, as SKBR3 has similar HLA-DR phenotype to MDA MB 231, we now 
suggest that the effects mediated by cytokine combinations on HLA-DR expression may 
be cell line specific. 
3.8.1.4. BT-20 
To further examine the effects of cytokine combinations on ER- BCCL, allelic 
expression on BT-20 was detected using the antibodies L243, pan HLA-DR; NFLD.D1, 
pan DRP1 *04; 7.3.19.1, DRp3. CELISA analysis also incorporated TAL8.1 for detection 
of HLA-DRP1 *13. As stated previously, we were unable to detect DRP1 *04 with 359-
16F10 due to shortage ofthis antibody. 
The results of flow cytometry, depicted in Figures 3.20A and 3.20B, revealed a 
small amount of constitutive generic HLA-DR (L243), which was unaffected by IL-4, but 
was decreased by TGF-P treatment. Since constitutive DRP1 *04 (NFLD.D1) and DRP3 
(7.3.19.1) was not observed, we assumed that HLA-DRP1 *13 and/or HLA-DRP4 were 
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expressed. However, DRP1 *13 and DRP4 proteins were not ascertained by flow 
cytometry due to shortage or lack of specific mAbs. Alternatively, it is possible that low 
levels of HLA-DR allelic products were indictable using allele specific mAbs, but were 
detectable using L243 since this Ab recognizes all DR types collectively. 
Neither IL-4, TGF -P 1, nor IL-4 + TGF -P 1 modulated expression of DRP 1 *04 or 
DRp3. In contrast, IFN-y strongly up-regulated generic HLA-DR and DRP3, but only 
slightly increased DRP 1 *04, as indicated by increased percentage of positive cells 
(Figure 3.20A) and fluorescence intensity (Figure 3.20B). Addition of IL-4 to IFNy 
marginally increased the percent of positive cells stained with L243 and NFLD.D1, but 
did not affect fluorescence intensity, while it reduced IFN-y induction ofDRp3. 
In contrast, IFNy + TGF -P 1 increased the percentage of cells expressing generic 
HLA-DR, DRP 1 *04, and DRP3, but only substantially increased expression of generic 
HLA-DR when fluorescent intensity was analyzed. IFN-y + IL-4 + TGF-P1 treatment 
resulted in the highest percentage and expression of generic HLA-DR, DRP1 *04, and 
DRp3, suggesting that these three cytokines could act synergistically to modulate HLA-
DRonBT-20. 
CELISA analysis (Figure 3 .20C) confirmed flow cytometry results for the most 
part. However, expression of constitutive generic HLA-DR was negligible, and although 
IL-4 slightly increased generic HLA-DR expression, this detection was less than twice 
the background and was also considered negligible. Furthermore, IFN-y, IFN-y + IL-4, 
IFN-y + TGF-p1, and IFN-y + IL-4 + TGF-P1 did not up-regulate DRPl *04 as 
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Figure 3.20. Effects of cytokines on HLA-DR allelic expression on BT-20. HLA-DR expression was assessed using 
antibodies: L243 (pan HLA-DR); TAL8.1 (DR~1*13); NFLD.D1 (pan DR~1*04); 7.3.19.1 (DR~3). Results are reported as: 
(A) histogram overlays where filled histograms= IgG isotype control, open histogram= Test mAb, and percents indicate the 
percentage of positive cells; (B) MFhest - MFisackgorund as measured by flow cytometry; and (C) ODTest- ODsackground as 
* ** measured by CELISA. p < 0.05. p < 0.01. 
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expression was less than twice the background. Other discrepancies included IFNy + IL-
4, IFNy + TGF-P1 and IFNy + IL-4 + TGF-P1 inducing similar amounts of generic HLA-
DR expression, suggesting that either IL-4 or TGF-P1 could act synergistically with IFN-
y. All three cytokines together also induced the highest expression of DRp3, but did not 
further augment generic HLA-DR or DRP 1 *04 as previously indicated by flow 
cytometry. The discrepancies identified here will be addressed in Chapter 4. 
CELISA analysis also revealed that DRP1 *13 (TAL 8.1) was not constitutively 
expressed on BT-20, suggesting that constitutive HLA-DR (L243) expression was HLA-
DRp4. DRP1 *13 expression was unaffected by IL-4, TGF-p1, or IL-4 + TGF-Pl. 
Expression also remained less than twice the background following IFN-y and IFN-y + 
IL-4. Addition ofTGF-P1 to IFN-y induced positive levels of expression, and IFN-y + IL-
4 + TGF-P 1 did not indicate any synergistic activity of all three cytokines on DRP 1 * 13 
expression. 
Taken together, flow and CELISA results for BT-20 suggest that DRP1 *04 was 
poorly up-regulated by IFN-y and combined cytokine treatments. Our results also suggest 
that TGF-P1 inhibits constitutive HLA-DR expression on BT-20, but in combination with 
IFN-y, TGF-P 1 augments IFN-y induction of generic and allelic HLA-DR. This suggests 
that TGF-P1 alone acts differently than when combined with IFN-y to modulate HLA-DR 
expression on BT-20. Furthermore, as we showed that IFN-y + TGF-P1 induced HLA-
DR expression on BT-20 and SKBR3, but suppressed expression on MDA MB 157 and 
MDA MB 231, we suggest the effects mediated by these cytokines are cell line specific. 
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3.8.1.5. Summary of the Differential Effects Mediated by Cytokines on HLA-DR 
Expression on ER-negative Breast Cancer Cell Lines 
A summary of the differential effects mediated by individual and combined 
cytokine treatments on ER- BCCL is presented in Table 3.3. Only MDA MB 231 and 
BT-20 constitutively expressed HLA-DR, and in each case, expression was down-
regulated by TGF-P 1. IL-4 + TGF-P 1 also reduced constitutive HLA-DR on MDA MB 
231, but not BT-20. In contrast, IL-4 did not modulate generic or allelic HLA-DR 
expression on any ER- breast cancer cell line. 
AllER- cell lines were responsive to IFN-y and up-regulated HLA-DR to varying 
degrees. This induction may depend on the allotypes expressed as DRP1 *04 was not up-
regulated on MDA MB 157, and BT-20 poorly up-regulated DRP1 *04 and DRP1 *13. 
IFN-y + IL-4 had inconsistent effects on MDA MB 231, SKBR3, and BT-20. 
However, flow cytometry indicated that IL-4 had antagonistic effects on IFN-y induced 
HLA-DR on MDA MB 231, but augmentative effects on SKBR3 which carries the same 
allotypes as MDA MB 231. TGF-P1 also had antagonistic effects on IFN-y induced 
HLA-DR on MDA MB 231 and MDA MB 157, while it had the opposite effect on 
SKBR3 and BT -20. 
All three cytokines together followed similar expression patterns as IFN-y + TGF-
p for each cell line. Thus, it appears that the modulatory effects of IFN-y + IL-4, IFN-y + 
TGF-p1, and IFN-y + IL-4 + TGF-P do not occur in an allotype-specific manner in ER-
breast cancer cell lines. 
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Table 3.3. Summary of the differential effects a on HLA-DR allelic products mediated by cytokine treatments on ER- breast 
cancer cell lines. 
Effects of Cytokine Treatment on Effects on HLA-DR 
Cell Line HLA-DR Constitutive HLA-DR Expression Expression in Relation to IFNy 
allele expression IL-4 TGF-~1 IL-4+ IFN-y IFN-y+ IFN-y+ IFN-y + 
TGF-~1 IL-4 TGF-~1 IL-4 + 
TGF-~1 
MDA HLA-DR - - - - i - ! ! 
MB 157 DR~1 *04 - - - - - - - -
DR~1 *15 - - - - i - ! ! 
MDA HLA-DR + - ! ! i ! (-) ! ! 
MB231 DR~1 *07 - - - - iw ! (-) ! ! 
DR~3 + - ! ! i ! (-) ! ! ER- HLA-DR + (-) ! (-) i - (i) i i - -
BT-20 DR~1 *04 - - - - i w (-) - i (-) i (-) 
DR~1*13 - - - - - - i i 
DR~3 - - - - iw ! (i) i i 
HLA-DR - - - - i i i i 
SKBR3 DR~1*07 - - - - i (-) i (-) i (-) -
DR~3 - - - - i i i (-) i (-) 
a Expression was considered positive if values were twice the background 
+ indicates detectable expression; - indicates no effect; i indicates increased expression; i w = weak increased expression; 
! indicates decreased expression; 
( ) indicates discrepant CELISA results. 
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3.8.2. Estrogen Receptor-alpha Positive Breast Cancer Cell Lines 
3.8.2.1. MCF-7 
The effects of cytokine. combinations on allelic expression of MCF-7 was 
detected using the antibodies L243, pan HLA-DR; NFLD.D10, HLA-DRP1 *15; and 
NFLD.M1, HLA-DRp3. CELISA analysis also incorporated TAL8.1 for detection of 
HLA-DRP 1 *03. Expression of HLA-DRP5 could not be evaluated due to lack of specific 
mAbs. 
Flow cytometry analysis did not reveal any constitutive generic HLA-DR (L243), 
DRP1 *15 (NFLD.D10), or DRP3 (NFLD.M1) expression on MCF-7. Generic HLA-DR 
and DRPl *15 were induced by IL-4 and IL-4 + TGF-pl, but not by TGF-p1, as indicated 
by increased percentage of positive cells (Figure 3.21A) and fluorescence intensity 
(Figure 3.21B). However, neither IL-4, nor TGF-P1, nor IL-4 + TGF-P1 modulated 
DRP3 expression. IFN-y strongly up-regulated expression of generic HLA-DR and 
DRP1 *15, but not DRp3, suggesting that DRP3 was poorly expressed by MCF-7. 
The combination of IL-4 and IFN-y increased the fluorescence intensity of cells 
stained with L243 and NFLD.DlO, but had marginal effects on the percentage of positive 
cells. In contrast, IFN-y + TGF-Pl had no effect on HLA-DR or DRP1 *15. IFN-y + IL-4 
and IFN-y + TGF-P both increased the percentage of cells stained with NFLD.Ml, but in 
both cases, expression was less than twice the background and was therefore considered 
negligible. The highest percentage and expression of HLA-DR, DRPl *15, and DRP3 
resulted following IFN-y + IL-4 + TGF-P1 treatment. 
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The results of CELIS A analysis, depicted in Figure 3.21 C, revealed some 
discrepancies with flow cytometry results, which will be addressed in Chapter 4. Neither 
IL-4 nor IL-4 + TGF-Pl induced generic HLA-DR (L243), DRP1 *15 (NFLD.D10), or 
DRP1 *03 (TAL 8.1). Furthermore, addition of TGF-P to IFN-y had no effect on general 
HLA-DR expression, while its effects on DRP1 *15, DRP1 *03, and DRP3 were 
negligible. Similarly, addition ofiL-4 did not augment IFNy-induced generic HLA-DR or 
DRP1 *03, and the slight up-regulation ofDRPl *15 was negligible. 
Taken together, flow and CELISA results establish that TGF-P does not inhibit 
IFN-y-induced HLA-DR on MCF-7. The results also indicate that TGF-P1 may act 
synergistically with IFN-y + IL-4 to up-regulate, rather than suppress, generic and allelic 
HLA-DR expression on ER+ BCCL. Differential up-regulation of HLA-DR allotypes 
was displayed by MCF-7 as both DRP1 *03 and DRP3 were not up-regulated by IFN-y. 
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Figure 3.21. Effects of cytokines on HLA-DR allelic expression on MCF-7. HLA-DR expression was assessed using Abs: 
L243 (pan HLA-DR); TAL8.1 (DRpl *03); NFLD.DlO (DRPl *15); NFLD.Ml (DRp3). Results are reported as: (A) histogram 
overlays, filled histograms = IgG isotype control, open histogram = Test mAb, and % indicate the percentage of positive cells; 
* (B) MFhest- MFisackgorund as measured by flow cytometry; and (C) ODrest- ODsackground as measured by CELISA. p < 0.05. 
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3.8.2.2. T47D 
To further evaluate the effects of cytokine co-culture on ER+ BCCL, experiments 
were performed on T47D. Since T47D only carries HLA-DRI31 *0102 [210] cytokine 
effects were detected using L243. 
Negligible amounts of constitutive HLA-DR were detected on T47D by flow 
cytometry (Figures 3.22A and 3.22B) and CELISA (Figure 3.22C). Expression was 
unmodulated by IL-4, TGF-131, or IL-4 + TGF-131, but was strongly induced by IFN-y, as 
indicated by increased percentage of positive cells (Figure 3.22A), fluorescence intensity 
(Figure 3.22B), and optical density (Figure 3.22C). Although the percentage of positive 
cells was relatively unaffected by addition of either IL-4 or TGF-131 to IFN-y treatment, 
IL-4 inhibited IFN-y-induced HLA-DR fluorescence intensity and optical density, while 
TGF-131 had no effect. Treatment with IFN-y + IL-4 + TGF-131 also resulted in inhibition 
ofiFN-y induced HLA-DR expression. 
As both T47D and MCF-7 are ER+ BCCL, these results confirm TGF-131 does not 
inhibit IFN-y-induced HLA-DR on ER+ BCCL. Furthermore, since TGF-131 did not 
augment IFN-y + IL-4 induction of generic and allelic HLA-DR on T47D, as previously 
observed on MCF-7, and these two cell lines have no common HLA-DR alleles, these 
results suggest that the effects mediated by cytokine combinations on HLA-DR 
expression are cell line specific. 
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Figure 3.22. Effects of cytokines on HLA-DR expression on T47D. HLA-DR expression 
was measured using the antibody L243 (pan HLA-DR). Results are reported as: (A) 
histogram overlays where filled histograms= IgG isotype control, open histogram= Test 
mAb, and percents indicate the percentage of positive cells; (B) MFhest- MFisackgorund as 
measured by flow cytometry; and (C) ODTest- ODsackground as measured by CELISA. 
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3.8.2.3. Summary of the Differential Effects Mediated by Cytokines on HLA-DR 
Expression on ER-positive breast cancer cell lines. 
A summary of the differential effects mediated by individual and cytokine 
combinations on HLA-DR expression for ER+ breast cancer cell lines is presented in 
Table 3.4. Neither MCF-7 nor T47D constitutively expressed HLA-DR, and in both cases 
expression was unaffected by TGF-Pl. Results for IL-4 and IL-4 + TGF-P1 were 
inconsistent on MCF-7, but flow cytometry suggested that IL-4 up-regulated generic 
HLA-DR and DRP1 *15. In contrast, T47D was unaffected by either treatment involving 
IL-4. 
Both cell lines were responsive to IFN-y to varying degrees, but DRP 1 *03 and 
DRP3 were not up-regulated on MCF-7, suggesting that these proteins were poorly 
expressed. 
IL-4 augmented IFN-y induced generic HLA-DR and DRP1 *15 on MCF-7, but 
antagonized HLA-DR on T47D. This suggested that the modulatory effects mediated by 
cytokines were cell line specific. However, TGF-Pl did not modulate expression on 
either cell line, indicated that TGF-P1 was not inhibitory to ER+ breast cancer cell lines. 
Intriguingly, weak positive expression of DRP 1 *03 and DRP3 was only detected 
on MCF-7 following IFN-y + IL-4 + TGF-P1, suggesting that allotypic expression may 
depend on the surrounding cytokine milieu. This treatment also up-regulated generic 
HLA-DR and DRPl *15 on MCF-7, while it down-regulated HLA-DR on T47D, again 
indicated that modulatory effects were cell line specific. 
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Table 3.4. Summary of the differential effects a on HLA-DR allelic products mediated by cytokine treatments on ER+ breast 
cancer cell lines. 
Effects of Cytokine Treatment on HLA- Effects on HLA-DR 
Cell Line HLA-DR Constitutive DR Expression Expression in Relation to IFNy 
allele expression IL-4 TGF-~1 IL-4 + IFN-y IFN-y+ IFN-y+ IFN-y + 
TGF-~1 IL-4 TGF-~1 IL-4+ 
TGF-~1 
HLA-DR - i (-) - i (-) i i (-) - i 
MCF-7 DR~1*03 - - - - - - - i 
ER+ DR~ I *15 - i (-) - i (-) i (-) i - i 
DR~3 - - - - - - - i (-) 
T47D HLA-DR 
- - - - i ! - ! 
a Expression was considered positive if values were twice the background. 
+ indicates detectable expression; - indicates no effect; j indicates increased expression; ! indicates decreased expression 
( ) indicates discrepant CELISA results. 
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3.9. Determining BCCL TGF-[31 Sensitivity 
Western blots were performed to determine BCCL responsiveness to TGF -~ 1 
stimulation, as indicated by phosphorylation of Smad2 and Smad3 proteins. As described 
in Section 1.4.3, Smad2/3 are key proteins involved in TGF-13 intracellular signaling that 
become activated upon phosphorylation, forming a complex with Smad4 which 
translocates to the nucleus and effects the transcription of TGF -13 sensitive genes. The 
presence ofphosphorylated-Smad2/3 (P-Smad2, P-Smad3) indicates active internal TGF-
~ signaling and functional TGF-13 receptors on the cell surface. Thus, the absence of P-
Smad2/3 suggests the absence of one or more of the TGF-13 receptors (TGFI3-RI, TGFI3-
RII) on the cell surface, or alternatively, that the receptors are present but nonfunctional. 
As shown in Figure 3.23, anti-P-Smad3 analysis indicated two bands in BT-20, 
MDA MB 157, MDA MB 231, MDA MD 468, and SKBR3. This work was performed in 
collaboration with Dr. Jules Dore using an Ab derived from rabbit anti-serum. P-Smad3 
is the lower of these two bands, with the upper band believed to be cross-reaction with 
total Smad3 or evidence of a contaminating Ab (Jules Dore , personal communication). 
P-Smad3 was found in all ER- BCCL, illustrating that ER- BCCL were sensitive 
to TGF-~1 treatment. Weak P-Smad3 expression was noted in SKBR3 compared to other 
ER- cell lines. Among the ER+ BCCL, P-Smad3 was detected in MCF-7, but not BT-474 
or T47D. Weak bands were visible in BT-474 and T47D, however, as these cell lines 
lacked Smad3 expression, this detection was believed to be artifactual or due to 
contaminating Ab in the rabbit anti-serum. Immunoblotting with anti-Smad3 confirmed 
there were equivalent amounts of Smad3 in treated and untreated cells. These results are 
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Figure 3.23. TGF-131-mediated phosphorylation of Smad3 in breast cancer cell lines. 
Cells were stimulated with 5 ng/ml TGF -~ 1 for 1 hour and Smad3 phosphorylation was 
determined by Western blotting. Total Smad3 and anti-a tubulin were detected as 
controls. The arrow indicates the location of P-Smad3. Results are representative 
examples of duplicate experiments. 
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consistent with a loss of TGF-~ sensitivity in most ER+ BCCL, as indicated in several 
previous studies [240, 244-248]. 
Notably, MCF-7, MDA MB 157, MDA MB 468, and SKBR3 (weak) were found 
to express constitutive P-Smad3. Furthermore, TGF-~1 treatment increased the amount of 
P-Smad3 in MCF-7, MDA MB 157, MDA MB 468, but not SKBR3. 
In contrast to P-Smad3, expression of P-Smad2 appeared more cell-line specific. 
P-Smad2 was detected in MDA MB 157, MDA MB 231, MDA MB 468 and BT-474, but 
was not detected in MCF-7, T47D, BT-20, or SKBR3. Furthermore, of cell lines 
displaying P-Smad2, none appeared to do so constitutively. Immunoblotting with anti-
Smad2 confirmed there were equivalent amounts of Smad2 in treated and untreated cells. 
These results suggest that only selective BCCL are capable of mediating P-Smad2-
dependent signaling in response to TGF -~ 1 stimulation. 
Taken together, analysis of Smad 2 and Smad 3 phosphorylation in BCCL suggest 
that only T47D may lack or have a nonfunctional TGF-~ receptor on the cell surface as 
neither P-Smad2 nor P-Smad3 was detected in this cell line. All other BCCL displayed P-
Smad2 and/or P-Smad3, or increased levels of P-Smad3 in response to TGF-~1 
stimulation (Table 3.5). However, no P-Smad2 or increase in constitutive P-Smad3 was 
detected in SKBR3, suggesting that TGF-~ 1 augmentation of IFN-y-induced HLA-DR 
expression in SKBR3 may be mediated through a Smad-independent pathway. 
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Figure 3.24. TGF-P1-mediated phosphorylation of Smad2 in breast cancer cell lines. 
Cells were stimulated with 5 ng/ml TGF-P 1 for 1 hour and Smad2 phosphorylation was 
determined by Western blotting. Total Smad2 and anti-a tubulin were detected as 
controls. Results are representative examples of duplicate experiments. 
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Table 3.5. Detection of Smad proteins in breast cancer cell lines through Western 
blotting. 
Breast Cancer Smad3 P-Smad3 Smad2 P-Smad2 
Cell Line NoTx TGF-(3 NoTx TGF-(3 NoTx TGF-(3 NoTx TGF-J3 
MCF-7 + + + + +w +w - -
BT-474 - - - - + + - + 
T47D - - - - + + - -
BT-20 + + - + + + - -
MDAMB 157 + + +w + + + - + 
MDAMB231 + + - + + + - + 
MDAMB468 +w +w + + + + - + 
SKBR3 +w +w +w +w + + - -
+=detectable express10n; +w =weak detectable express10n;- =no detectable expression. 
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Chapter 4: Discussion 
Ongoing research m our laboratory is focused on the mechanisms and 
significance of HLA-class II expression on breast cancer cells. A previous study by A.E. 
Edgecombe [21 0] clearly showed that a minority of breast cancer cell lines have 
constitutive class II expression, while the majority is inducible by treatment with IFN-y. 
Her work also revealed differential expression of HLA-class II (DR, DQ and DP) and co-
chaperones. Recently, our laboratory showed that DR-positive tumor cells in breast 
carcinoma tissues differentially express their DR alleles [249]. Subsequently, it was 
found that expression is influenced by IFN-y, IL-4 and TGF-13 and is clinically associated 
with ERa and age of diagnosis (Sharon Oldford, personal communication). This implies 
that HLA-DR expression by breast cancer cells is modulated by estrogen and the 
cytokine milieu. Based on the background of these findings, the work described in this 
thesis was aimed at determining how these interacting factors affect HLA-DR expression 
in ER+ and ER- cell lines. 
4.1. Summary of Key Findings 
• Constitutive and IFN-y-induced HLA-DR expression on ER+ and ER- BCCL was 
affected by culturing the cells in E2-containing and E2-depleted medium, 
suggesting that estrogen had modulatory effects on DR expression. The individual 
effects of estradiol could not be ascertained as reconstitution solvents (ethanol, 
DMSO, 1-butanol, and methanol) suppressed HLA-DR expression on breast 
cancer cell lines. 
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• TGF-P1 mRNA in ER+ and ER- BCCL was affected by culturing the cells inEz-
containing and E2-depleted medium, suggesting transcription was modulated by 
estradiol concentrations. 
• Two of 8 breast cancer cell lines constitutively expressed HLA-DR, which was 
inhibited by TGF-P1 and correlated with differential expression of constitutive P-
Smad3 and P-Smad2. 
• IFN-y up-regulated generic HLA-DR molecules on all cell lines to varymg 
degrees. Aside from DRP 1 *04, which was poorly up-regulated on BT -20 and 
MDA MB 157, all other allotypes were up-regulated. Overall, the degree of IFN-y 
induction did not depend on the allotypes expressed by particular breast 
carcinoma cells. 
• IL-4 alone and combined with IFN-y, selectively modulated HLA-DR expression 
in a cell line-specific manner. 
• TGF-P 1 mediated differential effects on HLA-DR expression on breast cancer 
cell lines. In contrast to studies indicating TGF-P suppression ofCIITA, TGF-P1 
augmented DR expression on SKBR3 and BT-20. Analysis of P-Smad2 and P-
Smad3 indicated these differential effects may be explained by differential 
expression of Smad signaling components, and suggested IFN-y + TGF-P1 
synergy may occur in a Smad-independent manner. TGF-P1 did not modulate DR 
on ER + cell lines. 
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• The effects of IL-4 + TGF-P on constitutive and IFN-y-induced HLA-DR 
expression suggest that the quantity and function of IL-4 and TGF-P receptors on 
the cell surface direct the effects of combined cytokine treatment. 
• Our study indicates that breast cancer cell lines mediate cell-line specific effects. 
Thus, studies employing cell lines need to be carefully evaluated before the 
results of in vitro studies can be translated to in vivo situations. 
4. 2. Study Concerns 
4. 2.1. Cell Lines 
Breast cancer cell lines used in this study were kindly provided by Dr. Shou-
Ching Tang and Dr. Alan Pater (Section 2.1 ). The identity of each of these cell lines was 
previously confirmed by A.E. Edgecombe via comparison of short tandem repeat 
sequences published by the ATCC [21 0]. Whether these breast cancer cell lines are 
representative of the tumors from which they originated, and whether their diversity 
reflects inter-tumoral heterogeneity remains matters of debate. Some argue that 
prolonged in vitro culture of breast cancer cells in artificial conditions modify the 
properties of cell lines making them genetically different from the initial population. 
Furthermore, inter-laboratory differences are known to occur for commonly used cell 
lines, conflicting data comparison. For example, MCF-7 cell stocks from different 
laboratories have been shown to differ in sensitivity to 17P-estradiol, associated with 
variations in ER protein and mRNA levels [250]. 
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4. 2. 2. Experimentation Concerns 
Cytokine-mediated effects on HLA-DR expression on breast cancer cell lines 
were analyzed by both flow cytometry and CELISA. However, sometimes discrepancies 
were evident between these two experimental assays, causing limitations that will be 
discussed in Section 4.5.1. 
4.3. Estrogen Modulation of HLA-DR expression on Breast Carcinoma Cell Lines 
4.3.1. Media Composition Affects HLA-DR Expression on Breast Carcinoma Cell Lines 
As previously reviewed in Section 1.5.1, numerous studies have indicated that 
17P-estradiol has immunomodulatory effects on MHC class II expression on a variety of 
cell types. To analyze the effects of estradiol on HLA-DR expression on breast cancer 
cell lines, we began by comparing HLA-DR expression on cells cultured in standard 
medium and E2-depleted medium which differed particularly in the content of steroidal 
and nonsteroidal estrogens. 
Collectively these results indicated that media composition, and particularly 
estrogen in culture media, differentially affected constitutive and IFN-y inducible HLA-
DR expression on breast cancer cell lines. Since media composition did not modulate 
HLA-DR expression on MDA MB 468, BT-20, MCF-7, or BT-474, our results did not 
indicate unanimous trends for ER- or ER + breast carcinoma cell lines. Thus, we suggest 
that the effects mediated by media composition and estrogen on HLA-DR expression are 
cell-line specific. Moreover, as IFN-y induction ofHLA-DR on SKBR3 (ER-) was higher 
in E2-containing media, our results suggested that estrogen could affect HLA-DR 
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expression on bothER+ and ER- cells lines. This posed the question of how estrogen-
mediated modulation may occur in ER- cell lines, and suggested that ER- breast cancer 
cells are not totally insensitive to estrogen. Through in vitro studies, others have also 
indicated that some ER- breast cancer cell lines respond to estrogens and antiestrogens, 
suggesting that these compounds act through an alternative mechanism than ERa [179]. 
Although we have concentrated on effects mediated potentially by differences in 
steroidal and non-steroidal estrogen content, it is possible that other factors may be 
implicated. For example, the amounts of creatine, glucose, insulin, thyroxine, and 
phosphorous differ between normal FCS and charcoal dextran-treated FCS according to 
the composition information provided by the manufactures (Invitrogen and Hyclone, 
respectively). The effects of such factors on HLA-DR expression on breast carcinoma 
cell lines is presently unknown, and thus may warrant further investigation. 
Notably, our results are contradictory to previous studies reporting constitutive 
HLA-DR expression on BT-20, MDA MB 231, T47D, SKBR3, and MCF-7 cultured in 
standard medium [21 0, 251]. These discrepancies are not surprising, given that 
differences in cell line passage number may affect the ability to express different 
molecules, and cultured cells may acquire mutations over time. Batches of FCS may also 
vary in hormone and chemical content, altering medium composition. 
In agreement with other studies [210, 212, 213, 252], we found strong HLA-DR 
up-regulation on MDA MB 231, SKBR3, MDA MB 157, BT-20, and T47D in response 
to IFN-y. 
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4.3.2. Differential Expression of ERa mRNA in Breast Carcinoma Cell Lines 
ERa transcription was examined in all 8 breast cancer cell lines by RT-PCR using 
primers specific to a 550-base-pair wild-type fragment from exon 2 of human ERa 
eDNA [226]. Consistent with documentation provided by the ATCC, we found ERa 
mRNA expression in BT-474, T47D, and MCF-7, but not in MDA MB 231, MDA MB 
468 and SKBR3 (Figure 3.4A). In addition, we found ERa mRNA in BT-20, which is 
classified as ER- by ligand binding analysis, but was previously shown to express a 
variant ERa transcript that contains an exon 5 deletion [236, 253]. Sequence analysis of 
this BT -20 variant ER transcript has revealed a frame-shift alteration resulting in a stop 
codon at the 5' end of exon 6, which translates into expression of a truncated form of the 
receptor lacking the majority of the hormone-binding domain [254]. Since our ERa 
primers were specific for exon 2, this variant would be amplified by RT-PCR. 
We also found ERa mRNA in MDA MB 157 which is in contrast to ATCC 
reports. We are confident that this discrepancy is not the result of a mislabeled cell line as 
the identity of each breast cancer cell line was confirmed by comparison with short 
tandem repeat sequences published by the ATCC [21 0]. 
The ERa transcript observed in MDA MB 157 was of similar size as wild-type 
ERa found in BT-474 (Figure 3.4B), but may also indicate an ERa variant. Variants 
include exon-deleted, exon-duplicated, or truncated ER mRNA transcripts that encode a 
variety of incomplete ER-like proteins missing some functional domains ofthe wild-type 
receptor [255, 256]. Variant ERa mRNAs have been reported in breast cancer cell lines 
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other than BT-20, including T47D and MCF-7 [253, 257-259]. A range of ER variant 
mRNAs also occur in clinical breast cancer and are believed associated with altered 
responsiveness to estrogens and/or antiestrogens [256, 260-262] and play a role in 
tumorgenesis [263, 264]. However, since transcription does not necessarily correlate with 
protein translation, future work to determine whether MDA MB 157 expresses ERa 
protein should include Western blot analysis and comparison of molecular weight of this 
protein with wild-type ERa. 
An alternative explanation for ERa amplification in MDA MB 157 is cross-
reaction of ERa primers with ERp. Our primers were checked using the AmplifY program 
for negative cross-reactivity with the wild-type ERP sequence, but 5 ERP isoforms are 
known to occur. In fact, four of these altered isoforms have been cloned and 
characterized from MDA MB 157 [265]. Since the human ERP is highly homologous to 
human ERa, particularly in the amino-terminal domain (96% amino acid homology) 
where our primers bind [175], it is possible that one of these isoforms was amplified by 
our primers. A recent BLAST search also confirmed that our primers may recognize 
mRNA of estrogen-receptor related variant protein (Accession # M69296), estrogen-
related receptor beta (Accession # NM_004452), and estrogen-related receptor beta2 
(Accession# AF094517). 
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4.3.3. Media Composition Affects ERa mRNA in Breast Carcinoma Cell Lines 
We found that ERa transcript amplification was much higher for T47D and MCF-
7 cultured in standard medium than E2-depleted medium, suggesting that estradiol levels 
influenced ERa transcription. These results may be explained by genetic instability 
provoked by cell culture conditions, such as was described in T47D-5 (T47D subline) 
which developed estradiol insensitivity when maintained for almost continuous 
exponential growth [266]. On the other hand, differences in ERa mRNA may involve 
factors that control expression of ERa. 
The expression of ERa mRNA is differentially regulated by estrogen in estrogen-
responsive breast cancer cell lines. Estrogen treatment has been shown to decrease ERa 
mRNA levels in MCF-7 cells [267, 268], and increase ERa mRNA levels in T47D cells 
[267, 269]. Studies examining short- and long-term culture ofT47D and MCF-7 cells in 
phenol red-free and estrogen-depleted medium also report considerable changes in 
morphology, growth rate, receptor content, and response to hormones and antihormones 
[270, 271]. These studies indicated that ER content steadily increased in MCF-7 cultured 
in low or estrogen-depleted medium [270, 271], whereas ER content and ER mRNA 
decreased in T47D in response to short-term and long-term estrogen deprivation [218, 
272]. Thus, our findings are in agreement with those reported for T47D, but are in 
contrast to those for MCF-7. 
Differential regulation by estrogen may also be due to different promoter usage. 
Cloning and sequencing of human ERa DNA has identified three promoters (A, B, C) 
which are coordinately regulated by estrogen [236]. It has been shown that all three 
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promoters are used by both MCF-7 and T47D for expression of ERa [236]. However, 
estrogen down-regulated all three promoters in MCF -7, but up-regulated all promoters in 
T47D [236]. This demonstrated that estrogen regulation varies in a cell-specific manner 
but not in a promoter-specific manner, and excluded the possibility that a single promoter 
controlled the expression of ER mRNA levels in breast cancer cells. Furthermore, 
Donaghue et al. [236] reported that BT-20 cells expressed low levels of ERa transcripts 
which were derived solely from promoter A, suggesting that low levels of ERa 
expression in BT-20 could be due to differential promoter usage, the number of 
promoters used, or lower activity of all promoters. Future research could examine 
whether similar differential promoter usage or differential promoter activity occurs in 
MCF-7 and T47D cultured in E2-depleted medium. 
A variety of signaling pathways may also influence ERa expressiOn. 
Hyperactivation of MAPK signaling pathways, as a result of overexpression or activation 
of epithelial growth factor receptor (EGF) and Her-2/neu [273, 274], correlates with 
down-regulation of ERa on breast carcinoma cells [275-277]. As T47D is Her-2/neu+ 
[278] and MCF-7 is Her-2/neu- [216, 276], this could potentially explain the reduction of 
ERa in T47D but not in MCF-7. However, our results suggest that Her-2/neu expression 
does not always correlate with down-regulation of ERa in breast cancer cell lines, as BT-
474, which overexpresses Her-2/neu [216, 276], did not display reduced ERa 
amplification when cultured in E2-depleted medium. Consistent with our findings, reports 
indicate that ERa is down-regulated in MCF-7 cells cultured under estrogen-depleted 
conditions due to hyperactivation of ERK1/2 [279, 280]. This inhibition may also be 
133 
attributable to nuclear factor-kappa B (NFKB) signaling, as inhibition of NFKB partially 
restored ERa activity and expression in MCF-7 [281]. These breast cancer cell lines may 
be capable of activating MAPK signaling in an autocrine manner, as Martinez-Carpio et 
al. [282] demonstrated that MDA MB 231 secretes and possesses EGF receptors. Several 
reports also indicate that MAPK can directly phosphorylate ERa on serine residue 118 
[283, 284]. Thus, if phosphorylation of this residue leads to ubiquination and degradation 
of ERa, then hyperactivation of MAPK as a result of culture in estrogen-depleted 
medium could lead to reduced ERa mRNA. Future research could examine whether 
medium composition modifies MAPK or NFKB signaling in MCF-7 and T47D. 
4.3.4. Effects of 17f3-estradiol Treatment on HLA-DR Expression on Breast Cancer Cell 
Lines 
A primary objective in this thesis was to examine the effects of 17P-estradiol on 
constitutive and IFN-y-induced HLA-DR expression on breast cancer cell lines. 
However, despite efforts to find alternative reconstitution solvents for estradiol, we were 
unable to determine the effects of estradiol on HLA-DR expression on MCF-7 or MDA 
MB 231 due to modulation of HLA-DR by ethanol, DMSO, 1-butanol, and methanol 
vehicle controls. These results thus emphasize the importance of including appropriate 
controls when examining the effects of estradiol on HLA-DR expression. 
Ethanol is known to affect MHC Class II expression. Studies on mice have 
indicated that ethanol decreased MHC Class II expression on B cells, and suppressed 
MHC Class II molecule-mediated T cell responses, but not MHC Class I molecule-
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mediated T cell responses, in a dose-response manner [285-287]. Ethanol also appears to 
mediate other effects on breast carcinoma cells, with results depending on ERa status. 
Reports indicate that culture of ER + breast cancer cell lines in ethanol containing 
medium is associated with increased proliferation rate, ERa content, and ER 
transcriptional activity, while no effects were seen with ER- breast cancer cells [288-
291]. In contrast, we found ethanol concentrations equalivant to that present within our 
10-6 - 10-9 M estradiol solutions were anti proliferative to MCF -7 (data not shown). 
However, these results may depend on the cell lines investigated, the concentration of 
ethanol used, the incubation period, and medium composition. 
Although we report that both methanol and 1-butanol inhibit MHC class II 
expression on breast cancer cells, studies suggest that primary alcohols do not always 
exert similar effects despite similar molecular structure. Etique et al. [292] compared the 
effects of methanol and 1-butanol to ethanol on MCF-7 cells and found that unlike 
ethanol, methanol and 1-butanol did not stimulate MCF-7 cell proliferation or increase 
aromatase mRNA. However, methanol-treated cells displayed increased ERa content, 
which was not evident in butanol-treated cells [292]. 
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4. 4. Cytokine Expression in Breast Cancer Cell Lines 
4.4.1. Cytokine mRNA 
As our second objective was to analyze the effects of IFN-y, IL-4, and TGF-~1 
combinations on HLA-DR expression on breast carcinoma cell lines, we wondered if the 
breast cancer cells were transcribing and possible secreting any of these factors. Thus, 
breast cancer cell lines were assessed using sequence specific primers and RT-PCR 
(Section 3.6). 
Constitutive IFN-y and IL-4 transcription was not detected in any of the 8 BCCL 
cultured in either standard or E2-depleted medium, suggesting that neither IFN-y nor IL-4 
was produced by the breast cancer cell lines themselves. 
In contrast, TGF -~ 1 transcription was detected in 8/8 breast cancer cell lines 
cultured in standard medium, and 7/8 cultured in E2-depleted medium. These findings 
were not surprising as others have shown that TGF -~ mRNA is overexpressed in breast 
cancers and neoplastic breast tissues [293]. TGF-~ may also be secreted directly by breast 
cancer cells and several breast cancer cell lines, including MDA MB 468, MCF-7, T47D, 
MDA MB 231, BT-20, SKBR3, and Hs578T [244, 294-296]. TGF-~ is secreted as a 
latent protein by tumor cells, but once activated, confers a selective advantage to the 
tumor in vivo by suppressing the cytotoxic activity of infiltrating lymphocytes [297] and 
antigen presentation by APCs [298, 299], allowing the tumor to proliferate and progress. 
The activation of latent TGF-~ is poorly understood, but is believed to involve certain 
proteases. Therefore, if breast cancer cell lines are capable of secreting both TGF-~ and 
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protease enzymes, they could activate TGF -P within culture media and possibly mediate 
an autocrine effect. 
We found that medium conditions influence TGF-P1 transcription. TGF-P1 
amplification was more intense in BT-474 and T47D cultured in standard medium, while 
it was more intense in MDA MB 157, MDA MB 231, MDA MB 468, MCF-7 and BT-20 
cultured in E2-depleted medium (Figure 3.13). TGF-P1 amplification was also detected in 
SKBR3 cultured in standard medium but not E2-depleted medium. These results 
suggested that estradiol influenced TGF-P 1 transcription in breast carcinoma cells. Since 
TGF -P 1 transcription did not correlate with estrogen receptor status, which is in 
agreement with previous reports [300], we suggest that estradiol modulation occurs in a 
cell line specific-manner. 
Although we found that TGF-P1 transcription was slightly increased in MCF-7 
cultured in E2-depleted medium, it appears that some controversy exists over this issue in 
the literature. Herman and Katzenellenbogen [30 1] assessed long-term effects of steroid 
deprivation and reported that mRNA for TGF-P1 was transiently increased at 2 to 10 
weeks of steroid deprivation. On the contrary, others have reported that estrogen did not 
modulate TGF-P1 mRNA levels in MCF-7 at 48 hour or 7 day time points [302, 303], 
which are more similar to our study. 
137 
4.4.2. Cytokine Receptor Concerns 
This study did not examine the expression of IFN-y, IL-4, or TGF-P receptors on 
the surface of breast cancer cell lines. However, our laboratory has previously showed 
that IFN-y significantly up-regulated HLA-DR on all breast cancer cell lines examined in 
this study [210]. Thus, these cell lines must possess IFN-y receptors and components of 
the IFN-y-signaling pathway as they displayed sensitivity to IFN-y stimulation. 
Reports also indicate that the IL-4R is highly expressed on human melanoma and 
ovarian carcinomas compared to normal cells [136]. More relevant to this study, IL-4 
receptors are overexpressed on breast cancer cell lines, and breast carcinomas relative to 
normal breast epithelium [136]. Displacement analysis of 125I-IL-4 binding to breast 
cancer cells has revealed that MCF-7, BT-20, ZR-75-1, and MDA MB 231 express high 
affinity IL-4Rs, with receptor numbers varying among cell lines [120]. Thus, we can be 
fairly confident that three of the cell lines we used expressed IL-4Rs. 
On the other hand, loss of TGF-P response due to dysregulation of TGF-P 
receptors type I (TPRI) and type II (TPRII) is well known to contribute to oncogenesis in 
a variety of cancer cells [304], including breast carcinoma [305]. Several ER+ breast 
cancer cell lines are known to be defective of TPRII [240], complicating analysis of 
TGF-P-mediated effects in breast cancer cell lines. In contrast, ER- BCCL generally 
retain expression of TPRII but may show a low level sensitivity to TGF-P [239]. The 
only reported exception to this dogma is that early passage MCF-7 cells, which were 
initially sensitive to TGF-p, gain resistance after long term passage [239, 245, 296]. 
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Sensitivity to TGF-13 may be restored in ER+ BCCL through stable transfection ofTI3RII 
[240, 247, 306]. Mutations of TI3RI are reported to occur in a low percentage of breast 
cancers [306], and restoration of TGF-13 signaling in breast cancer cell lines with silenced 
TGFI3I may occur through use of histone deacetylase inhibitors [306]. 
4.5. Cytokine Modulation of HLA-DR Expression on Breast Cancer Cell Lines 
To our knowledge, this is the first study to report selective up-regulation of HLA-
DR alleles on human cancer cell lines in response to combined cytokine treatment, and 
the first to examine differential HLA-DR allelic expression in E2-depleted medium. We 
decided that cells would be treated with 100 units/ml IFN-y, 500 units/ml IL-4, and 10 
ng/ml TGF -131 based on preliminary research, cytokine titrations, and previous published 
studies. The 96 hour incubation period was utilized as it was previously shown to be 
optimal for IFN-y induction ofHLA-DR on breast cancer cell lines [210]. 
4.5.1. Assay limitations 
HLA-DR specific antibodies, used to assess HLA-DR expression, were shown to 
bind strongly to HLA-DR allelic products on appropriate B cell line controls (Table 2.4). 
As HLA-DR molecular conformations may differ on breast carcinoma cells compared to 
B cell controls, our laboratory has previously established that these mAbs neither 
recognized cell-type restricted epitopes nor crossreacted with additional DRB allotypes 
based on examination of various cell types with known DR allotypes. These included 
IFN-y-treated ovarian and breast cancer cell lines, peripheral blood mononuclear cells 
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(from local donors), B cell lines (lOth IHW), mouse L-cell fibroblast lines transfected 
with HLA-DR molecules (11th IHW), and synovial tissue sections [249]. Thus, mAbs 
used in this assay were selected because they bound HLA-DR molecules on many cell 
types. Furthermore, each mAb was also previously shown to bind one or more breast 
cancer cell lines [210], indicating their suitability for binding HLA-DR on breast 
carcinoma cells. Based on this, failure to detect a particular HLA-DR product is likely 
due to lack of expression rather than weak antibody reactivity. 
Preliminary experiments indicated that despite equivalent detection of DRP 1 *04 
on B cell line controls (Table 2.4), 359-13F10 was much better than NFLD.D1 for 
detecting DRP1 *04 on BT-20 (Figure 3.2). This difference could pertain to the epitopes 
recognized by these antibodies as 359-13F10 binds the HLA-DRP1 *04 P1 domain [307] 
and NFLD.D1 binds the P2 domain [222]. Thus, glycosylation near the cell surface could 
inhibit accessibility to the NFLD.D1 epitope and be responsible for such findings. 
Consistent with this, NFLD.D1 was shown to bind strongly to intracellular DRP1 *04 
[210]. Unfortunately, the supply of 359-13F10 was limited so NFLD.D1 was utilized for 
detection of DRP 1 *04 on breast carcinoma cell lines. 
We were unable to study expression of DRP4 or DRP5 HLA-DR types on breast 
carcinoma cells due to lack of specific mAbs. Therefore, it is possible that additional 
HLA-DR types were also modulated in response to various cytokine treatments. 
Finally, cytokine-mediated modulation of HLA-DR expression was detected by 
both flow cytometry and CELISA; however, in some cases discrepancies were evident 
between flow cytometry and CELISA analysis (Tables 3.3 and 3.4). This may be due to 
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the ability to remove dead cells through gating in flow cytometry analysis, but inability to 
do similar removal by CELISA analysis. In this regard, primary antibodies often stick to 
dead cells and could skew CELISA optical densities, providing inaccurate results. We 
have also identified sensitivity differences between these two assays as constitutive and 
modulated expression was often detected by flow cytometry but not CELISA. 
4.5.2. Constitutive HLA-DR Expression 
As summarized in Tables 3.3 and 3.4, constitutive HLA-DR expression was 
detected on MDA MB 231 and inconsistently detected on BT-20 using the pan anti-HLA-
DR antibody L243. Examination of DRP1 *07 and DRP3 allelic products on MDA MB 
231 revealed that constitutive expression was predominately DRp3. Examination of 
DRP1 *04, DRP1 *13, and DRP3 allelic products on BT-20 failed to reveal any 
constitutive expression suggesting that constitutive expression detected by L243 was 
either DRP4, or that individual allotypic expression was below the limits of detection of 
allele specific mAbs. This finding also confirmed a previous report on BT-20 [210]. 
Constitutive expression on BT -20 was also inconsistent as it was detected by flow 
cytometry during preliminary experiments (Section 3.1) and during analysis of cytokine 
modulation of HLA-DR (Section 3.8.1.4), but was not detected by CELISA during the 
medium comparison study (Section 3.2). Thus, our results indicate sensitivity differences 
between the two assays and suggest that flow cytometry was more sensitive than 
CELISA for detection ofHLA-DR on breast cancer cell lines. 
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4.5.3. IFN-y 
IFN-y induced generic and allelic HLA-DR to varying degrees on all breast cancer 
cell lines (Tables 3.3 and 3.4), confirming previous findings [210, 213, 308]. Up-
regulation of nearly all HLA-DR molecules on breast carcinoma cells was not surprising 
as IFN-y is the most potent inducer of MHC class II expression [212]. However, 
differential induction of HLA-DR alleles on MDA MB 157, BT-20, MCF-7, and MDA 
MB 231 is intriguing as it suggested selective up-regulation of HLA-DR molecules on 
breast carcinoma cells in response to IFN-y. 
It is tempting to speculate that poor IFN-y induction ofDRj31 *04 in both MDA MB 
157 and BT -20 is inherent to DRj31 *04 as other alleles in these cell lines were expressed. 
However, since only two cell lines were analyzed, it is impossible to draw such 
conclusions. Another allotype, DRj33, which was poorly up-regulated on BT-20 and not 
up-regulated at all on MCF -7, was strongly up-regulated on MDA MB 231, illustrating 
the problem of drawing conclusions on the basis of a few cell lines. Similarly, DRj31 *07 
was poorly up-regulated on MDA MB 231, a line which strongly expresses HLA-DR, but 
moderately up-regulated on SKBR3, a line which expresses considerable less DR than 
MDA MB 231. Based on the small number of cell lines examined in this study, we 
suggest that allotypic expression is regulated internally in a cell line-specific manner. 
We suggest that DRj33 and DRj31 *03 are poorly expressed by MCF-7 as neither 
allele was up-regulated by IFN-y. These findings may be simply explained by loss of 
heterozygosity, as DRj33 and DRj31 *03 are commonly expressed as a haplotype. 
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Furthermore, our results are in contrast to a previous study in which 500 units/ml IFN-y 
provoked substantial up-regulation of DR~1 *03 and DR~3 on MCF-7 cultured in 
standard medium [210]. While our study differed in terms of both IFN-y concentration 
and medium composition, we have previously indicated that the concentration of IFN-y 
(Section 3.7.1) and the presence I absence of estradiol (Section 3.2) had minimal effects 
on generic HLA-DR expression on MCF-7. Thus, future research could examine if our 
cell line has lost the MHC complex on one of its chromosome 6. 
4.5.4. IL-4 
IL-4 did not modulate constitutive HLA-DR expression on MDA MB 157, MDA 
MB 231, SKBR3, BT-20 or T47D. However, IL-4 induced HLA-DR and DR~1 *15 on 
MCF-7 according to flow cytometry analysis (Table 3.4). Overall, addition of IL-4 did 
not affect IFN-y induced HLA-DR on MDA MB 157, but suppressed IFN-y induced 
HLA-DR on MDA MB 231 and T47D. In contrast, IFN-y + IL-4 augmented HLA-DR on 
SKBR3, and generic HLA-DR and DR~1 *15 on MCF-7. Taken together, the results 
suggest that IL-4 alone and in combination with IFN-y, selectively modulated HLA-DR 
on breast carcinoma cell lines. These effects also appeared to occur in a cell line-specific 
manner. 
IL-4 mediated modulation of HLA-DR has been previously reported in human 
monocytes [130], B cells [126, 127], melanoma cells [134], and renal cell carcinomas 
[135]. Such effects are believed to be dependent on JAK1/JAK3 activation of the STAT-
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6 pathway [ 122, 131-13 3]. Whether IL-4 mediated induction of HLA-DR on M CF-7 is 
also STAT -6-dependent is presently unclear and may warrant further investigation. 
Enhanced HLA-DR expression on MCF-7 and SKBR3 with IL-4 was modest at 
best, and the ability to detect these modest levels was inconsistent. However, the 
combination of IFN-y and IL-4 is known to augment MHC class II expression in primary 
microglial cells, melanoma carcinoma cells, and breast carcinoma cells [84, 136]. These 
findings are in contrast to other studies describing IL-4 suppression of IFN-y-induced 
CIIT A accumulation, and in turn, MHC class II expression on monocytes, murine 
microglial cell lines, and rat astrocytes [84, 130, 137-139]. Such studies indicated that IL-
4 did not inhibit phosphorylation of STAT-1 or USF-1 of the IFN-y signaling pathway, 
suggesting interaction with cis-acting elements in the CIIT A promoters [84]. 
Nevertheless, the discrepancy identified here may be due to the different cell types 
examined. 
The role of CIITA in IL-4 induction of MHC class II on B cells has been 
extensively studied. Itoh-Lindstrom et al. [80] demonstrated using CIITA_,_ mice that 
CIITA is required for IL-4 induction of MHC class II transcription in murine B220+ B 
cells and Mac-1 + cells. However, a more recent report indicated that while IL-4 caused a 
4-fold increase in MHC class II expression on B220+ murine splenic B cells, IL-4 did not 
affect mRNA levels of MHC class II or CIITA as determined by quantitative real-time 
RT-PCR [309]. Thus, post-transcriptional and post-translational mechanisms may 
contribute to increased MHC class II expression in response to IL-4. 
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Since we found that IL-4 modulated IFN-y-induced HLA-DR expression on MDA 
MB 231, SKBR3, BT-20, MCF-7, and T47D, this indicated that these cell lines were 
responsive to IL-4 and likely expressed IL-4Rs, confirming previous studies [120]. Based 
on our observations, only MDA MB 157 is questionable for IL-4 sensitivity, as there was 
minimal modulation of HLA-DR expression and affects on cell numbers were 
inconsistent (Appendix A). On this note, the differential effects mediated by IL-4 
addition on breast carcinoma cells may depend on the number of IL-4Rs present of the 
cell surface. Future research could examine whether an association exists between the 
quantity of IL-4Rs on breast cancer cells and the differential responses to individual and 
combined IL-4 treatments. 
4.5.5. TGF-fJJ 
We found that TGF -P 1 almost completely eradicated constitutive generic and 
allelic HLA-DR expression on MDA MB 231 and BT-20 breast carcinoma cells (Tables 
3.3 and 3.4). In combination with IFN-y, TGF-P1 inhibited IFN-y induction ofHLA-DR 
on MDA MB 157 and MBA MB 231, but surprisingly augmented IFN-y induced generic 
and allelic HLA-DR on BT-20 and SKBR3. TGF-P1 did not modulate IFN-y induced 
HLA-DR on MCF-7 or T47D, agreeing with previous studies that ER+ breast cancer cell 
lines lose responsiveness to TGF-P stimulation [239, 240, 245, 296]. More interestingly, 
results on BT-20 suggested that TGF-P1 may act differently when combined with IFN-y 
as TGF-P alone inhibited constitutive HLA-DR, but with IFN-y it increased HLA-DR. 
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TGF-f31 induction of HLA-DR on particular breast carcinoma cells is in contrast to 
previous reports describing TGF-f3-mediated suppression of CIITA and IFN-y-induced 
MHC class II expression in various cell types, including astrocytes [86], monocytes [87], 
macrophages [310], microglial cells [84], fibrosarcoma cells [88, 100, 101], epithelial 
cells [311], melanoma cells [312], and synovial cells [153]. In such studies, TGF-f3 
inhibited constitutive and IFN-y inducible CIIT A mRNA accumulation, and resulting 
MHC class II expression through interaction with CIITA pili and piV [86, 101]. 
However, this transcriptional inhibition was not due to destabilization of CIITA mRNA 
[88]. 
Piskurich et al. [100] revealed that TGF-f3 suppression of pill was more complete 
than that of piV in 2ITGH human fibrosarcoma cells. It is unknown whether TGF -f31 
mediates similar suppression of pill and piV in breast carcinoma cells, but this may 
correlate with the divergent patterns of TGF-f31 suppression on HLA-DR in breast 
carcinoma cell lines. Furthermore, as TGF-P did not completely abolish activity from 
either promoter [100], this provides a possible explanation as to why TGF-P did not 
completely eliminate constitutive or IFN-y induced HLA-DR expression on breast 
carcinoma cells. Future studies could examine breast carcinoma cell lines for differential 
usage of pili and piV under various physiological conditions. 
Inhibition ofiFN-y induced CIITA transcription upon exposure to TGF-f31 in breast 
carcinoma cells could result from a number of cellular modifications, including 
alterations in the number and/or affinity ofiFN-y receptors and/or interference with IFN-
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y-induced signaling events. Previous studies on astrocytes and monocytes showed that 
TGF-P treatment did not affect IFN-y induced tyrosine phosphorylation of JAKI, JAK2, 
and STAT-I, or IFN-y-induced IRF-I expression [86, 87, I54]. Thus, the effects ofTGF-
p on CIITA can not be explained by altered signaling through the JAK-STAT-I pathway. 
However, this does not exclude the possibility that TGF-P may still interfere with the 
binding of STAT-I, IRF-I, and USF-I to their respective elements on the CIITA 
promoters. 
It is possible that TGF-P inhibition of CIITA expression may be mediated by 
proteins that interact with the transcription factors binding the CIIT A promoter. A 
number of reports have shown that TGF-P-activated Smads interact with transcriptional 
coactivators such as CBP and p300 [313-3I7]. CBP and p300 have histone acetyl 
transferase activity and may act directly by recruiting the RNA polymerase II to the 
promoter. Thus, while TGF-P does not alter the ability of STAT-I to bind DNA [I 54], it 
may affect the ability of STAT -I binding to induce transcription. 
TGF-P activated Smads have been shown to recruit transcriptional corepressors 
and strongly inhibit transcription from TGF-P-responsive promoters by binding to 
specific Smad binding elements (SBE) [318-32I]. Analysis using Smad3-deficient mice 
and overexpression of Smad3 protein in murine astrocytes has demonstrated that Smad3 
is essential in mediating TGF-P negative regulation of CIITA [86]. This suggests that 
Smad3 is a potential effector for TGF-P regulation ofMHC class II expression. However, 
examination of the -70 to -50 bp sequence within the CIITA piV region did not reveal a 
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SBE or TGF-P inhibitory element [86], suggesting that Smad3 complexes do not directly 
inhibit CIIT A transcription by binding to this promoter. It is tempting to speculate that 
TGF -P 1 mediates similar action in breast carcinoma cells, but to the best of our 
knowledge these studies have not been conducted. 
Others have shown that IFN-y inhibits TGF-P-induced phosphorylation of Smad3, 
the association of Smad3 with Smad4, the accumulation of Smad3 in the nucleus, and the 
activation of TGF-P-responsive genes [322]. Acting through JAK1 and STAT-1, IFN-y 
was also shown to induce Smad7 in human fibrosarcoma and monocytic leukemia cells 
[3 22] which antagonized TG F-p 1 signaling [3 23, 3 24]. Thus, these studies suggest that 
the differential effects mediated by TGF-P1 on HLA-DR on breast carcinoma cells may 
be attributed to differences in Smad-signaling components. We have addressed this issue 
in terms of Smad2 and Smad3, but future studies could investigate if IFN-y induces 
Smad7 in breast carcinoma cell lines which inhibit TGF-P1 phosphorylation ofSmad3. 
Consequently, our study showing that addition of TGF-P1 augmented IFN-y-
induced HLA-DR expression on BT-20 and SKBR3 is novel. We do not believe that this 
is due to lack of estrogen in culture medium as Pouliot and Labrie [145] examined the 
regulation of Smad mRNA expression by estrogen and antiestrogens in ZR-75-1 ER+ 
BCCL and reported that neither estradiol nor dihydrotestosterone affected Smad2, 3, or 4 
mRNA levels in ZR-75-1 cells, suggesting that Smad expression is not regulated by sex 
steroids. Instead, our findings could be explained by differences in TGF -P 1 sensitivity or 
differences in TGF-P1 signaling components. Alternatively, such effects may be 
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mediated through a Smad-independent signaling pathway, preventing activation of 
Smad3 and its interaction with CIIT A. 
4.5.6. IL-4 + TGF-/31 
Modulation ofHLA-DR by IL-4 + TGF-P1 was only observed on MDA MB 231 
and MCF-7. In the case ofMDA MB 231, IL-4 + TGF-p1, like TGF-P1 alone, mediated 
suppression of constitutive HLA-DR. This was not unexpected since IL-4 alone did not 
modulate HLA-DR on MDA MB 231. In the case of MCF-7, IL-4 + TGF-P1 mediated 
similar effects as IL-4 alone, as HLA-DR expression was slightly increased. This finding 
also agreed with observations that MCF-7 was insensitive to TGF-Pl. 
IL-4 + TGF-P1 inhibited IFN-y-induced HLA-DR on MDA MB 157, MDA MB 
231, and T47D. As generic and allelic expression on MDA MB 157 was equivalent 
following treatment with IFN-y + IL-4 + TGF-P1 and IFN-y + TGF-p1, this further 
suggested that HLA-DR modulation on MDA MB 157 was insensitive to IL-4. 
Furthermore, as expression levels on MDA MB 231 were similar to that following IFN-y 
+ TGF-P1 treatment, we suggest that the effects mediated by combined cytokine 
stimulations are due to the quantity and functioning of specific cytokine receptors on the 
cell surface. 
Despite some discrepancies between flow cytometry and CELISA in expression 
of particular alleles on BT-20, SKBR3, and MCF-7, IL-4 + TGF-P1 appeared to augment 
IFN-y induction of HLA-DR on each of these cell lines. It was noted that the effects of 
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IFN-y + IL-4 + TGF-f31 were similar to IFNy-TGF-f31 for both MCF-7 and T47D, again 
suggesting that ER+ cell lines had lost sensitivity to TGF-f31. It was also noted that flow 
cytometry data indicated HLA-DR expression to be highest on BT-20 following IFN-y + 
IL-4 + TGF-f31, suggesting that all three cytokines may function in synergy to induce 
HLA-DR on specific cell lines. With exclusion of MDA MB 157, MCF-7, and T47D 
where cell lines displayed insensitivity to either IL-4 or TGF-f31, our results indicate that 
IFN-y + IL-4 + TGF-f31 mediated differential effects on HLA-DR expression on breast 
carcinoma cells, and these effects occurred in a cell line specific manner. 
4. 6. Factors Potentially Mediating Differential HLA Class II Expression by Breast 
Carcinoma Cell Lines 
We found selective up-regulation of HLA-DR allelic products on human breast 
cancer cell lines in an E2-depleted environment in response to individual and combined 
cytokine treatments. These findings correlate with a previous study in our laboratory 
indicating differential expression of HLA-DRB alleles on tumor cells in breast carcinoma 
[249]. In that study, 40% of HLA-DR+ tumors failed to express one or more of their DR 
allotypes [249]. Biologically, these findings may be significant as failure to express a 
particular HLA-DR allele on the cell surface may provide a selective advantage to the 
tumor if antigens on tumor cells are presented by HLA-DR for recognition by CD4+ 
tumor specific T cells. In this regard, and in accordance with earlier studies, our 
laboratory has established that HLA-DR expression on breast tumor cells is significantly 
associated with T-cell infiltration [249, 325], suggesting that HLA-DR is induced on 
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tumor cells in response to the cytokine milieu. Furthermore, others have shown that CD4+ 
T cells are capable of recognizing autologous tumor-specific antigens in an HLA class II 
restricted manner [326-328]. Thus, qualitative and quantitative alterations in the 
expression of HLA-DR molecules may dramatically affect the onset and maintenance of 
an immune response involving tumor rejection. 
We consistently found DR~ I *04 was poorly expressed on MDA MB 157 and BT-
20, while DR~ 1 *07 was weakly expressed on MDA MB 231, DR~ 1 *03 was weakly 
expressed on BT-20, and DR~3 was weakly expressed on MCF-7. These weak or 
differential expression of DRB genes by tumor cells may be due to promoter 
polymorphisms [329-332]. Expression of DRB genes is regulated mainly at the level of 
transcription and is characterized by the presence of S-X-Y motifs within the promoter 
region. Polymorphisms within X and Y box motifs have been shown to control the level 
of HLA-DRB1 gene expression and affect the recruitment of transcription factors and 
transcriptional activity [329, 332]. Furthermore, comparison of differential HLA-DRB 
promoter transcriptional activity with HLA-DRB mRNA levels indicated that differential 
DRB gene expression is regulated at both transcriptional and post-transcriptional levels 
[333, 334]. Whether breast carcinoma cells do not express, or weakly express, particular 
HLA-DR allotypes as a result of natural promoter polymorphisms, or genetic or 
epigenetic changes resulting from tumorgenesis is unknown. Thus, future research could 
examine DRB genes not up-regulated by IFN-y for possible nucleotide variations within 
promoter regions. Future work could also examine potential loss of heterozygosity and 
epigenetic alterations such as hypermethylation within CIITA promoter regions [335]. 
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IFN-y, IL-4, and TGF-13 receptor expression could also have drastically differed 
between cell lines, promoting differences in modulation of HLA-DR expression. In 
theory, one would speculate that cells with copious receptors would be more sensitive to 
cytokine treatment, and therefore up-regulate I down-regulate MHC class II expression to 
greater degree than cell lines with few cytokine receptors. On this note, we found 
selective and broad ranges of growth inhibition following all cytokine treatments 
(Appendix A) suggesting that cell lines differed in their sensitivity and response to 
particular cytokine(s). Thus, future studies could attempt to correlate differential class II 
expression with the expression ofiFN-y, IL-4 and TGF-13 receptors on the cell surface. 
In some cases, flow cytometry analysis indicated modulation of the intensity of 
HLA-DR expression, but comparable modulation was not indicated in the percentage of 
positive cells. This suggests that particular cytokine combinations increase the stability of 
HLA-DRB mRNA or the steady state expression of HLA-DR molecules, allowing DR 
proteins to be expressed longer on the cell surface. Alternatively, since HLA-DR 
molecules are contained in intracellular vesicles before transport and expression on the 
cell surface, these findings suggest that cytokines modulate the mobilization of MHC 
class II molecules in breast carcinoma cells. In addition, cytokine(s) may affect the 
expression of proteins involved in MHC class II antigen presentation, which could 
subsequently modulate class II expression on the cell surface. Our laboratory has 
previously shown that Ii and HLA-DM were up-regulated by IFN-y in some breast 
carcinoma cells expressing high amounts ofHLA-DR [210]. Future studies could conduct 
time course studies examining HLA-DR mRNA and protein expression, as well as 
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examine if addition of IL-4 and/or TGF-J31 to IFN-y modulates expression of Ii, HLA-
DO, and HLA-DM in breast carcinoma cells. 
4. 7 Analysis of the TGF-/3 Signaling Pathway in Breast Cancer Cell Lines 
As reviewed in Section 1.4.3, TGF-J31 signaling is mediated predominately via 
TGF-J3 receptors and their substrates, the Smad proteins. We analyzed the Smad signaling 
pathway to determine if differences in TGF-J31 sensitivity or signaling components could 
explain the differential effects mediated by IFN-y + TGF-J31 on HLA-DR expression. 
Smad proteins themselves do not display enzymatic activity, therefore, this signaling 
pathway is not amplified as it progresses. Thus, the relative level of Smad2 and Smad3 in 
a given cell can not only affect its ability to respond to TGF-J3, but also influence the 
nature of the response. 
We found 8/8 breast cancer cell lines expressed Smad2, while 6/8 expressed 
Smad3 (Table 3.5). However, of cell lines expressing Smad2/3, equivalent levels of 
Smad2 and Smad3 were detected between untreated and TGF-J31 treated samples. As 
Smad3 was not detected in BT-474 or T47D, this suggested that Smad3 was differentially 
expressed in breast cancer cell lines. In contrast, Smad2 appeared to be universally 
expressed. 
Constitutive P-Smad3 in MCF-7, MDA MB 157, MDA MB 468 and SKBR3 
(Figure 3.24) was unexpected as Smad3 is phosphorlyated in response to TGF-J3, and 
thus, these findings suggested autocrine activation of the Smad signaling pathway. As we 
have indicated that SKBR3 did not transcribe TGF -J31 when cultured in E2-depleted 
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medium based on mRNA analysis (Section 3.6), and that MCF-7 was insensitive to TGF-
Pl based on lack of HLA-DR modulation (Section 3.8.2.1), these results did not agree 
with previous findings. Furthermore, as no constitutive P-Smad2 was detected in any 
breast cancer cell line, this suggested that only selective components on the Smad 
signaling pathway were constitutively active. 
Since activated Smad3 is reported to interact with CIITA to inhibit HLA-DR 
expression [86], it was noted that constitutive P-Smad3 expression correlated with lack of 
constitutive HLA-DR on these particular cell lines. Consistent with this, constitutive 
HLA-DR expression on MDA MB 231 and BT-20 also correlated with the absence of 
constitutively active Smad2 and Smad3. However, no correlation was found for T47D, 
and thus the lack of constitutive expression of this cell line is unclear. 
The differential expression of P-Smad2 and P-Smad3 observed in response to 
TGF-P1 may partially explain the divergent effects mediated by TGF-P1 and IFN-y + 
TGF-P1 on HLA-DR expression in breast cancer cell lines. In this regard, MDA MB 157 
and MDA MB 231 both demonstrated sensitivity to TGF-P1 by phosphorylation of 
Smad2 and Smad3, suggesting such factors could suppress IFN-y induction of HLA-DR. 
Similarly, unmodulated IFN-y-induced HLA-DR expression on T47D following addition 
ofTGF-P1 may be explained by the lack P-Smad2, Smad3, and P-Smad3, suggesting that 
this cell line is unresponsive to TGF -P 1. 
MCF-7 did not express P-Smad2, but contained constitutive P-Smad3, with P-
Smad3 levels induced by TGF-Pl. Hence, both constitutive and TGF-P1 induced P-
Smad3 could theoretically interact with CIITA promoters and suppress HLA-DR 
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expression. Furthermore, induction of P-Smad3 by TGF-(31 in MCF-7 indicated active 
TGF -J31 signaling, which subsequently contradicts our previous findings that MCF -7 is 
insensitive to TGF-(31 based on its HLA-DR expression. This discrepancy may denote 
factors affecting the transport of P-Smad3 to the nucleus, or the interaction of P-Smad3 
with CIITA. Mutations in Smad3 appear to occur only rarely [336], but lack of Smad4 
expression has been reported in specific breast cancer cell lines, including MDA MB 468, 
and is essential in the activation of certain transcriptional responses [145, 337]. Dowdy et 
al. [338] reported up-regulation of Smad7 in endometrial cancers, suggesting that Smad7 
may be up-regulated in cancer cells and antagonize Smad3 signaling [339, 340]. In this 
regard, reports also indicate that Smad7 expression is induced by TGF-J3 [323, 339]. 
Based on these studies, future research could examine the expression of Smad4 and 
Smad7 proteins in MCF-7. 
More interesting, lack of P-Smad2 and unmodulated, weak expression of P-
Smad3 following TGF-(31 raised the question whether SKBR3 was indeed sensitive to 
TGF-(31. These results were also in agreement with our findings that TGF-(31 augmented, 
rather than suppressed, IFN-y-induced HLA-DR expression on SKBR3. Such findings 
suggest that TGF-(31-mediated augmentation of IFN-y-induced HLA-DR expression on 
SKBR3 occurred in a P-Smad2/3-independent manner. As TGF-J3 may signal through 
MAPKs including c-Jun N-terminal kinase [149], p38 MAPK [341], and ERK1/2 kinase 
[342], preliminary research investigated the role ofthe ERK signaling using an upstream 
MEKl/2 kinase inhibitor. These results did not indicate that TGF-J3 augmentation 
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occurred through ERK signaling, but did indicate that IFN-y induction of HLA-DR on 
SKBR3 is predominantly MEK1/2 dependent (data not shown). Future research could 
examine the roles of other alternative pathway, including Rho guanosine triphosphates, 
PI3K I AKT, and protein phosphate A. 
The results ofBT-20 were also unique. BT-20 expressed both Smad2 and Smad3, 
but only expressed P-Smad3 in response to TGF-f31 treatment. Thus, theoretically, P-
Smad3 could inhibit IFN-y induction of HLA-DR within this cell line. However, the 
reverse was found as addition of TGF-f3 augmented IFN-y-induced HLA-DR expression 
on BT-20. To explain such novel findings, we again suggest a Smad-independent 
signaling pathway in BT-20, similar to that speculated in SKBR3. 
4. 8. Conclusion 
The significance of HLA-DR expression on breast carcinoma cells is presently 
unclear. MHC class II molecules are not normally present on the epithelial cells of breast, 
but have been detected on late-pregnant and lactating epithelia, and on a portion of breast 
carcinomas [343]. Our laboratory has previously demonstrated that breast carcinoma cell 
lines differentially express HLA-DR molecules, but do not express CD80 and CD86 co-
stimulatory molecules typically found on APCs, and selectively express CD40 [21 0]. 
Whether the expression level of CD40 would be sufficient to activate CD4+ T cells is 
unknown, but suggests that breast carcinoma cells may act as non-professional APCs. 
In this regard, substantial evidence supports a role for MHC class II antigen 
expression on tumor cells in antitumor immunity. Armstrong et al. [251] showed that 
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class II-transfected tumor cells could directly activate tumor-specific CD4+ T cells in 
vitro and in vivo. Similarly, transfection of CIITA into MHC class II-negative murine 
mammary adenocarcinoma cells resulted in expression of MHC class II and tumor 
rejection requiring both CD4+ and CD8+ T cells [344]. Vaccination with irradiated tumor 
cells transduced to secrete granulocyte/macrophage colony-stimulating factor was also 
found to simulataneous induce TH1 and TH2 responses in mice [345]. Thus, HLA-DR 
expression on breast carcinoma cells may also contribute to the tumor immune response 
in vivo by presenting tumor-specific antigens to effector CD4+ T cells. 
The association of HLA-DR expression on breast carcinoma cells with a 
favorable clinical prognosis appears controversial. A number of studies suggested that 
DR expression was associated with favorable prognostic indicators such as well 
differentiated tumors [346], and PgR expression [347], while others report no effect [348-
351]. However, these studies examined generic HLA-DR expression using pan-HLA-DR 
antibodies. Therefore, it is unknown if all or just selective HLA-DR allotypes were 
expressed. 
This thesis provided a comprehensive analysis of whether IFN-y, IL-4, and TGF-
p 1 individually and collectively regulate the expression of HLA-DR allelic products on 
the cell surface of breast carcinoma cell lines in an estrogen-depleted environment. To 
our knowledge, this is the first study to show that breast carcinoma cell lines 
differentially regulate expression of HLA-DR allotypes in response to particular cytokine 
combinations. Significant modulation of HLA-DR expression on breast cancer cell lines 
by IFN-y, IL-4 and TGF-131 suggests that these cytokines may have important roles in 
157 
natural tumor immune defense mechanisms. When certain tumor-infiltrating lymphocytes 
are activated they may release IFN-y, IL-4, or TGF-~1 [108, 109, 352, 353], which may 
have significant direct effects on growth and modulation of antigen expression on tumor 
cells. Understanding the roles of cytokines in tumor immune responses should provide 
opportunities to develop better therapeutic strategies. 
158 
Chapter 5. References 
1. Starr,T.K., Jameson,S.C., and Hogquist,K.A., Positive and negative selection ofT 
cells. Annu.Rev.Immunol. 2003.21: 139-176. 
2. Rohn,W.M., Lee,Y.J., and Benveniste,E.N., Regulation of class II MHC 
expression. Crit Rev.Immunol. 1996. 16: 311-330. 
3. Latron,F., Jotterand-Bellomo,M., Maffei,A., Scarpellino,L., Bemard,M., 
Strominger,J.L., and Accolla,R.S., Active suppression of major histocompatibility 
complex class II gene expression during differentiation from B cells to plasma 
cells. Proc.Natl.AcadSci. US.A 1988. 85: 2229-2233. 
4. Dellabona,P., Latron,F., Maffei,A., Scarpellino,L., and Accolla,R.S., 
Transcriptional control ofMHC class II gene expression during differentiation 
from B cells to plasma cells. Jlmmunol. 1989. 142: 2902-2910. 
5. Klein,J. and Sato,A., The HLA system. First of two parts. NEngl.JMed 2000. 
343: 702-709. 
6. Brown,J.H., Jardetzky,T.S., Gorga,J.C., Stem,L.J., Urban,R.G., Strominger,J.L., 
and Wiley,D.C., Three-dimensional structure of the human class II 
histocompatibility antigen HLA-DRI. Nature 1993. 364: 33-39. 
7. Marsh,S.G., Albert,E.D., Bodmer,W.F., Bontrop,R.E., Dupont,B., Erlich,H.A., 
Geraghty,D.E., Hansen,J.A., Hurley,C.K., Mach,B., Mayr,W.R., Parham,P., 
Petersdorf,E.W., Sasazuki,T., Schreuder,G.M., Strominger,J.L., Svejgaard,A., 
Terasaki,P.I., and Trowsdale,J., Nomenclature for Factors of the HLA System, 
2004. Hum.Immunol. 2005. 66: 571-636. 
8. Marsh,S.G., Parham, P., and Barber, L. D., The HLA Facts Book. Academic 
Press, London 2000. 
9. Ghosh,P., Amaya,M., Mellins,E., and Wiley,D.C., The structure of an 
intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 
1995.378:457-462. 
10. Long,E.O., LaVaute,T., Pinet,V., and Jaraquemada,D., Invariant chain prevents 
the HLA-DR-restricted presentation of a cytosolic peptide. Jlmmunol. 1994. 153: 
1487-1494. 
11. Romagnoli,P. and Germain,R.N., The CLIP region of invariant chain plays a 
critical role in regulating major histocompatibility complex class II folding, 
transport, and peptide occupancy. JExp.Med 1994. 180: 1107-1113. 
159 
12. Bakke,O. and Dobberstein,B., MHC class II-associated invariant chain contains a 
sorting signal for endosomal compartments. Cel/1990. 63: 707-716. 
13. Peters,P.J., Neefjes,J.J., Oorschot,V., Ploegh,H.L., and Geuze,H.J., Segregation of 
MHC class II molecules from MHC class I molecules in the Golgi complex for 
transport to lysosomal compartments. Nature 1991. 349: 669-676. 
14. Neefjes,J.J., Stollorz,V., Peters,P.J., Geuze,H.J., and Ploegh,H.L., The 
biosynthetic pathway ofMHC class II but not class I molecules intersects the 
endocytic route. Cel/1990. 61: 171-183. 
15. Nagarajan,U.M., Lochamy,J., Chen,X., Beresford,G.W., Nilsen,R., Jensen,P.E., 
and Boss,J.M., Class II transactivator is required for maximal expression ofHLA-
DOB in B cells. Jimmunol. 2002. 168: 1780-1786. 
16. Riese,R.J., Wolf,P.R., Bromme,D., Natkin,L.R., Villadangos,J.A., Ploegh,H.L., 
and Chapman,H.A., Essential role for cathepsin Sin MHC class II-associated 
invariant chain processing and peptide loading. Immunity. 1996. 4: 357-366. 
17. Shi,G.P., Villadangos,J.A., Dranoff,G., Small,C., Gu,L., Haley,K.J., Riese,R., 
Ploegh,H.L., and Chapman,H.A., Cathepsin S required for normal MHC class II 
peptide loading and germinal center development. Immunity. 1999. 10: 197-206. 
18. Avva,R.R. and Cresswell,P., In vivo and in vitro formation and dissociation of 
HLA-DR complexes with invariant chain-derived peptides. Immunity. 1994. 1: 
763-774. 
19. Kelly,A.P., Monaco,J.J., Cho,S.G., and Trowsdale,J., A new human HLA class II-
related locus, DM. Nature 1991. 353: 571-573. 
20. Kropshofer,H., Vogt,A.B., Moldenhauer,G., Hammer,J., Blum,J.S., and 
Hammerling,G.J., Editing of the HLA-DR-peptide repertoire by HLA-DM. 
EMBOJ 1996. 15: 6144-6154. 
21. Kropshofer,H., Amdt,S.O., Moldenhauer,G., Hammerling,G.J., and Vogt,A.B., 
HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules 
at lysosomal pH. Immunity. 1997. 6: 293-302. 
22. Sherman,M.A., Weber,D.A., and Jensen,P.E., DM enhances peptide binding to 
class II MHC by release of invariant chain-derived peptide. Immunity. 1995. 3: 
197-205. 
23. Sloan,V.S., Cameron,P., Porter,G., Gammon,M., Amaya,M., Mellins,E., and 
Zaller,D.M., Mediation by HLA-DM of dissociation ofpeptides from HLA-DR. 
Nature 1995. 375: 802-806. 
160 
24. Weber,D.A., Evavold,B.D., and Jensen,P.E., Enhanced dissociation ofHLA-DR-
bound peptides in the presence ofHLA-DM. Science 1996. 274: 618-620. 
25. Denzin,L.K., Hammond,C., and Cresswell,P., HLA-DM interactions with 
intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing 
empty HLA-DR molecules. JExp.Med 1996. 184: 2153-2165. 
26; Sanderson,F., Kleijmeer,M.J., Kelly,A., Verwoerd,D., Tulp,A., Neefjes,J.J., 
Geuze,H.J., and Trowsdale,J., Accumulation ofHLA-DM, a regulator of antigen 
presentation, in MHC class II compartments. Science 1994. 266: 1566-1569. 
27. Arndt,S.O., Vogt,A.B., Markovic-Plese,S., Martin,R., Moldenhauer,G., Wolpl,A., 
Sun,Y., Schadendorf,D., Hammerling,G.J., and Kropshofer,H., Functional HLA-
DM on the surface of B cells and immature dendritic cells. EMBO J 2000. 19: 
1241-1251. 
28. Tonnelle,C., DeMars,R., and Long,E.O., DO beta: a new beta chain gene in HLA-
D with a distinct regulation of expression. EMBO J 1985. 4: 2839-2847. 
29. Young,J.A. and Trowsdale,J., The HLA-DNA (DZA) gene is correctly expressed 
as a 1.1 kb mature mRNA transcript. Immunogenetics 1990.31:386-388. 
30. Denzin,L.K., Sant'Angelo,D.B., Hammond,C., Surman,M.J., and Cresswell,P., 
Negative regulation by HLA-DO ofMHC class II-restricted antigen processing. 
Science 1997. 278: 106-109. 
31. Ting,J.P. and Trowsdale,J., Genetic control ofMHC class II expression. Cell 
2002. 109 Suppl: S21-S33. 
32. Harton,J.A. and Ting,J.P., Class II transactivator: mastering the art of major 
histocompatibility complex expression. Mol. Cell Bioi. 2000. 20: 6185-6194. 
33. Zika,E. and Ting,J.P., Epigenetic control ofMHC-II: interplay between CIITA 
and histone-modifying enzymes. Curr. Opin.lmmunol. 2005. 17: 58-64. 
34. Steimle,V., Durand,B., Barras,E., Zufferey,M., Hadam,M.R., Mach,B., and 
Reith,W., A novel DNA-binding regulatory factor is mutated in primary MHC 
class II deficiency (bare lymphocyte syndrome). Genes Dev. 1995. 9: 1021-1032. 
35. Masternak,K., Barras,E., Zufferey,M., Conrad,B., Corthals,G., Aebersold,R., 
Sanchez,J.C., Hochstrasser,D.F., Mach,B., and Reith,W., A gene encoding a 
novel RFX-associated transactivator is mutated in the majority ofMHC class II 
deficiency patients. Nat. Genet. 1998. 20: 273-277. 
161 
36. Durand,B., Sperisen,P., Emery,P., Barras,E., Zufferey,M., Mach,B., and Reith,W., 
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC 
class II deficiency. EMBO J 1997. 16: 1045-1055. 
37. Nagarajan,U.M., Louis-Plence,P., DeSandro,A., Nilsen,R., Bushey,A., and 
Boss,J.M., RFX-B is the gene responsible for the most common cause of the bare 
lymphocyte syndrome, an MHC class II immunodeficiency. Immunity. 1999. 10: 
153-162. 
38. Moreno,C.S., Beresford,G.W., Louis-Plence,P., Morris,A.C., and Boss,J.M., 
CREB regulates MHC class II expression in a CIITA-dependent manner. 
Immunity. 1999. 10: 143-151. 
39. Mantovani,R., The molecular biology of the CCAAT-binding factor NF-Y. Gene 
1999. 239: 15-27. 
40. Jabrane-Ferrat,N., Fontes,J.D., Boss,J.M., and Peterlin,B.M., Complex 
architecture of major histocompatibility complex class II promoters: reiterated 
motifs and conserved protein-protein interactions. Mol. Cell Biol. 1996. 16: 4683-
4690. 
41. Gstaiger,M., Knoepfel,L., Georgiev,O., Schaffner,W., and Hovens,C.M., A B-cell 
coactivator of octamer-binding transcription factors. Nature 1995. 373: 360-362. 
42. Strubin,M., Newell,J.W., and Matthias,P., OBF-1, a novel B cell-specific 
coactivator that stimulates immunoglobulin promoter activity through association 
with octamer-binding proteins. Cell1995. 80: 497-506. 
43. Luo,Y. and Roeder,R.G., Cloning, functional characterization, and mechanism of 
action ofthe B-cell-specific transcriptional coactivator OCA-B. Mol. Cell Biol. 
1995. 15: 4115-4124. 
44. Zhu,X.S., Linhoff,M.W., Li,G., Chin,K.C., Maity,S.N., and Ting,J.P., 
Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause 
stereospecific regulation of the class II major histocompatibility complex 
promoter. Mol. Cell Biol. 2000. 20: 6051-6061. 
45. Mastemak,K., Muhlethaler-Mottet,A., Villard,J., Zufferey,M., Steimle,V., and 
Reith,W., CIITA is a transcriptional coactivator that is recruited to MHC class II 
promoters by multiple synergistic interactions with an enhanceosome complex. 
Genes Dev. 2000. 14: 1156-1166. 
46. Fontes,J.D., Jiang,B., and Peterlin,B.M., The class II trans-activator CIITA 
interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 1997. 25: 
2522-2528. 
162 
47. Mahanta,S.K., Scholl,T., Yang,F.C., and Strominger,J.L., Transactivation by 
CIITA, the type II bare lymphocyte syndrome-associated factor, requires 
participation of multiple regions of the TAT A box binding protein. 
Proc.Nati.AcadSci. USA 1997. 94: 6324-6329. 
48. Kanazawa,S., Okamoto,T., and Peterlin,B.M., Tat competes with CIITA for the 
binding to P-TEFb and blocks the expression ofMHC class II genes in HIV 
infection. Immunity. 2000. 12: 61-70. 
49. Kretsovali,A., Agalioti,T., Spilianakis,C., Tzortzakaki,E., Merika,M., and 
Papamatheakis,J ., Involvement of CREB binding protein in expression of major 
histocompatibility complex class II genes via interaction with the class II 
transactivator. Moi.Cell Bioi. 1998. 18: 6777-6783. 
50. Fontes,J.D., Kanazawa,S., Jean,D., and Peterlin,B.M., Interactions between the 
class II transactivator and CREB binding protein increase transcription of major 
histocompatibility complex class II genes. Mol. Cell Bioi. 1999. 19: 941-947. 
51. Spilianakis,C., Kretsovali,A., Agalioti,T., Makatounakis,T., Thanos,D., and 
Papamatheakis,J., CIITA regulates transcription onset viaSer5-phosphorylation of 
RNA Pol II. EMBO J 2003. 22: 5125-5136. 
52. Riley,J.L., Westerheide,S.D., Price,J.A., Brown,J.A., and Boss,J.M., Activation of 
class II MHC genes requires both the X box region and the class II transactivator 
(CIITA). Immunity. 1995. 2:533-543. 
53. Steimle,V., Otten,L.A., Zufferey,M., and Mach,B., Complementation cloning of 
an MHC class II transactivator mutated in hereditary MHC class II deficiency (or 
bare lymphocyte syndrome). Cell1993. 75: 135-146. 
54. Muhlethaler-Mottet,A., Krawczyk,M., Mastemak,K., Spilianakis,C., 
Kretsovali,A., Papamatheakis,J., and Reith,W., The S box of major 
histocompatibility complex class II promoters is a key determinant for recruitment 
of the transcriptional co-activator CIITA. JBioi.Chem. 2004. 279: 40529-40535. 
55. Vilen,B.J., Cogswell,J.P., and Ting,J.P., Stereospecific alignment of the X andY 
elements is required for major histocompatibility complex class II DRA promoter 
function. Mol.Cell Bioi. 1991. 11:2406-2415. 
56. Mastemak,K., Peyraud,N., Krawczyk,M., Barras,E., and Reith,W., Chromatin 
remodeling and extragenic transcription at the MHC class II locus control region. 
Nat.Immunol. 2003. 4: 132-137. 
57. Reith,W. and Mach,B., The bare lymphocyte syndrome and the regulation of 
MHC expression. Annu.Rev.Immunol. 2001. 19: 331-373. 
163 
58. Cliang,C.H. and Flavell,R.A., Class II transactivator regulates the expression of 
multiple genes involved in antigen presentation. J.Exp.Med. 1995. 181: 765-767. 
59. Chin,K.C., Mao,C., Skinner,C., Riley,J.L., Wright,K.L., Moreno,C.S., Stark,G.R., 
Boss,J.M., and Ting,J.P., Molecular analysis of G 1B and G3A IFN gamma 
mutants reveals that defects in CIIT A or RFX result in defective class II MHC 
and Ii gene induction. Immunity. 1994. 1: 687-697. 
60. Westerheide,S.D., Louis-Plence,P., Ping,D., He,X.F., and Boss,J.M., HLA-DMA 
and HLA-DMB gene expression functions through the conserved S-X-Y region. 
J.Immunol. 1997. 158: 4812-4821. 
61. Kem,I., Steimle,V., Siegrist,C.A., and Mach,B., The two novel MHC class II 
transactivators RFX5 and CIITA both control expression ofHLA-DM genes. 
Int.Immunol. 1995. 7: 1295-1299. 
62. Taxman,D.J., Cressman,D.E., and Ting,J.P., Identification of class II 
transcriptional activator-induced genes by representational difference analysis: 
discoordinate regulation of the DN alpha/DO beta heterodimer. J.Immunol. 2000. 
165: 1410-1416. 
63. Khalil,H., Deshaies,F., Bellemare-Pelletier,A., Brunet,A., Faubert,A., Azar,G.A., 
and Thibodeau,J., Class II transactivator-induced expression ofHLA-DO(beta) in 
HeLa cells. Tissue Antigens 2002. 60: 372-382. 
64. Boss,J.M., A common set of factors control the expression of the MHC class II, 
invariant chain, and HLA-DM genes. Microbes.Infect. 1999. 1: 847-853. 
65. Germain,R.N., MHC-dependent antigen processing and peptide presentation: 
providing ligands forT lymphocyte activation. Cell1994. 76: 287-299. 
66. Fling,S.P., Arp,B., and Pious,D., HLA-DMA and -DMB genes are both required 
for MHC class II/peptide complex formation in antigen-presenting cells. Nature 
1994. 368: 554-558. 
67. Martin,B.K., Chin,K.C., Olsen,J.C., Skinner,C.A., Dey,A., Ozato,K., and 
Ting,J.P., Induction ofMHC class I expression by the MHC class II transactivator 
CIITA. Immunity. 1997. 6: 591-600. 
68. Gobin,S.J., Peijnenburg,A., Keijsers,V., and van den Elsen,P.J., Site alpha is 
crucial for two routes ofiFN gamma-induced MHC class I transactivation: the 
ISRE-mediated route and a novel pathway involving CIIT A. Immunity. 1997. 6: 
601-611. 
164 
69. Gobin,S.J., Peijnenburg,A., van,E.M., van,Z.M., van den,B.R., and van den 
Elsen,P.J., The RFX complex is crucial for the constitutive and CIITA-mediated 
transactivation ofMHC class I and beta2-microglobulin genes. Immunity. 1998. 9: 
531-541. 
70. Kretsovali,A., Spilianakis,C., Dimakopoulos,A., Makatounakis,T., and 
Papamatheakis,J., Self-association of class II transactivator correlates with its 
intracellular localization and transactivation. JBiol.Chem. 2001. 276: 32191-
32197. 
71. Linhoff,M.W., Harton,J.A., Cressman,D.E., Martin,B.K., and Ting,J.P., Two 
distinct domains within CIITA mediate self-association: involvement of the GTP-
binding and leucine-rich repeat domains. Mol. Cell Bioi. 2001. 21: 3001-3011. 
72. Sisk,T.J., Roys,S., and Chang,C.H., Self-association ofCIITA and its 
transactivation potential. Mol. Cell Biol. 2001. 21: 4919-4928. 
73. Hake,S.B., Mastemak,K., Kammerbauer,C., Janzen,C., Reith,W., and Steimle,V., 
CIIT A leucine-rich repeats control nuclear localization, in vivo recruitment to the 
major histocompatibility complex (MHC) class II enhanceosome, and MHC class 
II gene transactivation. Mol. Cell Bioi. 2000. 20: 7716-7725. 
74. Cressman,D.E., O'Connor,W.J., Greer,S.F., Zhu,X.S., and Ting,J.P., Mechanisms 
of nuclear import and export that control the subcellular localization of class II 
transactivator. Jlmmunol. 2001. 167: 3626-3634. 
75. Cressman,D.E., Chin,K.C., Taxman,D.J., and Ting,J.P., A defect in the nuclear 
translocation of CIIT A causes a form of type II bare lymphocyte syndrome. 
Immunity. 1999. 10: 163-171. 
76. Harton,J.A., Cressman,D.E., Chin,K.C., Der,C.J., and Ting,J.P., GTP binding by 
class II transactivator: role in nuclear import. Science 1999. 285: 1402-1405. 
77. Boss,J.M. and Jensen,P.E., Transcriptional regulation of the MHC class II antigen 
presentation pathway. Curr. Opin.Immunol. 2003. 15: 105-111. 
78. Chang,C.H., Fontes,J.D., Peterlin,M., and Flavell,R.A., Class II transactivator 
(CIITA) is sufficient for the inducible expression of major histocompatibility 
complex class II genes. JExp.Med. 1994. 180: 1367-1374. 
79. Steimle,V., Siegrist,C.A., Mottet,A., Lisowska-Grospierre,B., and Mach,B., 
Regulation of MHC class II expression by interferon-gamma mediated by the 
transactivator gene CIITA. Science 1994. 265: 106-109. 
165 
80. Itoh-Lindstrom,Y., Piskurich,J.F., Felix,N.J., Wang,Y., Brickey,W.J., Platt,J.L., 
Koller,B.H., and Ting,J.P., Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-
induced MHC class II expression in mice lacking class II transactivator due to 
targeted deletion ofthe GTP-binding domain. Jlmmunol. 1999. 163: 2425-2431. 
81. Rohn,W., Tang,L.P., Dong,Y., and Benveniste,E.N., IL-l beta inhibits IFN-
gamma-induced class II MHC expression by suppressing transcription of the class 
II transactivator gene. Jlmmunol. 1999. 162: 886-896. 
82. Lu,H.T., Riley,J.L., Babcock,G.T., Huston,M., Stark,G.R., Boss,J.M., and 
Ransohoff,R.M., Interferon (IFN) beta acts downstream ofiFN-gamma-induced 
class II transactivator messenger RNA accumulation to block major 
histocompatibility complex class II gene expression and requires the 48-kD DNA-
binding protein, ISGF3-gamma. JExp.Med 1995. 182: 15'17-1525. 
83. Han,Y., Zhou,Z.H., and Ransohoff,R.M., TNF-alpha suppresses IFN-gamma-
induced MHC class II expression in HTl 080 cells by destabilizing class II trans-
activator mRNA. Jlmmunol. 1999. 163: 1435-1440. 
84. O'Keefe,G.M., Nguyen,V.T., and Benveniste,E.N., Class II transactivator and 
class II MHC gene expression in microglia: modulation by the cytokines TGF-
beta, IL-4, IL-13 and IL-10. Eur.Jlmmunol. 1999. 29: 1275-1285. 
85. Grimm,M., Spiecker,M., De,C.R., Shin,W.S., and Liao,J.K., Inhibition of major 
histocompatibility complex class II gene transcription by nitric oxide and 
antioxidants. JBiol.Chem. 2002. 277: 26460-26467. 
86. Dong,Y., Tang,L., Letterio,J.J., and Benveniste,E.N., The Smad3 protein is 
involved in TGF-beta inhibition of class II transactivator and class II MHC 
expression. Jlmmunol. 2001. 167: 311-319. 
87. Nandan,D. and Reiner,N.E., TGF-beta attenuates the class II transactivator and 
reveals an accessory pathway ofiFN-gamma action. Jlmmunol. 1997. 158: 1095-
1101. 
88. Lee,Y.J., Han,Y., Lu,H.T., Nguyen,V., Qin,H., Howe,P.H., Hocevar,B.A., 
Boss,J.M., Ransohoff,R.M., and Benveniste,E.N., TGF-beta suppresses IFN-
gamma induction of class II MHC gene expression by inhibiting class II 
transactivator messenger RNA expression. Jlmmunol. 1997. 158: 2065-2075. 
89. Ivashkiv,L.B., Ayres,A., and Glimcher,L.H., Inhibition ofiFN-gamma induction 
of class II MHC genes by cAMP and prostaglandins. Immunopharmacology 1994. 
27: 67-77. 
166 
90. Kwak,B., Mulhaupt,F., Myit,S., and Mach,F., Statins as a newly recognized type 
ofimmunomodulator. Nat.Med 2000. 6: 1399-1402. 
91. Youssef,S., Stuve,O., Patarroyo,J.C., Ruiz,P.J., Radosevich,J.L., Hur,E.M., 
Bravo,M., Mitchell,D.J., Sobel,R.A., Steinman,L., and Zamvil,S.S., The HMG-
CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis 
in central nervous system autoimmune disease. Nature 2002. 420: 78-84. 
92. Pai,R.K., Convery,M., Hamilton,T.A., Boom,W.H., and Harding,C.V., Inhibition 
ofiFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein 
from Mycobacterium tuberculosis: a potential mechanism for immune evasion. 
Jlmmunol. 2003. 171: 175-184. 
93. Luder,C.G., Lang,C., Gira1do-Velasquez,M., Algner,M., Gerdes,J., and Gross,U., 
Toxoplasma gondii inhibits MHC class II expression in neural antigen-presenting 
cells by down-regulating the class II transactivator CIIT A. JNeuroimmunol. 
2003. 134: 12-24. 
94. Hegde,N.R., Chevalier,M.S., and Johnson,D.C., Viral inhibition ofMHC class II 
antigen presentation. Trends Immunol. 2003. 24: 278-285. 
95. LeibundGut-Landmann,S., Waldburger,J.M., Krawczyk,M., Otten,L.A., Suter,T., 
Fontana,A., cha-Orbea,H., and Reith,W., Mini-review: Specificity and expression 
ofCIITA, the master regulator ofMHC class II genes. Eur.Jlmmunol. 2004. 34: 
1513-1525. 
96. Muhlethaler-Mottet,A., Otten,L.A., Steimle,V., and Mach,B., Expression ofMHC 
class II molecules in different cellular and functional compartments is controlled 
by differential usage of multiple promoters of the transactivator CIIT A. EMBO J 
1997.16:2851-2860. 
97. Barbieri,G., Deffrennes,V., Prod'homme,T., Vedrenne,J., Baton,F., Cortes,C., 
Fischer,A., Bono,M.R., Lisowska-Grospierre,B., Charron,D., and caide-
Loridan,C., Isoforms ofthe class II transactivator protein. Int.Immunol. 2002. 14: 
839-848. 
98. Dong,Y., Rohn,W.M., and Benveniste,E.N., IFN-gamma regulation of the type IV 
class II transactivator promoter in astrocytes. Jlmmunol. 1999. 162: 4731-4739. 
99. Muhlethaler-Mottet,A., Di,B.W., Otten,L.A., and Mach,B., Activation of the 
MHC class II transactivator CIITA by interferon-gamma requires cooperative 
interaction between Stat1 and USF-1. Immunity. 1998. 8: 157-166. 
100. Piskurich,J.F., Linhoff,M.W., Wang,Y., and Ting,J.P., Two distinct gamma 
interferon-inducible promoters of the major histocompatibility complex class II 
167 
transactivator gene are differentially regulated by STAT1, interferon regulatory 
factor 1, and transforming growth factor beta. Mol. Cell Bioi. 1999. 19: 431-440. 
101. Piskurich,J.F., Wang,Y., Linhoff,M.W., White,L.C., and Ting,J.P., Identification 
of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, 
STAT1, and TGF-beta-regulated expression ofthe class II transactivator gene. 
Jlmmunol. 1998. 160: 233-240. 
102. van der,S.N., Quinten,E., and van den Elsen,P.J., Transcriptional regulation ofthe 
MHC class II trans-activator (CIITA) promoter III: identification of a novel 
regulatory region in the 5'-untranslated region and an important role for cAMP-
responsive element binding protein 1 and activating transcription factor-1 in 
CIITA-promoter III transcriptional activation in B lymphocytes. Jlmmunol. 2002. 
169: 5061-5071. 
103. Endo,T.A., Masuhara,M., Yokouchi,M., Suzuki,R., Sakamoto,H., Mitsui,K., 
Matsumoto,A., Tanimura,S., Ohtsubo,M., Misawa,H., Miyazaki,T., Leonor,N., 
Taniguchi,T., Fujita,T., Kanakura,Y., Komiya,S., and Yoshimura,A., A new 
protein containing an SH2 domain that inhibits JAK kinases. Nature 1997. 387: 
921-924. 
104. Yasukawa,H., Misawa,H., Sakamoto,H., Masuhara,M., Sasaki,A., Wakioka,T., 
Ohtsuka,S., Imaizumi,T., Matsuda,T., Ihle,J.N., and Yoshimura,A., The JAK-
binding protein JAB inhibits Janus tyrosine kinase activity through binding in the 
activation loop. EMBO J 1999. 18: 1309-1320. 
105. Sutherland,K.D., Lindeman,G.J., Choong,D.Y., Wittlin,S., Brentzell,L., 
Phillips,W., Campbell,I.G., and Visvader,J.E., Differential hypermethylation of 
SOCS genes in ovarian and breast carcinomas. Oncogene 2004.23: 7726-7733. 
106. Plaut,M., Pierce,J.H., Watson,C.J., Hanley-Hyde,J., Nordan,R.P., and Paul,W.E., 
Mast cell lines produce lymphokines in response to cross-linkage ofFc epsilon RI 
or to calcium ionophores. Nature 1989.339:64-67. 
107. Ben-Sasson,S.Z., Le,G.G., Conrad,D.H., Finkelman,F.D., and Paul,W.E., IL-4 
production by T cells from naive donors. IL-2 is required for IL-4 production. 
Jlmmunol. 1990. 145: 1127-1136. 
108. Camp,B.J., Dyhrman,S.T., Memoli,V.A., Mott,L.A., and Barth,R.J., Jr., In situ 
cytokine production by breast cancer tumor-infiltrating lymphocytes. 
Ann. Sur g. On col. 1996. 3: 1 7 6-184. 
109. Reome,J.B., Hylind,J.C., Dutton,R.W., and Dobrzanski,M.J., Type 1 and type 2 
tumor infiltrating effector cell subpopulations in progressive breast cancer. 
Clin.Immunol. 2004. 111: 69-81. 
168 
110. Kay,N.E. and Pittner,B.T., IL-4 biology: impact on normal and leukemic CLL B 
cells. Leuk.Lymphoma 2003. 44: 897-903. 
111. Nelms,K., Keegan,A.D., Zamorano,J., Ryan,J.J., and Paul,W.E., The IL-4 
receptor: signaling mechanisms and biologic functions. Annu.Rev.Immunol. 1999. 
17:701-738. 
112. ldzerda,R.L., March,C.J., Mosley,B., Lyman,S.D., Vanden,B.T., Gimpel,S.D., 
Din,W.S., Grabstein,K.H., Widmer,M.B., Park,L.S., and., Human interleukin 4 
receptor confers biological responsiveness and defines a novel receptor 
superfamily. JExp.Med. 1990. 171: 861-873. 
113. Keegan,A.D., Nelms,K., White,M., Wang,L.M., Pierce,J.H., and Paul,W.E., An 
IL-4 receptor region containing an insulin receptor motif is important for IL-4-
mediated IRS-1 phosphorylation and cell growth. Cel/1994. 76: 811-820. 
114. Russell,S.M., Keegan,A.D., Harada,N., Nakamura,Y., Noguchi,M., Leland,P., 
Friedmann,M.C., Miyajima,A., Puri,R.K., Paul,W.E., and., Interleukin-2 receptor 
gamma chain: a functional component of the interleukin-4 receptor. Science 1993. 
262: 1880-1883. 
115. Kondo,M., Takeshita,T., Ishii,N., Nakamura,M., Watanabe,S., Arai,K., and 
Sugamura,K., Sharing of the interleukin-2 (IL-2) receptor gamma chain between 
receptors for IL-2 and IL-4. Science 1993. 262: 1874-1877. 
116. Obiri,N.I., Debinski,W., Leonard,W.J., and Puri,R.K., Receptor for interleukin 13. 
Interaction with interleukin 4 by a mechanism that does not involve the common 
gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. JBiol.Chem. 
1995.270:8797-8804. 
117. Murata,T., Taguchi,J., and Puri,R.K., Interleukin-13 receptor alpha' but not alpha 
chain: a functional component of interleukin-4 receptors. Blood 1998. 91: 3884-
3891. 
118. Kammer, W., Lischke,A., Moriggl,R., Groner,B., Ziemiecki,A., Gumiak,C.B., 
Berg,L.J ., and Friedrich,K., Homodimerization of interleukin-4 receptor alpha 
chain can induce intracellular signaling. JBiol.Chem. 1996. 271: 23634-23637. 
119. Palmer-Crocker,R.L., Hughes,C.C., and Pober,J.S., IL-4 and IL-13 activate the 
JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells 
through a common pathway that does not involve the gamma c chain. 
JC/in.Invest 1996. 98: 604-609. 
120. Leland,P., Taguchi,J., Husain,S.R., Kreitman,R.J., Pastan,I., and Puri,R.K., 
Human breast carcinoma cells express type II IL-4 receptors and are sensitive to 
169 
antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in 
vitro and in vivo. Mol.Med. 2000. 6: 165-178. 
121. Murata,T., Noguchi,P.D., and Puri,R.K., Receptors for interleukin (IL)-4 do not 
associate with the common gamma chain, and IL-4 induces the phosphorylation 
of JAK2 tyrosine kinase in human colon carcinoma cells. JBiol.Chem. 1995. 270: 
30829-30836. 
122. Witthuhn,B.A., Silvennoinen,O., Miura,O., Lai,K.S., Cwik,C., Liu,E.T., and 
Ihle,J.N., Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 
and 4 in lymphoid and myeloid cells. Nature 1994. 370: 153-157. 
123. Pemis,A., Witthuhn,B., Keegan,A.D., Nelms,K., Garfein,E., Ihle,J.N., Paul,W.E., 
Pierce,J.H., and Rothman,P., Interleukin 4 signals through two related pathways. 
Proc.Natl.Acad.Sci. USA 1995. 92: 7971-7975. 
124. Gooch,J.L., Christy,B., and Yee,D., STAT6 mediates interleukin-4 growth 
inhibition in human breast cancer cells. Neoplasia. 2002. 4: 324-331. 
125. Myers,M.G., Jr., Sun,X.J., and White,M.F., The IRS-1 signaling system. Trends 
Biochem.Sci. 1994. 19: 289-293. 
126. Noelle,R., Krammer,P.H., Ohara,J., Uhr,J.W., and Vitetta,E.S., Increased 
expression of Ia antigens on resting B cells: an additional role forB-cell growth 
factor. Proc.Natl.Acad.Sci. USA 1984. 81: 6149-6153. 
127. Roehm,N.W., Leibson,H.J., Zlotnik,A., Kappler,J., Marrack,P., and Cambier,J.C., 
Interleukin-induced increase in Ia expression by normal mouse B cells. 
JExp.Med. 1984. 160: 679-694. 
128. Rousset,F., Malefijt,R.W., Slierendregt,B., Aubry,J.P., Bonnefoy,J.Y., 
Defrance,T., Banchereau,J., and de Vries,J.E., Regulation ofFc receptor for IgE 
(CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by 
human IL-4 and IFN-gamma. Jlmmunol. 1988. 140: 2625-2632. 
129. Menge,A.C. and Mestecky,J., Surface expression of secretory component and 
HLA class II DR antigen on glandular epithelial cells from human endometrium 
and two endometrial adenocarcinoma cell lines. JClin.Immunol. 1993. 13: 259-
264. 
130. Gerrard,T.L., Dyer,D.R., and Mostowski,H.S., IL-4 and granulocyte-macrophage 
colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but 
not HLA-DQ antigens on human monocytes. Jlmmunol. 1990. 144: 4670-4674. 
170 
131. Kaplan,M.H., Schindler,U., Smiley,S.T., and Grusby,M.J., Stat6 is required for 
mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996. 4: 
313-319. 
132. Takeda,K., Tanaka,T., Shi,W., Matsumoto,M., Minami,M., Kashiwamura,S., 
Nakanishi,K., Yoshida,N., Kishimoto,T., and Akira,S., Essential role ofStat6 in 
IL-4 signalling. Nature 1996. 380: 627-630. 
133. Patel,B.K., Pierce,J.H., and LaRochelle,W.J., Regulation ofinterleukin 4-
mediated signaling by naturally occurring dominant negative and attenuated 
forms ofhuman Stat6. Proc.Natl.AcadSci.US.A 1998.95: 172-177. 
134. Hoon,D.S., Banez,M., Okun,E., Morton,D.L., and Irie,R.F., Modulation of human 
melanoma cells by interleukin-4 and in combination with gamma-interferon or 
alpha-tumor necrosis factor. Cancer Res. 1991. 51: 2002-2008. 
135. Hoon,D.S., Okun,E., Banez,M., Irie,R.F., and Morton,D.L., Interleukin 4 alone 
and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and 
modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 
1991. 51: 5687-5693. 
136. Obiri,N.I., Siegel,J.P., Varricchio,F., and Puri,R.K., Expression of high-affinity 
IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. 
Clin.Exp.Immunol. 1994. 95: 148-155. 
137. Loughlin,A.J., Woodroofe,M.N., and Cuzner,M.L., Modulation of interferon-
gamma-induced major histocompatibility complex class II and Fe receptor 
expression on isolated microglia by transforming growth factor-beta 1, 
interleukin-4, noradrenaline and glucocorticoids. Immunology 1993. 79: 125-130. 
138. Suzumura,A., Sawada,M., Itoh,Y., and Marunouchi,T., Interleukin-4 induces 
proliferation and activation of microglia but suppresses their induction of class II 
major histocompatibility complex antigen expression. JNeuroimmunol. 1994. 53: 
209-218. 
139. Morga,E. and Heuschling,P., Interleukin-4 down-regulates MHC class II antigens 
on cultured rat astrocytes. Glia 1996. 17: 17 5-179. 
140. Frolik,C.A., Dart,L.L., Meyers,C.A., Smith,D.M., and Spom,M.B., Purification 
and initial characterization of a type beta transforming growth factor from human 
placenta. Proc.Natl.AcadSci. USA 1983. 80: 3676-3680. 
141. Elliott,R.L. and Blobe,G.C., Role of transforming growth factor Beta in human 
cancer. JC!in.Oncol. 2005. 23: 2078-2093. 
171 
142. Piek,E., Heldin,C.H., and ten,D.P., Specificity, diversity, and regulation in TGF-
beta superfamily signaling. FASEB J 1999. 13: 2105-2124. 
143. Lopez-Casillas,F., Wrana,J.L., and Massague,J., Betaglycan presents ligand to the 
TGF beta signaling receptor. Cel/1993. 73: 1435-1444. 
144. Chen,W., Kirkbride,K.C., How,T., Nelson,C.D., Mo,J., Frederick,J.P., 
Wang,X.F., Lefkowitz,R.J., and Blobe,G.C., Beta-arrestin 2 mediates endocytosis 
of type III TGF-beta receptor and down-regulation of its signaling. Science 2003. 
301: 1394-1397. 
145. Pouliot,F. and Labrie,C., Expression profile of agonistic Smads in human breast 
cancer cells: absence of regulation by estrogens. Int.J Cancer 1999. 81: 98-103. 
146. Eppert,K., Scherer,S.W., Ozcelik,H., Pirone,R., Hoodless,P., Kim,H., Tsui,L.C., 
Bapat,B., Gallinger,S., Andrulis,I.L., Thomsen,G.H., Wrana,J.L., and Attisano,L., 
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein 
that is functionally mutated in colorectal carcinoma. Cel/1996. 86: 543-552. 
147. Schutte,M., DPC4/SMAD4 gene alterations in human cancer, and their functional 
implications. Ann.Oncol. 1999. 10 Suppl4: 56-59. 
148. Engel,M.E., McDonnell,M.A., Law,B.K., and Moses,H.L., Interdependent SMAD 
and JNK signaling in transforming growth factor-beta-mediated transcription. 
JBiol.Chem. 1999. 274: 37413-37420. 
149. Hocevar,B.A., Brown,T.L., and Howe,P.H., TGF-beta induces fibronectin 
synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent 
pathway. EMBOJ 1999. 18: 1345-1356. 
150. Bhowmick,N.A., Ghiassi,M., Bakin,A., Aakre,M., Lundquist,C.A., Engel,M.E., 
Arteaga,C.L., and Moses,H.L., Transforming growth factor-beta1 mediates 
epithelial to mesenchymal transdifferentiation through a RheA-dependent 
mechanism. Mol.Biol.Cel/2001. 12: 27-36. 
151. Bakin,A.V., Tomlinson,A.K., Bhowmick,N.A., Moses,H.L., and Arteaga,C.L., 
Phosphatidylinositol 3-kinase function is required for transforming growth factor 
beta-mediated epithelial to mesenchymal transition and cell migration. 
JBiol.Chem. 2000.275: 36803-36810. 
152. Petritsch,C., Beug,H., Balmain,A., and Oft,M., TGF-beta inhibits p70 S6 kinase 
via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 2000. 14: 3093-
3101. 
172 
153. Navarrete,S.A., Kehlen,A., Schutte,W., Langner,J., and Riemann,D., Regulation 
by transforming growth factor-beta1 of class II mRNA and protein expression in 
fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int.Immunol. 
1998. 10: 601-607. 
154. Panek,R.B., Lee,Y.J., and Benveniste,E.N., TGF-beta suppression ofiFN-
gamma-induced class II MHC gene expression does not involve inhibition of 
phosphorylation of JAK1, JAK2, or signal transducers and activators of 
transcription, or modification ofiFN-gamma enhanced factor X expression. 
Jlmmunol. 1995. 154: 610-619. 
155. Wrana,J.L., Attisano,L., Wieser,R., Ventura,F., and Massague,J., Mechanism of 
activation of the TGF-beta receptor. Nature 1994. 370: 341-347. 
156. Massague,J. and Chen,Y.G., Controlling TGF-beta signaling. Genes Dev. 2000. 
14: 627-644. 
157. Hu,P.P., Datto,M.B., and Wang,X.F., Molecular mechanisms oftransforming 
growth factor-beta signaling. Endocr.Rev. 1998. 19: 349-363. 
158. Hayashi,H., Abdollah,S., Qiu,Y., Cai,J., Xu,Y.Y., Grinnell,B.W., 
Richardson,M.A., Topper,J.N., Gimbrone,M.A., Jr., Wrana,J.L., and Falb,D., The 
MAD-related protein Smad7 associates with the TGFbeta receptor and functions 
as an antagonist ofTGFbeta signaling. Cell1997. 89: 1165-1173. 
159. Nakao,A., Imamura,T., Souchelnytskyi,S., Kawabata,M., Ishisaki,A., Oeda,E., 
Tamaki,K., Hanai,J., Heldin,C.H., Miyazono,K., and ten,D.P., TGF-beta receptor-
mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997. 16: 
5353-5362. 
160. Huang,W.Y., Newman,B., Millikan,R.C., Schell,M.J., Hulka,B.S., and 
Moorman,P.G., Hormone-related factors and risk of breast cancer in relation to 
estrogen receptor and progesterone receptor status. Am.JEpidemiol. 2000. 151: 
703-714. 
161. Jensen,E.V. and Jordan,V.C., The estrogen receptor: a model for molecular 
medicine. Clin.Cancer Res. 2003. 9: 1980-1989. 
162. Osbome,C.K., Schiff,R., Fuqua,S.A., and Shou,J., Estrogen receptor: current 
understanding of its activation and modulation. Clin.Cancer Res. 2001. 7: 4338s-
4342s. 
163. Kelsey,J.L., A review of the epidemiology ofhuman breast cancer. 
Epidemiol.Rev. 1979. 1: 74-109. 
173 
164. Jonat,W., Pritchard,K.I., Sainsbury,R., and Klijn,J.G., Trends in endocrine 
therapy and chemotherapy for early breast cancer: a focus on the premenopausal 
patient. J.Cancer Res.Clin.Oncol. 2006. 132: 275-286. 
165. Simpson,E.R., Mahendroo,M.S., Means,G.D., Kilgore,M.W., Hinshelwood,M.M., 
Graham-Lorence,S., Amarneh,B., Ito,Y., Fisher,C.R., Michael,M.D., and., 
Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. 
Endocr.Rev. 1994. 15: 342-355. 
166. Kirma,N., Gill,K., Mandava,U., and Tekmal,R.R., Overexpression ofaromatase 
leads to hyperplasia and changes in the expression of genes involved in apoptosis, 
cell cycle, growth, and tumor suppressor functions in the mammary glands of 
transgenic mice. Cancer Res. 2001. 61: 1910-1918. 
167. Lippman,M.E. and Dickson,R.B., Mechanisms of normal and malignant breast 
epithelial growth regulation. J. Steroid Biochem. 1989. 34: 107-121. 
168. Suzuki,T., Moriya,T., Ishida,T., Kimura,M., Ohuchi,N., and Sasano,H., In situ 
production of estrogens in human breast carcinoma. Breast Cancer 2002. 9: 296-
302. 
169. Chen,S., Itoh,T., Wu,K., Zhou,D., and Yang,C., Transcriptional regulation of 
aromatase expression in human breast tissue. J.Steroid Biochem.Mol.Biol. 2002. 
83: 93-99. 
170. Parker,M.G., Steroid and related receptors. Curr.Opin.Cell Bioi. 1993. 5: 499-
504. 
171. Razandi,M., Pedram,A., Greene,G.L., and Levin,E.R., Cell membrane and nuclear 
estrogen receptors (ERs) originate from a single transcript: studies of ERalpha 
and ERbeta expressed in Chinese hamster ovary cells. Mol.Endocrinol. 1999. 13: 
307-319. 
172. Toran-Allerand,C.D., Guan,X., MacLusky,N.J., Horvath,T.L., Diano,S., 
Singh,M., Connolly,E.S., Jr., Nethrapalli,I.S., and Tinnikov,A.A., ER-X: a novel, 
plasma membrane-associated, putative estrogen receptor that is regulated during 
development and after ischemic brain injury. J.Neurosci. 2002. 22: 8391-8401. 
173. Razandi,M., Pedram,A., Merchenthaler,I., Greene,G.L., and Levin,E.R., Plasma 
membrane estrogen receptors exist and functions as dimers. Mol.Endocrinol. 
2004.18:2854-2865. 
174. Walter,P., Green,S., Greene,G., Krust,A., Bornert,J.M., Jeltsch,J.M., Staub,A., 
Jensen,E., Scrace,G., Waterfield,M., and., Cloning of the human estrogen 
receptor eDNA. Proc.Natl.Acad.Sci.US.A 1985. 82: 7889-7893. 
174 
175. Mosselman,S., Polman,J., and Dijkema,R., ER beta: identification and 
characterization of a novel human estrogen receptor. FEES Lett. 1996. 392: 49-
53. 
176. Kuiper,G.G., Enmark,E., Pelto-Huikko,M., Nilsson,S., and Gustafsson,J.A., 
Cloning of a novel receptor expressed in rat prostate and ovary. 
Proc.Natl.Acad.Sci. US.A 1996. 93: 5925-5930. 
177. Tremblay,G.B., Tremblay,A., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., 
Labrie,F., and Giguere,V., Cloning, chromosomal localization, and functional 
analysis ofthe murine estrogen receptor beta. Mol.Endocrinol. 1997. 11: 353-365. 
178. Dotzlaw,H., Leygue,E., Watson,P.H., and Murphy,L.C., Expression of estrogen 
receptor-beta in human breast tumors. JClin.Endocrinol.Metab 1997. 82: 2371-
2374. 
179. Vladusic,E.A., Hornby,A.E., Guerra-Vladusic,F.K., Lakins,J., and Lupu,R., 
Expression and regulation of estrogen receptor beta in human breast tumors and 
cell lines. Oncol.Rep. 2000. 7: 157-167. 
180. Klein-Hitpass,L., Ryffel,G.U., Heitlinger,E., and Cato,A.C., A 13 bp palindrome 
is a functional estrogen responsive element and interacts specifically with 
estrogen receptor. Nucleic Acids Res. 1988. 16: 647-663. 
181. Kumar,V. and Chambon,P., The estrogen receptor binds tightly to its responsive 
element as a ligand-induced homodimer. Cel/1988. 55: 145-156. 
182. Chen,D., Pace,P.E., Coombes,R.C., and Ali,S., Phosphorylation of human 
estrogen receptor alpha by protein kinase A regulates dimerization. Mol. Cell Bioi. 
1999. 19: 1002-1015. 
183. Shiau,A.K., Barstad,D., Loria,P.M., Cheng,L., Kushner,P.J., Agard,D.A., and 
Greene,G.L., The structural basis of estrogen receptor/coactivator recognition and 
the antagonism ofthis interaction by tamoxifen. Cel/1998. 95: 927-937. 
184. Onate,S.A., Tsai,S.Y., Tsai,M.J., and O'Malley,B.W., Sequence and 
characterization of a coactivator for the steroid hormone receptor superfamily. 
Science 1995. 270: 1354-1357. 
185. Hanstein,B., Eckner,R., DiRenzo,J., Halachmi,S., Liu,H., Searcy,B., 
Kurokawa,R., and Brown,M., p300 is a component of an estrogen receptor 
coactivator complex. Proc.Natl.Acad.Sci. US.A 1996. 93: 11540-11545. 
186. Shang,Y., Hu,X., DiRenzo,J., Lazar,M.A., and Brown,M., Cofactor dynamics and 
sufficiency in estrogen receptor-regulated transcription. Cel/2000. 103: 843-852. 
175 
187. Smith,C.L., Nawaz,Z., and O'Malley,B.W., Coactivator and corepressor 
regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-
hydroxytamoxifen. Mol.Endocrinol. 1997. 11: 657-666. 
188. Anzick,S.L., Kononen,J., Walker,R.L., Azorsa,D.O., Tanner,M.M., Guan,X.Y., 
Sauter,G., Kallioniemi,O.P., Trent,J.M., and Meltzer,P.S., AIB1, a steroid 
receptor coactivator amplified in breast and ovarian cancer. Science 1997. 277: 
965-968. 
189. Frasor,J., Danes,J.M., Komm,B., Chang,K.C., Lyttle,C.R., and 
Katzenellenbogen,B.S., Profiling of estrogen up- and down-regulated gene 
expression in human breast cancer cells: insights into gene networks and 
pathways underlying estrogenic control of proliferation and cell phenotype. 
Endocrinology 2003. 144: 4562-4574. 
190. Sommer,S. and Fuqua,S.A., Estrogen receptor and breast cancer. Semin. Cancer 
Bioi. 2001. 11: 339-352. 
191. Pappo,I., Meirshon,I., Kami,T., Siegelmann-Danielli,N., Stahl-Kent,V., 
Sandbank,]., Wasserman,!., and Halevy,A., The characteristics of malignant 
breast tumors in hormone replacement therapy users versus nonusers. 
Ann.Surg.Oncol. 2004. 11: 52-58. 
192. Osbome,C.K., Zhao,H., and Fuqua,S.A., Selective estrogen receptor modulators: 
structure, function, and clinical use. J Clin. Oneal. 2000. 18: 3172-3186. 
193. Lippman,M.E., An assessment of current achievements in the systemic 
management of breast cancer. Breast Cancer Res. Treat. 1984. 4: 69-77. 
194. Kumar,V., Green,S., Stack,G., Berry,M., Jin,J.R., and Chambon,P., Functional 
domains of the human estrogen receptor. Cell1987. 51: 941-951. 
195. Kumar,V., Green,S., Staub,A., and Chambon,P., Localisation ofthe oestradiol-
binding and putative DNA-binding domains of the human oestrogen receptor. 
EMBOJ 1986. 5: 2231-2236. 
196. Webster,N.J., Green,S., Tasset,D., Ponglikitmongkol,M., and Chambon,P., The 
transcriptional activation function located in the hormone-binding domain of the 
human oestrogen receptor is not encoded in a single exon. EMBO J 1989. 8: 
1441-1446. 
197. Tzukerman,M.T., Esty,A., Santiso-Mere,D., Danielian,P., Parker,M.G., 
Stein,R.B., Pike,J.W., and McDonnell,D.P., Human estrogen receptor 
transactivational capacity is determined by both cellular and promoter context and 
176 
mediated by two functionally distinct intramolecular regions. Mol.Endocrinol. 
1994. 8: 21-30. 
198. Picard,D., Kumar,V., Chambon,P., and Yamamoto,K.R., Signal transduction by 
steroid hormones: nuclear localization is differentially regulated in estrogen and 
glucocorticoid receptors. Cell Regul. 1990. 1: 291-299. 
199. Tabibzadeh,S.S., Sivarajah,A., Carpenter,D., Ohlsson-Wilhelm,B.M., and 
Satyaswaroop,P.G., Modulation ofHLA-DR expression in epithelial cells by 
interleukin 1 and estradiol-17 beta. JClin.Endocrinol.Metab 1990. 71: 740-747. 
200. Debout,C., Lefroit-Joliy,M., Neveu,T., and Izard,J., 17 beta estradiol affects the 
expression of guinea pig blood leukocyte MHC antigens. JSteroid 
Biochem.Mol.Biol. 1991. 38: 695-701. 
201. Saito,S., Foegh,M.L., Motomura,N., Lou,H., Kent,K., and Ramwell,P.W., 
Estradiol inhibits allograft-inducible major histocompatibility complex class II 
antigen expression and transplant arteriosclerosis in the absence of 
immunosuppression. Transplantation 1998. 66: 1424-1431. 
202. Lou,H., Kodama,T., Zhao,Y.J., Maurice,P., Wang,Y.N., Katz,N., and 
Foegh,M.L., Inhibition of transplant coronary arteriosclerosis in rabbits by 
chronic estradiol treatment is associated with abolition ofMHC class II antigen 
expression. Circulation 1996. 94: 3355-3361. 
203. Saito,S., Motomura,N., Lou,H., Ramwell,P.W., and Foegh,M.L., Specific effects 
of estrogen on growth factor and major histocompatibility complex class II 
antigen expression in rat aortic allograft. J Tho rae. Cardiovasc. Surg. 1997. 114: 
803-809. 
204. Cenci,S., Toraldo,G., Weitzmann,M.N., Roggia,C., Gao,Y., Qian,W.P., Sierra,O., 
and Pacifici,R., Estrogen deficiency induces bone loss by increasing T cell 
proliferation and lifespan through IFN-gamma-induced class II transactivator. 
Proc.Natl.Acad.Sci. US.A 2003. 100: 10405-10410. 
205. Lambert,K.C., Curran,E.M., Judy,B.M., Milligan,G.N., Lubahn,D.B., and 
Estes,D.M., Estrogen Receptor {alpha} (ER{alpha}) Deficiency in Macrophages 
Results in Increased Stimulation of CD4+ T Cells while 17 {beta}-Estradiol Acts 
through ER{alpha} to Increase IL-4 and GATA-3 Expression in CD4+ T Cells 
Independent of Antigen Presentation. J.Immunol. 2005. 175: 5716-5723. 
206. Adamski,J., Ma,Z., Nozell,S., and Benveniste,E.N., 17beta-Estradiol inhibits class 
II major histocompatibility complex (MHC) expression: influence on histone 
modifications and cbp recruitment to the class II MHC promoter. Mol.Endocrinol. 
2004. 18: 1963-1974. 
177 
207. Adamski,J. and Benveniste,E.N., 17beta-estradiol activation of the c-Jun N-
terminal kinase pathway leads to down-regulation of class II major 
histocompatibility complex expression. Mol.Endocrinol. 2005. 19: 113-124. 
208. Beresford,G.W. and Boss,J.M., CIITA coordinates multiple histone acetylation 
modifications at the HLA-DRA promoter. Nat.Immunol. 2001. 2: 652-657. 
209. Weston,C.R. and Davis,R.J., The JNK signal transduction pathway. 
Curr.Opin.Genet.Dev. 2002. 12: 14-21. 
210. Edgecombe, A. E. HLA Class II Expression on Breast Cancer Cells. 2002. 
Ref Type: Thesis/Dissertation 
211. Spurrell,D.R., Oldford,S.A., Frost,T., Larsen,B., Codner,D., Edgecombe,A., and 
Drover,S., Discordant expression ofHLA class II-associated co-chaperones and 
HLA-DRB alleles in cultured fibroblast-like synoviocytes. Hum.Immunol. 2004. 
65: 1516-1529. 
212. Jabrane-Ferrat,N., Faille,A., Loiseau,P., Poirier,O., Charron,D., and Calvo,F., 
Effect of gamma interferon on HLA class-I and -II transcription and protein 
expression in human breast adenocarcinoma cell lines. Int.JCancer 1990. 45: 
1169-1176. 
213. Sedlak,J., Speiser,P., Zeillinger,R., Krugluger,W., Wiltschke,C., Kubista,E., and 
Chorvath,B., Cytokine (IFN-alpha, IFN-gamma, IL-l-alpha, TNF-alpha)-induced 
modulation of HLA cell surface expression in human breast cancer cell lines. 
Neoplasma 1992. 39: 269-272. 
214. Welshons,W.V., Wolf,M.F., Murphy,C.S., and Jordan,V.C., Estrogenic activity of 
phenol red. Mol. Cell Endocrinol. 1988. 57: 169-178. 
215. Bindal,R.D., Carlson,K.E., Katzenellenbogen,B.S., and Katzenellenbogen,J.A., 
Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic 
activity in commercial preparations ofphenol red. JSteroid Biochem. 1988. 31: 
287-293. 
216. Lacroix,M. and Leclercq,G., Relevance ofbreast cancer cell lines as models for 
breast tumours: an update. Breast Cancer Res. Treat. 2004. 83: 249-289. 
217. Berthois,Y., Katzenellenbogen,J.A., and Katzenellenbogen,B.S., Phenol red in 
tissue culture media is a weak estrogen: implications concerning the study of 
estrogen-responsive cells in culture. Proc.Natl.Acad.Sci. USA 1986. 83: 2496-
2500. 
178 
218. Pink,J.J., Bilimoria,M.M., Assikis,J., and Jordan,V.C., Irreversible loss ofthe 
oestrogen receptor in T47D breast cancer cells following prolonged oestrogen 
deprivation. Br.JCancer 1996. 74: 1227-1236. 
219. Lampson,L.A. and Levy,R., Two populations ofla-like molecules on a human B 
cell line. Jlmmunol. 1980. 125: 293-299. 
220. Drover,S., Karr,R.W., Fu,X.T., and Marshall,W.H., Analysis of monoclonal 
antibodies specific for unique and shared determinants on HLA-DR4 molecules. 
Hum.Immunol. 1994. 40: 51-60. 
221. Drover,S., Marshall,W.H., and Younghusband,H.B., A mouse monoclonal 
antibody with HLA-DR4 associated specificity. Tissue Antigens 1985. 26: 340-
343. 
222. Fu,X.T., Drover,S., Marshall,W.H., and Karr,R.W., HLA-DR residues accessible 
under the peptide-binding groove contribute to polymorphic antibody epitopes. 
Hum.Immunol. 1995. 43: 243-250. 
223. Bodmer,J.G., Heyes, J. M., and Lindsay, J., Studies of monoclonal antibodies to 
the HLA-D region: DQwl, DRw52. Springer-Verlag, Berlin 1985. 
224. Koning,F., Schreuder,I., Giphart,M., and Bruning,H., A mouse monoclonal 
antibody detecting a DR-related MT2-like specificity: serology and biochemistry. 
Hum.Immunol. 1984. 9: 221-230. 
225. Radka,S.F., Amos,D.B., Quackenbush,L.J., and Cresswell,P., HLA-DR7-specific 
monoclonal antibodies and a chimpanzee anti-DR7 serum detect different 
epitopes on the same molecule. Immunogenetics 1984. 19: 63-76. 
226. Jazaeri,O., Shupnik,M.A., Jazaeri,A.A., and Rice,L.W., Expression of estrogen 
receptor alpha mRNA and protein variants in human endometrial carcinoma. 
Gynecol.Oncol. 1999. 74: 38-47. 
227. Kotake,S., Schumacher,H.R., Jr., and Wilder,R.L., A simple nested RT-PCR 
method for quantitation of the relative amounts of multiple cytokine mRNAs in 
small tissue samples. Jlmmunol.Methods 1996. 199: 193-203. 
228. Marrogi,A.J., Munshi,A., Merogi,A.J., Ohadike,Y., El-Habashi,A., Marrogi,O.L., 
and Freeman,S.M., Study of tumor infiltrating lymphocytes and transforming 
growth factor-Pas prognostic factors in breast carcinoma. Int.JCancer 1997. 74: 
492-501. 
179 
229. Patemo,G.D., Mercer,F.C., Chayter,J.J., Yang,X., Robb,J.D., and Gillespie,L.L., 
Molecular cloning ofhuman er1cDNA and its differential expression in breast 
tumors and tumor-derived cell lines. Gene 1998. 222: 77-82. 
230. Gottwald,E., Muller,O., and Polten,A., Semiquantitative reverse transcription-
polymerase chain reaction with the Agilent 2100 Bioanalyzer. Electrophoresis 
2001.22:4016-4022. 
231. Murphy,S.J., Dore,J.J., Edens,M., Coffey,R.J., Bamard,J.A., Mitchell,H., 
Wilkes,M., and Leof,E.B., Differential trafficking of transforming growth factor-
beta receptors and ligand in polarized epithelial cells. Mol.Biol.Cell2004. 15: 
2853-2862. 
232. Rajendran,K.G., Lopez,T., and Parikh,!., Estrogenic effect of phenol red in MCF-
7 cells is achieved through activation of estrogen receptor by interacting with a 
site distinct from the steroid binding site. Biochem.Biophys.Res. Commun. 1987. 
142: 724-731. 
233. Green,S., Walter,P., Kumar,V., Krust,A., Bomert,J.M., Argos,P., and 
Chambon,P ., Human oestrogen receptor eDNA: sequence, expression and 
homology to v-erb-A. Nature 1986. 320: 134-139. 
234. Balfe,P., McCann,A., McGoldrick,A., McAllister,K., Kennedy,M., Dervan,P., and 
Kerin,M.J., Estrogen receptor alpha and beta profiling in human breast cancer. 
Eur.JSurg.Oncol. 2004. 30: 469-474. 
235. Lu,M., Lopez,R., Nakajo,S., Nakaya,K., and Jing,Y., Expression of estrogen 
receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding 
protein II genes is coordinately regulated in human breast cancer cells. Oncogene 
2005.24:4362-4369. 
236. Donaghue,C., Westley,B.R., and May,F.E., Selective promoter usage of the 
human estrogen receptor-alpha gene and its regulation by estrogen. 
Mol.Endocrinol. 1999. 13: 1934-1950. 
237. Santen,R.J., Song,R.X., Zhang,Z., Kumar,R., Jeng,M.H., Masamura,A., 
Lawrence,J., Jr., Berstein,L., and Yue,W., Long-term estradiol deprivation in 
breast cancer cells up-regulates growth factor signaling and enhances estrogen 
sensitivity. Endocr.Relat Cancer 2005. 12 Suppl1: S61-S73. 
238. The Merck Index, Thirteen Edition. Merck Research Laboratories, Merck and 
Co.Inc., Whitehouse Station, NJ., 2001. 
180 
239. Brattain,M.G., Ko,Y., Banerji,S.S., Wu,G., and Willson,J.K., Defects ofTGF-beta 
receptor signaling in mammary cell tumorigenesis. 
JMammary. GlandBiol.Neoplasia. 1996. 1: 365-372. 
240. Kalkhoven,E., Roelen,B.A., de Winter,J.P., Mummery,C.L., van den Eijnden-van 
Raaij AJ, van der Saag,P.T., and van der,B.B., Resistance to transforming growth 
factor beta and activin due to reduced receptor expression in human breast tumor 
cell lines. Cell Growth Differ. 1995. 6: 1151-1161. 
241. Marth,C., Zech,J., Bock,G., Mayer,!., and Daxenbichler,G., Effects ofretinoids 
and interferon-gamma on cultured breast cancer cells in comparison with tumor 
necrosis factor alpha. Int.JCancer 1987. 40: 840-845. 
242. Mortarini,R., Belli,F., Parmiani,G., and Anichini,A., Cytokine-mediated 
modulation ofHLA-class II, ICAM-1, LFA-3 and tumor-associated antigen 
profile of melanoma cells. Comparison with anti-proliferative activity by riLl-
beta, rTNF-alpha, riFN-gamma, riL4 and their combinations. Int.JCancer 1990. 
45: 334-341. 
243. Tibbo, J. The Selective Expression ofHLA Class II Molecules by Human Breast 
Carcinoma Cell Lines. 1998. 
Ref Type: Thesis/Dissertation 
244. Arteaga,C.L., Tandon,A.K., Von Hoff,D.D., and Osborne,C.K., Transforming 
growth factor beta: potential autocrine growth inhibitor of estrogen receptor-
negative human breast cancer cells. Cancer Res. 1988. 48: 3898-3904. 
245. Ko,Y., Banerji,S.S., Liu,Y., Li,W., Liang,J., Soule,H.D., Pauley,R.J., 
Willson,J.K., Zborowska,E., and Brattain,M.G., Expression of transforming 
growth factor-beta receptor type II and tumorigenicity in human breast 
adenocarcinoma MCF-7 cells. JCell Physio/1998. 176: 424-434. 
246. Arteaga,C.L., Carty-Dugger,T., Moses,H.L., Hurd,S.D., and Pietenpol,J.A., 
Transforming growth factor beta 1 can induce estrogen-independent 
tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 
1993. 4: 193-201. 
247. Sun,L., Wu,G., Willson,J.K., Zborowska,E., Yang,J., Rajkarunanayake,I., 
Wang,J., Gentry,L.E., Wang,X.F., and Brattain,M.G., Expression of transforming 
growth factor beta type II receptor leads to reduced malignancy in human breast 
cancer MCF-7 cells. JBiol.Chem. 1994.269: 26449-26455. 
248. Mazars,P., Barboule,N., Baldin,V., Vidal,S., Ducommun,B., and Valette,A., 
Effects ofTGF-beta 1 (transforming growth factor-beta 1) on the cell cycle 
181 
regulation ofhuman breast adenocarcinoma (MCF-7) cells. FEBS Lett. 1995. 362: 
295-300. 
249. Oldford,S.A., Robb,J.D., Watson,P.H., and Drover,S., HLA-DRB alleles are 
differentially expressed by tumor cells in breast carcinoma. lnt.J. Cancer 2004. 
112: 399-406. 
250. Jones,C., Payne,J., Wells,D., Delhanty,J.D., Lakhani,S.R., and Kortenkamp,A., 
Comparative genomic hybridization reveals extensive variation among different 
MCF-7 cell stocks. Cancer Genet.Cytogenet. 2000. 117: 153-158. 
251. Armstrong,T.D., Clements,V.K., and Ostrand-Rosenberg,S., Class II-transfected 
tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are 
APCs for tumor-encoded antigens in vivo. J.Immunother. 1998. 21: 218-224. 
252. Nouri,A.M., Hussain,R.F., Dos Santos,A.V., Gillott,D.J., and Oliver,R.T., 
Induction ofMHC antigens by tumour cell lines in response to interferons. 
Eur.J. Cancer 1992. 28A: 111 0-1115. 
253. Castles,C.G., Fuqua,S.A., Klotz,D.M., and Hill,S.M., Expression of a 
constitutively active estrogen receptor variant in the estrogen receptor-negative 
BT-20 human breast cancer cell line. Cancer Res. 1993. 53: 5934-5939. 
254. Fuqua,S.A., Fitzgerald,S.D., Charnness,G.C., Tandon,A.K., McDonnell,D.P., 
Nawaz,Z., O'Malley,B.W., and McGuire,W.L., Variant human breast tumor 
estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991. 51: 
105-109. 
255. Leygue,E., Huang,A., Murphy,L.C., and Watson,P.H., Prevalence of estrogen 
receptor variant messenger RNAs in human breast cancer. Cancer Res. 1996. 56: 
4324-4327. 
256. Murphy,L.C., Leygue,E., Dotzlaw,H., Douglas,D., Coutts,A., and Watson,P.H., 
Oestrogen receptor variants and mutations in human breast cancer. Ann.Med 
1997. 29: 221-234. 
257. Graham,M.L., Krett,N.L., Miller,L.A., Leslie,K.K., Gordon,D.F., Wood,W.M., 
Wei,L.L., and Horwitz,K.B., T47DCO cells, genetically unstable and containing 
estrogen receptor mutations, are a model for the progression of breast cancers to 
hormone resistance. Cancer Res. 1990. 50: 6208-6217. 
258. Wang,Y. and Miksicek,R.J., Identification of a dominant negative form ofthe 
human estrogen receptor. Mol. Endocrinol. 1991. 5: 1707-1715. 
182 
259. Pink,J.J., Wu,S.Q., Wolf,D.M., Bilimoria,M.M., and Jordan,V.C., A novel80 kDa 
human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids 
Res. 1996. 24: 962-969. 
260. McGuire,W.L., Chamness,G.C., and Fuqua,S.A., Estrogen receptor variants in 
clinical breast cancer. Mol.Endocrinol. 1991. 5: 1571-1577. 
261. Fuqua,S.A., Wiltschke,C., Zhang,Q.X., Borg,A., Castles,C.G., Friedrichs,W.E., 
Hopp,T., Hilsenbeck,S., Mohsin,S., O'Connell,P., and Allred,D.C., A 
hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. 
Cancer Res. 2000. 60: 4026-4029. 
262. Palmieri,C., Lam,E.W., Mansi,J., MacDonald,C., Shousha,S., Madden,P., 
Omoto,Y., Sunters,A., Wamer,M., Gustafsson,J.A., and Coombes,R.C., The 
expression of ER beta ex in human breast cancer and the relationship to endocrine 
therapy and survival. Clin.Cancer Res. 2004. 10: 2421-2428. 
263. Leygue,E., Dotzlaw,H., Watson,P.H., and Murphy,L.C., Altered expression of 
estrogen receptor-alpha variant messenger RNAs between adjacent normal breast 
and breast tumor tissues. Breast Cancer Res. 2000. 2: 64-72. 
264. Okada,K., Ichii,S., Hatada,T., Ishii,H., and Utsunomiya,J., Comparison of variant 
expression of estrogen receptor mRNA in normal breast tissue and breast cancer. 
Int.JOncol. 1998. 12: 1025-1028. 
265. Tong,D., Schuster,E., Seifert,M., Czerwenka,K., Leodolte,S., and Zeillinger,R., 
Expression of estrogen receptor beta isoforms in human breast cancer tissues and 
cell lines. Breast Cancer Res. Treat. 2002. 71: 249-255. 
266. Reddel,R.R., Alexander,I.E., Koga,M., Shine,J., and Sutherland,R.L., Genetic 
instability and the development of steroid hormone insensitivity in cultured T 4 7D 
human breast cancer cells. Cancer Res. 1988. 48: 4340-4347. 
267. Clayton,S.J., May,F.E., and Westley,B.R., Insulin-like growth factors control the 
regulation of oestrogen and progesterone receptor expression by oestrogens. 
Mol.Cell Endocrinol. 1997. 128: 57-68. 
268. Saceda,M., Lippman,M.E., Chambon,P., Lindsey,R.L., Ponglikitmongkol,M., 
Puente,M., and Martin,M.B., Regulation ofthe estrogen receptor in MCF-7 cells 
by estradiol. Mol.Endocrinol. 1988. 2: 1157-1162. 
269. Read,L.D., Greene,G.L., and Katzenellenbogen,B.S., Regulation of estrogen 
receptor messenger ribonucleic acid and protein levels in human breast cancer cell 
lines by sex steroid hormones, their antagonists, and growth factors. 
Mol.Endocrinol. 1989. 3: 295-304. 
183 
270. Welshons,W.V. and Jordan,V.C., Adaptation of estrogen-dependent MCF-7 cells 
to low estrogen (phenol red-free) culture. Eur.JCancer Clin.Oncol. 1987. 23: 
1935-1939. 
271. Katzenellenbogen,B.S., Kendra,K.L., Norman,M.J., and Berthois,Y., 
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF -7 
human breast cancer cells grown in the short-term and long-term absence of 
estrogens. Cancer Res. 1987.47: 4355-4360. 
272. Murphy,C.S., Meisner,L.F., Wu,S.Q., and Jordan,V.C., Short- and long-term 
estrogen deprivation ofT47D human breast cancer cells in culture. Eur.JCancer 
Clin.Oncol. 1989. 25: 1777-1788. 
273. Chrysogelos,S.A. and Dickson,R.B., EGF receptor expression, regulation, and 
function in breast cancer. Breast Cancer Res. Treat. 1994. 29: 29-40. 
274. Slamon,D.J., Clark,G.M., Wong,S.G., Levin,W.J., Ullrich,A., and McGuire,W.L., 
Human breast cancer: correlation of relapse and survival with amplification of the 
HER-2/neu oncogene. Science 1987.235: 177-182. 
275. Toi,M., Hamada,Y., Nakamura,T., Mukaida,H., Suehiro,S., Wada,T., Toge,T., 
Niimoto,M., and Hattori,T., Immunocytochemical and biochemical analysis of 
epidermal growth factor receptor expression in human breast cancer tissues: 
relationship to estrogen receptor and lymphatic invasion. Int.JCancer 1989. 43: 
220-225. 
276. Konecny,G., Pauletti,G., Pegram,M., Untch,M., Dandekar,S., Aguilar,Z., 
Wilson,C., Rong,H.M., Bauerfeind,I., Felber,M., Wang,H.J., Beryt,M., 
Seshadri,R., Hepp,H., and Slamon,D.J., Quantitative association between HER-
2/neu and steroid hormone receptors in hormone receptor-positive primary breast 
cancer. JNatl.Cancer Inst. 2003. 95: 142-153. 
277. Okuyama,N., Hatano,Y., Park,Y., Shimatani,S., Sasamoto,S., Katou,N., 
Takagi,K., Y amazaki,S., Inoue,A., Hemmi,H., Shimatake,H., Y anagida,M., and 
Miura,M., Quantitation of c-erbB-2 gene amplification in breast cancer tissue by 
competitive PCR. Tumour.Biol. 1999. 20: 153-161. 
278. Millson,A., Suli,A., Hartung,L., Kunitake,S., Bennett,A., Nordberg,M.C., 
Hanna,W., Wittwer,C.T., Seth,A., and Lyon,E., Comparison of two quantitative 
polymerase chain reaction methods for detecting HER2/neu amplification. 
JMol.Diagn. 2003. 5: 184-190. 
279. Miller,D.L., el-Ashry,D., Cheville,A.L., Liu,Y., McLeskey,S.W., and Kem,F.G., 
Emergence of M CF-7 cells overexpressing a transfected epidermal growth factor 
184 
receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR 
in breast cancer growth and progression. Cell Growth Differ. 1994. 5: 1263-1274. 
280. Oh,A.S., Lorant,L.A., Holloway,J.N., Miller,D.L., Kem,F.G., and el-Ashry,D., 
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer 
cells. Mol.Endocrinol. 2001. 15: 1344-1359. 
281. Holloway,J.N., Murthy,S., and el-Ashry,D., A cytoplasmic substrate of mitogen-
activated protein kinase is responsible for estrogen receptor-alpha down-
regulation in breast cancer cells: the role of nuclear factor-kappaB. 
Mol.Endocrinol. 2004. 18: 1396-1410. 
282. Martinez-Carpio,P.A., Mur,C., Rosel,P., and Navarro,M.A., Constitutive and 
regulated secretion of epidermal growth factor and transforming growth factor-
beta! in MDA-MB-231 breast cancer cell line in 11-day cultures. Cell Signal. 
1999. 11:753-757. 
283. Kato,S., Endoh,H., Masuhiro,Y., Kitamoto,T., Uchiyama,S., Sasaki,H., 
Masushige,S., Gotoh,Y., Nishida,E., Kawashima,H., Metzger,D., and 
Chambon,P., Activation of the estrogen receptor through phosphorylation by 
mitogen-activated protein kinase. Science 1995. 270: 1491-1494. 
284. Smith,C.L., Cross-talk between peptide growth factor and estrogen receptor 
signaling pathways. Biol.Reprod 1998. 58: 627-632. 
285. Chang,M.P. and Norman,D.C., Ethanol impairs major histocompatibility complex 
(MHC) class II molecule-mediated but not MHC class I molecule-mediated T cell 
response in alcohol-consuming mice. Immunopharmacol.Immunotoxicol. 1999. 
21: 65-87. 
286. Weiss,P.A., Collier,S.D., and Pruett,S.B., Effect of ethanol on B cell expression 
of major histocompatibility class II proteins in immunized mice. 
Immunopharmacology 1998. 39: 61-72. 
287. Weiss,P.A., Collier,S.D., and Pruett,S.B., Role of glucocorticoids in ethanol-
induced decreases in expression ofMHC class II molecules on B cells and 
selective decreases in spleen cell number. Toxicol.Appl.Pharmacol. 1996. 139: 
153-162. 
288. Etique,N., Chardard,D., Chesnel,A., Merlin,J.L., Flament,S., and Grillier-
Vuissoz,I., Ethanol stimulates proliferation, ERalpha and aromatase expression in 
MCF-7 human breast cancer cells. Int.JMol.Med 2004. 13: 149-155. 
185 
289. Singletary,K.W., Frey,R.S., 'and Yan,W., Effect of ethanol on proliferation and 
estrogen receptor-alpha expression in human breast cancer cells. Cancer Lett. 
2001. 165: 131-137. 
290. Przylipiak,A., Rabe,T., Hafner,J., Przylipiak,M., and Runnebaum,R., Influence of 
ethanol on in vitro growth ofhuman mammary carcinoma cell line MCF-7. 
Arch.Gynecol.Obstet. 1996. 258: 137-140. 
291. Fan,S., Meng,Q., Gao,B., Grossman,J., Yadegari,M., Goldberg,I.D., and 
Rosen,E.M., Alcohol stimulates estrogen receptor signaling in human breast 
cancer cell lines. Cancer Res. 2000. 60: 5635-5639. 
292. Etique,N., Chardard,D., Chesnel,A., Flament,S., and Grillier-Vuissoz,l., Analysis 
of the effects of different alcohols on MCF -7 human breast cancer cells. 
Ann.N YAcad.Sci. 2004. 1030: 78-85. 
293. Coombes,R.C., Barrett-Lee,P., and Luqmani,Y., Growth factor expression in 
breast tissue. J.Steroid Biochem.Mol.Biol. 1990. 37: 833-836. 
294. Chakravarthy,D., Green,A.R., Green,V.L., Kerin,M.J., and Speirs,V., Expression 
and secretion ofTGF-beta isoforms and expression ofTGF-beta-receptors I, II 
and III in normal and neoplastic human breast. Int.J.Oncol. 1999. 15: 187-194. 
295. Knabbe,C., Lippman,M.E., Wakefield,L.M., Flanders,K.C., Kasid,A., 
Derynck,R., and Dickson,R.B., Evidence that transforming growth factor-beta is a 
hormonally regulated negative growth factor in human breast cancer cells. Cell 
1987. 48: 417-428. 
296. Zugmaier,G. and Lippman,M.E., Effects ofTGF beta on normal and malignant 
mammary epithelium. Ann.N YAcad.Sci. 1990. 593: 272-275. 
297. Kehrl,J.H., Wakefield,L.M., Roberts,A.B., Jakowlew,S., varez-Mon,M., 
Derynck,R., Spom,M.B., and Fauci,A.S., Production of transforming growth 
factor beta by human T lymphocytes and its potential role in the regulation ofT 
cell growth. J.Exp.Med. 1986. 163: 1037-1050. 
298. Bogdan,C., Paik,J., Vodovotz,Y., and Nathan,C., Contrasting mechanisms for 
suppression of macrophage cytokine release by transforming growth factor-beta 
and interleukin-10. JBiol.Chem. 1992. 267: 23301-23308. 
299. J3.-iedl,E., Strobl,H., Majdic,O., and Knapp,W., TGF-beta 1 promotes in vitro 
generation of dendritic cells by protecting progenitor cells from apoptosis. 
Jlmmunol. 1997. 158: 1591-1597. 
186 
300. Murphy,L.C. and Dotzlaw,H., Regulation of transforming growth factor alpha and 
transforming growth factor beta messenger ribonucleic acid abundance in T-47D, 
human breast cancer cells. Mol.Endocrinol. 1989. 3: 611-617. 
301. Herman,M.E. and Katzenellenbogen,B.S., Alterations in transforming growth 
factor-alpha and -beta production and cell responsiveness during the progression 
of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 
1994. 54: 5867-5874. 
302. Arrick,B.A., Korc,M., and Derynck,R., Differential regulation of expression of 
three transforming growth factor beta species in human breast cancer cell lines by 
estradiol. Cancer Res. 1990. 50: 299-303. 
303. Jeng,M.H., ten,D.P., Iwata,K.K., and Jordan,V.C., Regulation of the levels of 
three transforming growth factor beta mRNAs by estrogen and their effects on the 
proliferation ofhuman breast cancer cells. Mol. Cell Endocrinol. 1993. 97: 115-
123. 
304. Lynch,M.A., Nakashima,R., Song,H., DeGroff,V.L., Wang,D., Enomoto,T., and 
Weghorst,C.M., Mutational analysis of the transforming growth factor beta 
receptor type II gene in human ovarian carcinoma. Cancer Res. 1998. 58: 4227-
4232. 
305. Gobbi,H., Arteaga,C.L., Jensen,R.A., Simpson,J.F., Dupont,W.D., Olson,S.J., 
Schuyler,P.A., Plummer,W.D., Jr., and Page,D.L., Loss of expression of 
transforming growth factor beta type II receptor correlates with high tumour grade 
in human breast in-situ and invasive carcinomas. Histopathology 2000. 36: 168-
177. 
306. Ammanamanchi,S. and Brattain,M.G., Restoration of transforming growth factor-
beta signaling through receptor RI induction by histone deacetylase activity 
inhibition in breast cancer cells. JBiol.Chem. 2004. 279: 32620-32625. 
307. Alber,C.A., Watts,R., Klohe,E.P., Drover,S., Marshall,W.H., Radka,S.F., and 
Karr,R.W., Multiple regions ofHLA-DR beta 1 chains determine polymorphic 
epitopes recognized by monoclonal antibodies. Jlmmunol. 1989. 143: 2248-2255. 
308. Gastl,G., Marth,C., Leiter,E., Gattringer,C., Mayer,!., Daxenbichler,G., Flener,R., 
and Huber,C., Effects of human recombinant alpha 2 arg-interferon and gamma-
interferon on human breast cancer cell lines: dissociation of antiproliferative 
activity and induction ofHLA-DR antigen expression. Cancer Res. 1985. 45: 
2957-2961. 
187 
309. Pai,R.K., Askew,D., Boom,W.H., and Harding,C.V., Regulation of class II MHC 
expression in APCs: roles of types I, III, and IV class II transactivator. Jlmmunol. 
2002. 169: 1326-1333. 
310. Delvig,A.A., Lee,J.J., Chrzanowska-Lightowlers,Z.M., and Robinson,J.H., TGP-
beta1 and IPN-gamma cross-regulate antigen presentation to CD4 T cells by 
macrophages. JLeukoc.Biol. 2002. 72: 163-166. 
311. Gabrielian,K., Osusky,R., Sippy,B.D., Ryan,S.J., and Hinton,D.R., Effect of TOP-
beta on interferon-gamma-induced HLA-DR expression in human retinal pigment 
epithelial cells. Invest Ophthalmol. Vis.Sci. 1994. 35: 4253-4259. 
312. Reimold,A.M., Kara,C.J., Rooney,J.W., and Glimcher,L.H., Transforming growth 
factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved 
proximal promoter elements. Jlmmunol. 1993. 151: 4173-4182. 
313. Yang,W.S., Han,N.J., Kim,C.S., Ahn,H., Lee,S.K., Lee,K.U., and Park,S.K., 
STAT1-independent down-regulation ofinterferon-gamma-:induced class II 
transactivator and HLA-DR expression by transforming growth factor beta-1 in 
human glomerular endothelial cells. Nephron Exp.Nephrol. 2005. 100: e124-e131. 
314. Janknecht,R., Wells,N.J., and Hunter,T., TOP-beta-stimulated cooperation of 
smad proteins with the coactivators CBP/p300. Genes Dev. 1998. 12: 2114-2119. 
315. Peng,X.H., Zhang,Y., Wu,R.Y., and Derynck,R., The tumor suppressor 
Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in 
TOP-beta-induced transcriptional activation. Genes Dev. 1998. 12: 2153-2163. 
316. Pouponnot,C., Jayaraman,L., and Massague,J., Physical and functional interaction 
ofSMADs and p300/CBP. JBiol.Chem. 1998. 273: 22865-22868. 
317. Shen,X., Hu,P.P., Liberati,N.T., Datto,M.B., Prederick,J.P., and Wang,X.P., TOP-
beta-induced phosphorylation of Smad3 regulates its interaction with coactivator 
p300/CREB-binding protein. Mol.Biol.Cell1998. 9: 3309-3319. 
318. Wotton,D., Lo,R.S., Lee,S., and Massague,J., A Smad transcriptional corepressor. 
Cell1999. 97: 29-39. 
319. Akiyoshi,S., Inoue,H., Hanai,J., Kusanagi,K., Nemoto,N., Miyazono,K., and 
Kawabata,M., c-Ski acts as a transcriptional co-repressor in transforming growth 
factor-beta signaling through interaction with smads. JBiol.Chem. 1999. 274: 
35269-35277. 
188 
320. Luo,K., Stroschein,S.L., Wang,W., Chen,D., Martens,E., Zhou,S., and Zhou,Q., 
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta 
signaling. Genes Dev. 1999. 13: 2196-2206. 
321. Krakowski,A.R., Laboureau,J., Mauviel,A., Bissell,M.J., and Luo,K., 
Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-
beta signaling by sequestration of the Smad proteins. Proc.Natl.Acad.Sci. US.A 
2005. 102: 12437-12442. 
322. Ulloa,L., Doody,J., and Massague,J., Inhibition of transforming growth factor-
beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999. 
397: 710-713. 
323. Nakao,A., Afrakhte,M., Moren,A., Nakayama,T., Christian,J.L., Heuchel,R., 
Itoh,S., Kawabata,M., Heldin,N.E., Heldin,C.H., and ten,D.P., Identification of 
Smad7, a TGFbeta-inducible antagonist ofTGF-beta signalling. Nature 1997. 
389: 631-635. 
324. Heldin,C.H., Miyazono,K., and ten,D.P., TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature 1997. 390: 465-471. 
325. Zuk,J.A. and Walker,R.A., Immunohistochemical analysis ofHLA antigens and 
mononuclear infiltrates of benign and malignant breast. JPathol. 1987. 152: 275-
285. 
326. Perez,S.A., Sotiropoulou,P.A., Sotiriadou,N.N., Mamalaki,A., Gritzapis,A.D., 
Echner,H., Voelter,W., Pawelec,G., Papamichail,M., and Baxevanis,C.N., HER-
2/neu-derived peptide 884-899 is expressed by human breast, colorectal and 
pancreatic adenocarcinomas and is recognized by in-vitro-induced specific 
CD4(+) T cell clones. Cancer Immunol.Immunother. 2002. 50: 615-624. 
327. Sotiriadou,R., Perez,S.A., Gritzapis,A.D., Sotiropoulou,P.A., Echner,H., 
Heinzel,S., Mamalaki,A., Pawelec,G., Voelter,W., Baxevanis,C.N., and 
Papamichail,M., Peptide HER2(776-788) represents a naturally processed broad 
MHC class II-restricted T cell epitope. Br.JCancer 2001. 85: 1527-1534. 
328. Dadmarz,R., Sgagias,M.K., Rosenberg,S.A., and Schwartzentruber,D.J., CD4+ T 
lymphocytes infiltrating human breast cancer recognise autologous tumor in an 
MHC-class-II restricted fashion. Cancer Immunol.Immunother. 1995. 40: 1-9. 
329. Emery,P., Mach,B., and Reith,W., The different level of expression ofHLA-
DRB1 and -DRB3 genes is controlled by conserved isotypic differences in 
promoter sequence. Hum.Immunol. 1993. 38: 137-147. 
189 
330. Louis,P., Vincent,R., Cavadore,P., Clot,J., and Eliaou,J.F., Differential 
transcriptional activities ofHLA-DR genes in the various haplotypes. Jlmmunol. 
1994.153:5059-5067. 
331. Qiu,X. and Singal,D.P., Allelic polymorphism in the upstream regulatory region 
ofHLA-DRB genes: functional role of conserved consensus motifs. 
Transplant.Proc. 1995. 27: 682-683. 
332. Singal,D.P. and Qiu,X., Polymorphism in both X andY box motifs controls level 
of expression ofHLA-DRBl genes. Immunogenetics 1996. 43: 50-56. 
333. Leen,M.P. and Gorski,J., Differential expression of isomorphic HLA-DR beta 
genes is not a sole function of transcription. Hum.Immunol. 1996. 50: 111-120. 
334. Vincent,R., Louis,P., Gongora,C., Papa,I., Clot,J., and Eliaou,J.F., Quantitative 
analysis of the expression of the HLA-DRB genes at the transcriptional level by 
competitive polymerase chain reaction. Jlmmunol. 1996. 156: 603-610. 
335. van den Elsen,P.J., van der,S.N., Vietor,H.E., Wilson,L., van,Z.M., and 
Gobin,S.J., Lack of CIITA expression is central to the absence of antigen 
presentation functions of trophoblast cells and is caused by methylation of the 
IFN-gamma inducible promoter (PIV) of CIIT A. Hum.Immunol. 2000. 61: 850-
862. 
336. Jonson,T., Gorunova,L., Dawiskiba,S., ndren-Sandberg,A., Stenman,G., ten,D.P., 
Johansson,B., and Hoglund,M., Molecular analyses of the 15q and 18q SMAD 
genes in pancreatic cancer. Genes Chromosomes. Cancer 1999. 24: 62-71. 
337. Fink,S.P., Mikkola,D., Willson,J.K., and Markowitz,S., TGF-beta-induced 
nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. 
Oncogene 2003.22: 1317-1323. 
338. Dowdy,S.C., Mariani,A., Reinholz,M.M., Keeney,G.L., Spelsberg,T.C., 
Podratz,K.C., and Janknecht,R., Overexpression of the TGF-beta antagonist 
Smad7 in endometrial cancer. Gynecol.Oncol. 2005. 96: 368-373. 
339. Nagarajan,R.P., Zhang,J., Li,W., and Chen,Y., Regulation ofSmad7 promoter by 
direct association with Smad3 and Smad4. JBiol.Chem. 1999. 274: 33412-33418. 
340. von,G.G., Susztak,K., Rezvani,F., Bitzer,M., Liang,D., and Bottinger,E.P., Smad3 
and Smad4 mediate transcriptional activation of the human Smad7 promoter by 
transforming growth factor beta. JBiol.Chem. 2000. 275: 11320-11326. 
190 
341. Yu,L., Hebert,M.C., and Zhang,Y.E., TGF-beta receptor-activated p38 MAP 
kinase mediates Smad-independent TGF-beta responses. EMBO J 2002. 21: 
3749-3759. 
342. Kim,E.S., Kim,M.S., and Moon,A., Transforming growth factor (TGF)-beta in 
conjunction with H-ras activation promotes malignant progression ofMCF10A 
breast epithelial cells. Cytokine 2005. 29: 84-91. 
343. Bartek,J., Petrek,M., Vojtesek,B., Bartkova,J., Kovarik,J., and Rejthar,A., HLA-
DR antigens on differentiating human mammary gland epithelium and breast 
tumours. Br.JCancer 1987. 56: 727-733. 
344. Meazza,R., Comes,A., Orengo,A.M., Ferrini,S., and Accolla,R.S., Tumor 
rejection by gene transfer of the MHC class II transactivator in murine mammary 
adenocarcinoma cells. Eur.Jlmmunol. 2003. 33: 1183-1192. 
345. Hung,K., Hayashi,R., Lafond-Walker,A., Lowenstein,C., Pardoll,D., and 
Levitsky,H., The central role ofCD4(+) T cells in the antitumor immune 
response. JExp.Med 1998. 188: 2357-2368. 
346. Zuk,J.A. and Walker,R.A., HLA class II sublocus expression in benign and 
malignant breast epithelium. JPathol. 1988. 155: 301-309. 
347. Brunner,C.A., Gokel,J.M., Riethmuller, and Johnson,J.P., Expression ofHLA-D 
subloci DR and DQ by breast carcinomas is correlated with distinct parameters of 
favourable prognois. Eur.JCancer 1991. 27: 411-416. 
348. Moller,P., Mattfeldt,T., Gross,C., Schlosshauer,P., Koch,A., Koretz,K., 
Moldenhauer,G., Kaufmann,M., and Otto,H.F., Expression ofHLA-A, -B, -C,-
DR, -DP, -DQ, and ofHLA-D-associated invariant chain (Ii) in non-neoplastic 
mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. 
Am.JPathol. 1989. 135: 73-83. 
349. Wintzer,H.O., Benzing,M., and von,K.S., Lacking prognostic significance of beta 
2-microglobulin, MHC class I and class II antigen expression in breast 
carcinomas. Br.JCancer 1990. 62: 289-295. 
350. Redondo,M., Garcia,J., Villar,E., Rodrigo,!., Perea-Milla,E., Serrano,A., and 
Morell,M., Major histocompatibility complex status in breast carcinogenesis and 
relationship to apoptosis. Hum.Pathol. 2003. 34: 1283-1289. 
351. Lucin,K., Iternicka,Z., and Jonjic,N., Prognostic significance ofT-cell infiltrates, 
expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma. 
Pathol.Res.Pract. 1994. 190: 1134-1140. 
191 
352. Tuttle,T.M., McCrady,C.W., Inge,T.H., Salour,M., and Bear,H.D., gamma-
Interferon plays a key role in T-cell-induced tumor regression. Cancer Res. 1993. 
53: 833-839. 
353. Nagai,S. and Toi,M., Interleukin-4 and breast cancer. Breast Cancer 2000. 7: 181-
186. 
192 
Chapter 6: Appendix A 
1400000 
1000000 
icE 800000 
8 
- 600000 8 
400000 
200000 
600000 
500000 
e 4ooooo 
l! 
c 8 300000 
8 
200000 
100000 
600000 
500000 
e 4ooooo 
~ 8 300000 
ii 
0 200000 
100000 
MCF-7 
No Tx IFNr ll-4 TGF~ IL-4 + IFNy + IFNy + IFNr + 
TGF~ ll-4 TGFp IL-4 + 
TGF~ 
T470 
No Tx IFNr IL-4 TGFp IL-4 + IFNr + IFNr + IFNr + 
TGFP IL-4 TGF~ IL-4 + 
TGF~ 
MDAMB 157 
No Tx IFNy IL-4 TGFp IL-4 + IFNr + IFNr + IFNr + 
TGFP IL-4 TGFp IL-4 + 
TGFP 
700000 
600000 
500000 
E 
~ 400000 
8 ii 300000 
0 
200000 
100000 
BT-20 
No Tx IFNr IL-4 TGFp IL-4 + IFNr + IFNr + IFNr + 
~ 
c 
" 0 0 
ii 
0 
800000 
600000 
400000 
TGFp IL-4 TGF~ IL-4 + 
TGFp 
MDA MB 231 
No Tx IFNr IL-4 TGF~ IL-4 + IFNr + IFNr + IFNr + 
600000 
500000 
e 4ooooo 
l! 
c 8 300000 
8 
200000 
100000 
TGF~ IL-4 TGFp IL-4 + 
TGF~ 
SKBR3 
No Tx IFNr IL-4 TGF~ IL-4 + IFNr + IFNy + IFNr + 
TGFp IL-4 TGF~ IL-4 + 
TGFp 
Figure 6.1. The anti proliferative I cytotoxic effects of cytokines on breast cancer cell 
lines. Counts were conducted using a hemocytometer and phase contrast microscopy. 
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